| Excerpt | Reference |
|---|
| "Bone marrow morphology suggested multiple myeloma, but treatment with cytotoxic drugs had no beneficial effect on the amyloidosis." | ( Dawkins, RL; Zilko, PJ, 1975) |
| "Twenty-seven patients with far-advanced multiple myeloma, resistant to standard agents, were treated with either adriamycin (eight patients) or bleomycin (19 patients)." | ( Bailar, JC; Bakemeier, RF; Bennett, JM; Carbone, PP; Ezdinli, E; Levitt, M; Oken, M; Silber, R, 1978) |
| "A woman with multiple myeloma relapsed after 6 years of satisfactory tumor control with melphalan therapy." | ( Cantell, K; Ideström, K; Killander, D; Nilsson, K; Strander, H; Willems, J, 1979) |
| "Successful therapy for a case of multiple myeloma with a spontaneously crystallizing cryoglobulin of the IgG2-kappa light chain variety was achieved, using both continuous-flow cell centrifugation plasmapheresis to rapidly lower the M component and combination chemotherapy with phenylalanine mustard, prednisone, procarbazine, and vincristine to control the myeloma process." | ( Bogaars, HA; Calabresi, P; Cummings, FJ; Diamond, I; Kalderon, AE; Kaplan, SR; Melnicoff, I; Park, CH, 1979) |
| "A patient with multiple myeloma had pancytopenia after treatment with melphalan and prednisone and died of an interstitial pneumonia." | ( Olsen, TS; von Eyben, F, 1978) |
| "Of 476 patients with multiple myeloma treated during a 9-year period, 11 developed acute myelogenous leukemia or sideroblastic anemia." | ( Alexanian, R; Gonzalez, F; Trujillo, JM, 1977) |
| "A 53-year-old man with multiple myeloma and plasma cell luekemia developed severe, acute bilateral optic neuroretinitis 8 days after chemotherapy with BCNU, procarbazine, cyclophosphamide, and prednisolone." | ( Lennan, RM; Taylor, HR, 1978) |
| "Twenty-eight patients with multiple myeloma responding to prior melphalan-prednisone combinations, but without additional chemotherapy, were followed until relapse." | ( Alexanian, R; Gehan, E; Haut, A; Saiki, J; Weick, J, 1978) |
| "Fourteen patients with multiple myeloma resistant to melphalan plus prednisone were treated with BCNU 50 mg/m2 plus cyclophosphamide 200 mg/m2 on day 1, adriamycin 20 mg/m2 on day 2 and prednisone 60 mg orally, daily for days 1 through 5." | ( Klahr, C; Presant, CA, 1978) |
| "Patients with asymptomatic or smoldering multiple myeloma should not be treated but should be observed closely for progression." | ( Elveback, LR; Kyle, RA, 1976) |
| "Described is a patient with multiple myeloma who, during long-term treatment with alkylating agents, developed cutaneous Kaposi's sarcoma." | ( Kapadia, SB; Krause, JR, 1977) |
| "In a case of classical myelomatosis treated with melphalan, a clone of cells with a chromosomal abnormality was found in the bone marrow during remission." | ( Bedford, J; Holt, JM; Spriggs, AI, 1976) |
| "Seventy-three patients with symptomatic multiple myeloma at Memorial Sloan-Kettering Cancer Center were treated with melphalan from 1963-1967." | ( Lee, BJ, 1976) |
| "In each patient, multiple myeloma responded to therapy and progress was satisfactory until the development of acute leukemia." | ( Bayrd, ED; Kyle, RA; Pierre, RV, 1975) |
| "A patient with multiple myeloma in whom acute erythroleukaemia developed 5 years following treatment with irradiation and melphalan is reported." | ( Brederoo, P; den Ottolander, GD; te Velde, J; van Zwet, TL; Willemze, R; Zwaan, FE, 1976) |
| "A patient with plasma cell myeloma presented in severe renal failure but was otherwise considered a good risk candidate for chemotherapy." | ( DeFronzo, RA; Humphrey, RL; Sterioff, S; Wright, JR; Zachary, JB, 1975) |
| "Growth of a plasma cell myeloma (Adj PC-5) was studied in mice made lathyritic by the administration of beta-amino-proprionitrile (BAPN)." | ( Martino, LJ; Taylor, JJ; Yeager, VL, 1975) |
| "Two patients with multiple myeloma and one patient with a plasma-cytoma are reported in whom acute leukaemia developed following long-term treatment with melphalan." | ( Dahlke, MB; Nowell, PC, 1975) |
| "In the Vth MRC myelomatosis trial, the survival of 314 patients randomised to receive ABCM (adriamycin, BCNU, cyclophosphamide, and melphalan) as first-line treatment was significantly longer than that of 316 patients given intermittent melphalan (M7) (p = 0." | ( Chapman, C; Dunn, J; Kelly, K; MacLennan, IC, 1992) |
| "Resistance to chemotherapy in refractory multiple myeloma is frequently associated with expression of multidrug resistance (MDR)." | ( Durie, BG; Lokhorst, HM; Löwenberg, B; Marie, JP; Nooter, K; Solbu, G; Sonneveld, P; Suciu, S; Zittoun, R, 1992) |
| "Curative therapy for multiple myeloma continues to be an elusive goal." | ( Artim, R; Davidson, H; Gandara, D; George, C; MacKenzie, MR; Meyers, F; Ray, G; Schiff, S; Shields, J; Wold, H, 1992) |
| "A 56-year-old woman hospitalized with multiple myeloma developed myoclonic and tonic-clonic seizures following administration of intravenous morphine with sodium bisulfite preservative at doses exceeding 400 mg/h." | ( Meisel, SB; Welford, PK, 1992) |
| "Fifteen patients with relapsed multiple myeloma (MM) were treated with menogaril 160 mg/m2 intravenously (IV) every 28 days." | ( Brodkin, RA; Brown, RC; Case, LD; Cruz, JM; Dalton, HB; Jackson, DV; Muss, HB; Ramseur, WL; Richards, F; Zekan, PJ, 1992) |
| "Two cases of IgA multiple myeloma treated with syngeneic bone marrow transplant and a non-total body irradiation (TBI) conditioning regimen are reported." | ( Brodsky, I; Bulova, S; Crilley, P; Leasure, N; Topolsky, D, 1992) |
| "Untreated twenty patients of multiple myeloma were treated with the chemotherapy protocol as follows: Initial induction therapy;MP continuous or MP intermittent----IFN alpha----steroid pulse." | ( Asaoku, H; Ishikawa, H; Iwato, K; Kawano, M; Kuramoto, A; Nobuyoshi, M; Sakai, A; Tanabe, O; Tanaka, H, 1992) |
| "The patient was diagnosed as having multiple myeloma, and combination chemotherapy was begun." | ( Aotuka, N; Asai, T; Hashimoto, S; Hirasawa, A; Itoh, K; Kawano, E; Morio, S; Nakamura, H; Oh, H; Yoshida, S, 1992) |
| "Thirty-one patients with multiple myeloma refractory to therapy or relapsing after response to initial therapy were treated with Fludarabine Phosphate utilizing a daily intravenous schedule for five consecutive days." | ( Bonnet, JD; Crowley, JJ; Grever, MR; Hynes, HE; Keppen, MD; Kraut, EH; Salmon, SE, 1990) |
| "80 patients with resistant or relapsing multiple myeloma received a combination of vincristine, cyclophosphamide, lomustine, melphalan and methylprednisolone (MOCCA) as a second-line chemotherapy." | ( , 1992) |
| "Eighteen patients with advanced multiple myeloma resistant to VAD chemotherapy (vincristine, Adriamycin, dexamethasone) were treated with intravenous melphalan in a single-pulse dose of 50-70 mg/m2." | ( Maniatis, A; Papanastasiou, K; Stamatelou, M; Tsakanikas, S, 1991) |
| "These data indicate that multiple myeloma is diagnosed earlier now than in the past, and this must be taken into account when comparing survival data in treated series." | ( Ascari, E; Bertoloni, D; Gobbi, PG; Luoni, R; Riccardi, A; Rutigliano, L; Ucci, G, 1991) |
| "Eleven patients with advanced multiple myeloma refractory to standard doses of alkylating agents and salvage therapy with vincristine, adriamycin and dexamethasone (VAD) were treated with high dose cyclophosphamide, BCNU and VP-16 (CBV) with autologous blood stem cell support." | ( Alexanian, R; Barlogie, B; Dicke, KA; Hester, JP; Horwitz, LH; LeMaistre, CF; Spinolo, JA; Ventura, GJ; Wallerstein, RO; Yau, JC, 1990) |
| "277 untreated multiple myeloma patients of stage 1 (n = 33), II (n = 106) and III (n = 138) entered the study." | ( Bartels, H; Bartl, R; Braun, HJ; Coldewey, R; Deicher, H; Fischer, JT; Gramatzki, M; Leo, R; Peest, D; von Broen, IM, 1990) |
| "Taking the disease characteristics of multiple myeloma into consideration, the better result obtained with multi-drug combination chemotherapy in the treatment of stage III patients is consistent with other studies supporting the superiority of multi-drug combination chemotherapy for patients with overt systemic disease." | ( Hamajima, N; Hirabayashi, N; Kamiya, O; Kato, R; Kawashima, K; Kobayashi, M; Mizuno, H; Nitta, M; Shimizu, K; Takeyama, H, 1990) |
| "Forty-nine consecutive patients with multiple myeloma were analysed for treatment response in relation to dose of orally administered melphalan (induction therapy)." | ( Fernberg, JO; Johansson, B; Lewensohn, R; Mellstedt, H, 1990) |
| "94 patients with refractory multiple myeloma were treated in a multicentre trial with combinations of cytotoxic drugs including anthracyclines." | ( Ahrenberg, P; Ala Harja, K; Almqvist, A; Elonen, E; Hallman, H; Hänninen, A; Ilvonen, M; Isomaa, B; Jouppila, J; Palva, IP, 1990) |
| "136 untreated multiple myeloma patients of stage II and III were collected in the study." | ( Cammerer, U; Coldewey, R; Deicher, H; Hein, R; Hoffmann, L; Konyar, H; Kreuser, ED; Peest, D; Selbach, J; von Broen, IM, 1990) |
| "Twenty patients with refractory multiple myeloma were treated with methylglyoxal-bis(guanylhydrazone) (MGBG), an inhibitor of polyamine synthesis." | ( O'Connell, MJ; Oken, MM; Ritch, PS; Rosen, ST; Wiernik, PH; Winter, JN; Wolter, JM, 1990) |
| "Twenty-one patients with multiple myeloma were treated with idarubicin 45 mg/m2 orally day 1 and prednisone 60 mg/m2 day 1-4 every three weeks." | ( Alberts, AS; Falkson, G; Rapoport, BL; Uys, A, 1990) |
| "In a 59-year-old man with multiple myeloma (kappa-light chain paraproteinaemia) in stage IIIB, bone marrow infiltration with atypical plasma cells was reduced by five cytostatic treatment courses with vincristine, melphalan, cyclophosphamide and prednisone (VMCP protocol), but anaemia requiring blood transfusion persisted (haemoglobin concentration 5." | ( Baumgartner, G; Fortelny, A; Pecherstorfer, M; Schmoranzer, F; Vesely, M, 1990) |
| "Seventy patients with progressive multiple myeloma received combination chemotherapy with cyclophosphamide and prednisolone (CP), BCNU, cyclophosphamide, procarbazine and prednisolone (BCPP), and MCNU, cyclophosphamide, melphalan and prednisolone (MCMP) as first line treatment." | ( Ito, T; Saito, Y; Uzuka, Y, 1990) |
| "A case of multiple myeloma refractory to various anticancer drugs was effectively treated with the combination of K 18 with prednisolone, which led to a remarkable decrease of serum M-protein and overall recovery." | ( Himori, T; Ishioka, C; Kanamaru, R; Konishi, Y; Mimata, Y; Sato, T; Wakui, A, 1987) |
| "Patients with multiple myeloma (MM) commonly become refractory to chemotherapy despite a favorable response to induction treatment." | ( Dalton, WS; Fay, JW; Lee, J; Stone, MJ; Tong, AW; Tsuruo, T; Wang, RM, 1989) |
| "50 previously untreated patients with multiple myeloma received two-phase treatment: repeated cycles of 4 day infusion with vincristine, doxorubicin, and methylprednisolone (VAMP) followed by high-dose melphalan (HDM), with autologous bone marrow transplantation where possible." | ( Bell, J; Clark, PI; Gore, ME; Judson, IR; Maitland, JA; Meldrum, M; Milan, S; Millar, B; Selby, PJ; Viner, C, 1989) |
| "32 previously untreated patients with multiple myeloma received vincristine, doxorubicin ('Adriamycin'), and dexamethasone (VAD) as first-line therapy." | ( Aston, L; Gaminara, E; Hamon, M; Joyner, M; Kearney, J; McCarthy, D; Mitchell, T; Newland, A; Samson, D; Van de Pette, J, 1989) |
| "Patients aged 70 yr or older with multiple myeloma were treated, when suitable, according to concurrent trial protocols for younger patients, with the exception that the cytostatic regimen was not allocated at random." | ( Ahrenberg, P; Ala-Harja, K; Almqvist, A; Hänninen, A; Ilvonen, M; Isomaa, B; Järvenpää, E; Jouppila, J; Kilpi, H; Palva, IP, 1989) |
| "50 patients were treated for multiple myeloma with 5-drug combination chemotherapy between Jan 1979 and Feb 1980." | ( , 1989) |
| "We report the case of a patient with multiple myeloma who developed acute life-threatening water intoxication following treatment with oral indomethacin and low dose intravenous cyclophosphamide." | ( Murray, JA; Webberley, MJ, 1989) |
| "A 66 year-old woman with multiple myeloma developed hypoparathyroidism during combination chemotherapy with melphalan, prednisolone, and alpha-interferon (INF)." | ( Kobayashi, N; Murakami, H; Naruse, T; Omine, M; Tsuchida, A; Ueki, K; Yano, S, 1989) |
| "Thirty-four patients with refractory multiple myeloma were treated with 4-d continuous infusions of vincristine and adriamycin in combination with 4-d pulsed high-dose dexamethasone (VAD)." | ( Bast, EJ; Dekker, AW; Lokhorst, HM; Meuwissen, OJ, 1989) |
| "86 previously untreated patients with multiple myeloma stage III entered a randomized trial comparing combination chemotherapy (VMCP/VBAP) (n = 42) with intermittent oral melphalan and prednisone (MP) treatment (n = 44)." | ( Ahre, A; Björeman, M; Björkholm, M; Brenning, G; Gahrton, G; Gyllenhammar, H; Järnmark, M; Johansson, B; Juliusson, G; Osterborg, A, 1989) |
| "In the Vth MRC myelomatosis trial, patients treated with a combination of adriamycin, carmustine, cyclophosphamide and melphalan are living significantly longer than those treated with melphalan alone, and this survival advantage persists after correction for the most important prognostic factor, beta 2 microglobulin." | ( Bergsagel, DE, 1989) |
| "The association of neutrophilia with multiple myeloma, the occurrence of AMoL after prolonged Melphalan therapy for the multiple myeloma and the strategy of therapy for secondary leukemia is discussed." | ( Abe, K; Fujimura, K; Imamura, N; Inada, T; Kuramoto, A; Mtasiwa, DM, 1989) |
| "Ten patients with multiple myeloma (two refractory and eight relapsing) received vincristine and adriamycin infusion therapy with oral high-dose dexamethasone (VAD regimen)." | ( Ma, MX; Wu, SL; Yiu, JR, 1989) |
| "She had a history of multiple myeloma and had been treated with melphalan, vincristine and prednisolone." | ( Dan, KZ; Futaki, M; Gomi, S; Inokuchi, K; Kuriya, S; Kuwabara, T; Nomura, T; Ogata, K; Ohki, I; Shinohara, T, 1989) |
| "Two previously treated patients with multiple myeloma were given combination therapy of daily HLBI (3-6 x 10(6) I." | ( Fukuzawa, Y; Kawamura, T; Ohno, R, 1989) |
| "A 56-year-old patient with multiple myeloma experienced an extravasation of doxorubicin (DOX) and vincristine administered as a 96-hour infusion." | ( Dordal, MS; Dorr, RT; Koenig, LM; McCloskey, TM; Taylor, CW, 1989) |
| "18 previously untreated patients with multiple myeloma were entered in a clinical study of a combination chemotherapy, carboquone (CQ) and prednisolone (P) (CQ-P)." | ( Akashi, M; Kitagawa, S; Miura, Y; Ohta, M; Saito, M; Sakamoto, S; Takaku, F; Yoshida, M, 1989) |
| "Patients with multiple myeloma were treated chemotherapeutically with a combination of melphalan, ifosfamide, prednisolone, nitrosourea and vincristine (MIP-NV therapy)." | ( Ishii, H, 1988) |
| "Seven patients with advanced multiple myeloma, refractory to therapy with alkylating agent-VAD (vincristine-adriamycin-dexamethasone), received a regimen combining high-dose melphalan with total body irradiation supported by autologous bone marrow transplantation." | ( Alexanian, R; Barlogie, B; Dicke, KA; Horwitz, L; Jagannath, S; Spitzer, G; Zagars, G, 1987) |
| "In a 74-year-old female with multiple myeloma treated with melphalan for 19 months, erythroleukemia developed 23 months after the start of treatment." | ( Streuli, R; Voellmy, W, 1987) |
| "Four patients with multiple myeloma refractory to conventional chemotherapy received high-dose melphalan." | ( Barrett, AP; Buckley, DJ, 1987) |
| "67 previously untreated patients with multiple myeloma were entered on a randomized clinical trial to determine whether the use of combination chemotherapy including vincristine, carmustine, alkylating agents, and prednisone was more effective than conventional therapy with melphalan and prednisone." | ( Bjark, P; Bondevik, A; Bull, O; Dehli, O; Kildahl-Andersen, O; Kvambe, V; Lamvik, J; Nordahl, E; Ytrehus, K, 1986) |
| "Six patients with multiple myeloma were treated with HLBI-MP regimen; HLBI 300 X 10(4)U/day daily, Melphalan 4 mg/day p." | ( Fujii, Y; Hara, M; Nakamura, T, 1987) |
| "One hundred seventy-three patients with multiple myeloma were treated from the time of diagnosis with standard oral melphalan and prednisone at 28-day intervals until they became refractory to treatment." | ( Belch, A; Brox, L; Koch, M; Palmer, M; Pollock, E, 1987) |
| "99 patients with multiple myeloma were treated over a period of 6 1/2 years; 62 of these were initially treated with vincristine, carmustine, cyclophosphamide, melphalan and prednisone: M 2-Protocol." | ( Ho, AD; Hunstein, W; Keilholz, U; Theml, H; Wittkamp, S, 1986) |
| "Twenty previously treated patients with multiple myeloma were treated with rDNA human alpha-2 interferon (INTRON A) in a phase II trial." | ( Bonnem, E; Boyd, MA; Case, DC; Dorsk, BM; Hiebel, J; Paul, SD; Shepp, MA; Sonneborn, HL, 1986) |
| "A total of 33 evaluable patients with multiple myeloma refractory to alkylating agents were treated with the regimen vincristine, BCNU, doxorubicin, and prednisone (VBAP) at 3-week intervals in a single institution for a 5-yr period." | ( Bladé, J; Cervantes, F; Feliu, E; Grañena, A; Marín, P; Montserrat, E; Nomdedeu, B; Rozman, C, 1986) |
| "Fourteen patients with multiple myeloma (MM) were given chemotherapy courses for 7 days followed by 21-day intervals, combined with an immunomodulating treatment, namely lysozyme (LZM), 2 g daily for three weeks every other interval." | ( Campobasso, N; Dammacco, F; Iodice, G; Ronco, M; Vacca, A, 1985) |
| "Seven patients with refractory multiple myeloma (readily evaluable for response) were treated in a Phase II trial with poly(I,C)-LC using a 3 times per week intravenous schedule." | ( Durie, BG; Jett, JR; Levine, AS; Levy, HB; Voakes, J, 1985) |
| "Optimal therapy in patients with multiple myeloma relies on methods which indicate stability or progression of disease." | ( Joshua, DE; Kronenberg, H; Wearne, A, 1985) |
| "In 12 of 18 patients with multiple myeloma refractory to treatment with the combination of vincristine, melphalan, cyclophosphamide, and prednisone, favorable results were obtained by replacing vincristine in this combination with vindesine." | ( Monasch, E; Pegels, HG; van der Lelie, H; von dem Borne, AE, 1986) |
| "The effects of the treatment of multiple myeloma (MM) with APD-bisphosphonate on bone destruction, the dissemination pattern of the MM, and toxicity for normal and malignant cells were investigated in an animal model, the 5T2 MM." | ( Bijvoet, OL; Brondijk, RJ; Croese, JW; Haaijman, JJ; Kazil, M; Radl, J; Reitsma, PH; van den Enden-Vieveen, MH; Zurcher, C, 1985) |
| "Sixteen patients with multiple myeloma refractory to alkylating agents were treated with vincristine 0." | ( Gomez, GA; Han, T; Henderson, ES; Ozer, H, 1985) |
| "In three patients with multiple myeloma, stage IIIA, a complete remission lasting from 6 to 8 years was attained, in spite of the fact that not all of them received treatment." | ( Andreeva, NE, 1985) |
| "We describe the case of a woman with multiple myeloma, who developed fulminant encephalopathy following 4 days of continuous vincristine, adriamycin, and day 1-4 pulse dexamethasone (VAD) combination therapy." | ( Ludwig, H; Maida, E; Scheithauer, W, 1985) |
| "Twenty-nine patients with multiple myeloma, 16 untreated and 13 relapsing after treatment with melphalan and/or cyclophosphamide, were treated with Peptichemio (PTC), vincristine (VCR) and prednisone (PRD)." | ( Ascari, E; Merlini, G; Montecucco, CM; Pavesi, F; Riccardi, A; Riccardi, PG, 1985) |
| "Twenty-eight patients with multiple myeloma have been treated with a quadruple chemotherapeutic regimen consisting of 1, 3 bis (2-chloroethyl)-1-nitrosourea (BCNU), cyclophosphamide, melphalan, and prednisolone." | ( Azam, L; Delamore, IW, 1974) |
| "UNTREATED PATIENTS SUFFERING FROM MYELOMATOSIS WERE ALLOCATED AT RANDOM FOR TREATMENT BY THE DAILY ORAL ADMINISTRATION OF EITHER CYCLOPHOSPHAMIDE OR MELPHALAN: 141 received cyclophosphamide and 133 melphalan." | ( , 1971) |
| "A patient suffering from multiple myeloma developed pulmonary fibrosis, of a type known to be associated wtih busulphan, whilst being treated with Melphalan." | ( Chakera, TM; Codling, BW, 1972) |
| "A patient with multiple myeloma and hypercalcemia responded to cytotoxic chemotherapy." | ( Chakmakjian, ZH; Lieberman, ZH; Matthews, JL; Stone, MJ, 1982) |
| "Patients with newly diagnosed multiple myeloma were randomly allotted to an intermittent high-dose melphalan/prednisone (MP) treatment (120 patients) or a continuous low-dose melphalan (M) regimen (99 patients)." | ( Ahre, A; Björkholm, M; Brenning, G; Engstedt, L; Gahrton, G; Hällen, J; Holm, G; Johansson, B; Johansson, SG; Karnström, L; Killander, A; Lerner, R; Lockner, D; Lönnqvist, B; Mellstedt, H; Simonsson, B; Stalfelt, AM; Ternstedt, B; Wadman, B, 1983) |
| "Previously untreated patients with multiple myeloma were entered on a randomized clinical trial to determine whether the use of alternating combination chemotherapy, including vincristine, doxorubicin, alkylating agents, and prednisone (160 patients) was more effective than conventional chemotherapy with melphalan and prednisone (77 patients), and whether the addition of the immunomodulating agent levamisole to maintenance chemotherapy enhanced the survival of patients achieving remission." | ( Amare, M; Bonnet, JD; Dixon, DO; Durie, BG; Haut, A; Salmon, SE; Weick, JK, 1983) |
| "7 cases of multiple myeloma with a history of exposure to benzene, radioactive iodine, chemotherapy for Hodgkin's disease and of repeated injections of autovaccine to Staphylococcus albus hemolyticus are described." | ( Aksoy, M; Bakioğlu, I; Dinçol, G; Erdem, S; Hepyüksel, T; Kutlar, A, 1984) |
| "Sera from 4 patients with multiple myeloma were incubated with 45Ca-labelled bones, some pretreated with mithramycin." | ( Anderson, KM; Rubenstein, M; Sky-Peck, H, 1982) |
| "In 14 patients with advanced refractory multiple myeloma, the effect of high-dose cytosine arabinoside (ara-C) administration was evaluated." | ( Alexanian, R; Barlogie, B; Dreicer, R; Kantarjian, H; Plunkett, W, 1984) |
| "Twenty patients with plasma cell myeloma were treated with high-dose (10 mg/kg) intermittent administration of cyclophosphamide for remission induction and maintenance therapy." | ( Ikeda, Y; Mizuno, H; Ninomiya, N; Ohnishi, K; Ohta, H; Tokoro, K; Yasuma, A, 1983) |
| "62 patients with multiple myeloma were primarily treated with the combination vincristin + melphalan + cyclophosphamide + prednisolone (VMCP)." | ( Anger, G; Wutke, K, 1983) |
| "In order to ascertain whether multiple myeloma patients resistant to one alkylating agent would respond to a second one, high-dose intermittent cyclophosphamide was administered to 12 patients showing resistance to melphalan and prednisone." | ( Bladé, J; Estapé, J; Feliú, E; Millá, A; Montserrat, E; Rozman, C, 1983) |
| "A patient with multiple myeloma developed periodic blood neutropenia (periodicity of 15-25 days) after 3 yr of intermittent treatment with cytotoxic agents." | ( Chanana, AD; Chandra, P; Chikkappa, G; Cronkite, EP; Thompson, KH, 1980) |
| "Fifteen patients with multiple myeloma were treated with sodium fluoride (50 mg twice daily) plus calcium carbonate (1 g four times daily) or with the same fluoride-calcium dosage plus vitamin D (50,000 U twice weekly)." | ( Jowsey, J; Kyle, RA, 1980) |
| "Twenty-four untreated patients with myelomatosis were studied in order to characterize their anaemia, using standard haematological and ferrokinetic techniques, together with measurements of circulating erythropoietin, erythropoietin sensitivity of marrow cultures and in vitro measurements of haem synthesis." | ( Cavill, I; Jacobs, A; Kaaba, S; May, A; Smith, S; Ting, WC; Whittaker, JA, 1982) |
| "Fifteen patients with multiple myeloma, two of whom had plasma cell leukemia, were treated between May 1974 and December 1978." | ( Gobbi, PG; Merlini, G; Perugini, S; Riccardi, A; Riva, G; Sardi, C, 1982) |
| "Patients with multiple myeloma and renal insufficiency should, therefore, be examined for reversible causes of renal dysfunction, since if found and treated, a substantial improvement in prognosis is achieved." | ( Bernstein, SP; Humes, HD, 1982) |
| "We report a case of multiple myeloma in a 48-year-old woman treated with phenytoin for 55 months." | ( Aymard, JP; Colomb, JN; Faure, G; Guerci, O; Herbeuval, R; Lederlin, P; Witz, F, 1981) |
| "Osteolytic lesions of bone in multiple myeloma may be treated by florides." | ( Gloor, HJ; Truniger, B; Wetterwald, O, 1980) |
| "Interferon (IFN) treatment trials in multiple myeloma have yielded discordant results regarding response rates, maintenance duration, and survival times." | ( Cohen, AM; Eckhardt, S; Günczler, P; Huber, H; Ludwig, H; Morant, R; Nachbaur, D; Polliack, A; Seewann, HL; Senn, HJ, 1995) |
| "Two patients with advanced multiple myeloma were treated with oral low-dose cyclosporin A." | ( Dutcher, JP; Leaf, AN; Liao, Z; Paietta, E; Rosenstreich, DL; Wiernik, PH, 1994) |
| "One hundred and fifty-six patients with multiple myeloma were treated over a period of 12 years at St." | ( Carter, M; Clark, PI; Ganjoo, RK; Gregory, W; Johnson, PW; Lim, JM; Love, SB; Mahmoud, MM; Malpas, JS; Williams, AH, 1995) |
| "406 untreated multiple myeloma patients of stage I (n = 54), II (n = 148) and III (n = 204) were enrolled in the trial." | ( Bartels, H; Bartl, R; Braun, HJ; Coldewey, R; Deicher, H; Fett, W; Fischer, JT; Göbel, B; Leo, R; Peest, D, 1995) |
| "We report a patient with multiple myeloma who developed severe congestive cardiomyopathy while receiving interferon alpha that did not reverse subsequent to discontinuation of interferon therapy." | ( Adkins, D; Bowers, C; Graham, M; Petruska, P; Spitzer, G; Vrahnos, D; Zimmerman, S, 1994) |
| "The treatment of multiple myeloma remains unsatisfactory and new active agents are needed." | ( Alexanian, R; Arbuck, S; Delasalle, K; Dimopoulos, MA; Huber, M; Luckett, R; Weber, D, 1994) |
| "A total of 15 patients with refractory multiple myeloma (MM; 4 primary unresponsive and 11 relapsed and resistant to re-induction/salvage therapy) received i." | ( Ganjoo, RK; Malpas, JS; Williams, A, 1995) |
| "A total of 142 patients with multiple myeloma received VAD as remission induction therapy." | ( Anderson, H; Fitzsimmons, L; Morgenstern, GR; Ranson, M; Ryder, D; Scarffe, JH; Wieringa, GS; Young, R, 1995) |
| "Some patients with advanced refractory multiple myeloma can achieve objective responses from highdose chemoradiotherapy with peripheral blood stem cell rescue." | ( Chen, MG; Garton, JP; Gertz, MA; Greipp, PR; Inwards, DJ; Letendre, L; Litzow, MR; Pineda, AA; Solberg, LA; Witzig, TE, 1995) |
| "Twenty-three adults with advanced multiple myeloma (15 responsive to chemotherapy, 8 resistant) received cyclophosphamide 120 mg/kg and busulfan 14-16 mg/kg followed by the infusion of BM or blood progenitor cells." | ( Berenson, J; Gajewski, J; Lee, M; Lieb, G; Nimer, S; Schiller, G; Territo, M; Vescio, R, 1994) |
| "This small study of six patients with multiple myeloma showed that three courses of high dose therapy with or without stem cell rescue can be performed with relative safety." | ( Casassus, P; Colombat, P; Harousseu, JL; Laporte, JP; Linassier, C; Milpied, N, 1994) |
| "Nineteen patients with multiple myeloma resistant to standard alkylating agent therapy or to the VAD regimen received carboplatin at a planned daily dose of 100 mg/M2 on four successive days." | ( Barlogie, B; Bonnet, J; Crowley, J; Hayden, K; Salmon, SE; Weick, JK, 1994) |
| "Standard therapy for multiple myeloma consists of cytotoxic chemotherapy plus glucocorticoids." | ( Barlogie, B; Crowley, JJ; Finley, P; Grogan, TM; Pugh, RP; Salmon, SE, 1994) |
| "A 57-year-old man with IgG multiple myeloma developed pulmonary infiltration caused by pulmonary amyloidosis, for which continuous transdermal dimethyl sulfoxide (DMSO) treatment was given." | ( Aizawa, K; Hamano, T; Iwasaki, T; Kakishita, E; Kobayashi, K, 1994) |
| "We describe a patient with multiple myeloma who developed secondary acute myelomonocytic leukemia after long-term melphalan treatment." | ( Bairey, OS; Sandbank, Y; Shaklai, M, 1993) |
| "Twenty patients with multiple myeloma and 14 with squamous cell carcinoma, who had presented with hemoglobin levels < 11 g/dl, were treated with rHuEPO, 150 U/kg, three times/week." | ( Fritz, E; Leitgeb, C; Ludwig, H; Pecherstorfer, M, 1993) |
| "In 19 patients with recently diagnosed multiple myeloma 3-week cycles of vincristine, BCNU, melphalan, cyclophosphamide and prednisone alternating with interferon were administered over 6-12 months." | ( Gola, A; Kotlarek-Haus, S; Urbaniak-Kujda, D; Usnarska-Zubkiewicz, L; Wołowiec, D, 1993) |
| "Fifty-six patients with refractory multiple myeloma were treated with intermittent courses of etoposide, doxorubicin, cyclophosphamide and high-dose betamethasone (EACB) every 4th week." | ( Björeman, M; Björkholm, M; Brenning, G; Carlson, K; Celsing, F; Gahrton, G; Grimfors, G; Juliusson, G; Ohrling, M; Osterborg, A, 1993) |
| "A mouse model system for multiple myeloma was used to evaluate the potential therapeutic efficacy of sequential therapy with 153Sm-EDTMP, melphalan, and BMT." | ( Berger, JD; Claringbold, PG; Glancy, RJ; Manning, LS; O'Donoghue, HL; Turner, JH, 1993) |
| "No apparent worsening of multiple myeloma has been observed over the treatment period ranging from 5 to 34 months (cumulative duration of treatment 55 months)." | ( Benedet, P; Chapuis, B; Leski, M; Pechère Bertschi, A; Ruedin, P, 1993) |
| "Eighteen patients with multiple myeloma and tumor nodules in the spine had MR imaging of the same site in the spine before and after treatment." | ( Anglade, MC; Dao, T; Divine, M; Golli, M; Haioun, C; Mathieu, D; Rahmouni, A; Reyes, F; Vasile, N, 1993) |
| "Follow-up data of 320 multiple myeloma (MM) patients entering the German Myeloma Treatment Group (GMTG) trial MM01 were analysed for factors predicting overall (OAS) and tumour related survival (TRS)." | ( Coldewey, R; Deicher, H; Diehl, V; Georgii, A; Hoeppner, E; Karow, J; Leo, R; Peest, D; Sailer, M; Vykoupil, C, 1993) |
| "Patients with stage III multiple myeloma and at least one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles in addition to antimyeloma therapy." | ( Ballester, O; Bell, R; Berenson, JR; Blacklock, HA; Bordoni, R; Dimopoulos, MA; George, S; Heffernan, M; Keller, A; Knight, RD; Kovacs, MJ; Lichtenstein, A; Lipton, A; Porter, L; Reitsma, DJ; Seaman, J; Simeone, J, 1996) |
| "Twenty-one previously untreated multiple myeloma (MM) patients and 10 previously treated patients with refractory or relapsed disease received two or three cycles of intermediate-dose melphalan (70 mg/m2) (IDM), administered intravenously every 6 weeks." | ( Dekker, AW; Lokhorst, HM; Meuwissen, OJ; Sonneveld, P; van der Griend, R; van Marwijk Kooy, M; van Oers, RH; Wijermans, PW, 1996) |
| "Patients had a diagnosis of multiple myeloma and had not previously been treated for this disease." | ( Crowley, J; Modiano, MR; Salmon, SE; Villar-Werstler, P, 1996) |
| "To evaluate the outcome of patients with multiple myeloma (MM) who received high-dose therapy followed by autologous bone marrow (BM) or peripheral-blood stem-cell (PBSC) infusion." | ( Appelbaum, FR; Barnett, T; Bensinger, WI; Buckner, CD; Chauncey, T; Clift, RA; Demirer, T; Fefer, A; Holmberg, L; Klarnet, J; Lilleby, K; Maloney, DG; Maziarz, RT; McSweeney, P; Rowley, SD; Schiffman, K; Storb, R; Weaver, CH, 1996) |
| "Cytostatic treatment of multiple myeloma in combination with repetitive i." | ( Frickhofen, N; Friedrich, JM; Hoffmeister, A; Mattfeldt, T; Merkle, E; Prümmer, O; Weber, CK, 1996) |
| "To analyze the outcome of patients with multiple myeloma (MM) who were potential candidates for early high-dose therapy (HDT) intensification followed by autotransplantation from a series treated with conventional chemotherapy." | ( Alcalá, A; Bladé, J; Conde, E; Conzález-Brito, G; Escudero, ML; Estapé, J; Fontanillas, M; García-Conde, J; Maldonado, J; Montserrat, E; Moro, MJ; Pascual, A; Rozman, C; San Miguel, JF; Trujillo, J, 1996) |
| "Important progress in the therapy of multiple myeloma has been done in the nineties." | ( Adam, Z; Hájek, R; Král, Z; Krejcí, M; Vásová, I; Vorlícek, J, 1996) |
| "To ascertain if multiple myeloma cells surviving exposure to chemotherapy alter their BCL-2 expression, we treated the myeloma cell lines 8226, IM-9, and U266 as well as a primary myeloma cell culture with various injurious agents." | ( Berenson, J; Fady, C; Lichtenstein, A; Liu, J; Tu, Y; Vescio, R; Xu, FH, 1996) |
| "Important progress in the therapy of multiple myeloma has been done in the nineties." | ( Adam, Z; Hájek, R; Král, Z; Vásová, I, 1996) |
| "In patients with multiple myelomas treated with biphosphonates in randomized studies a reduction of the number of new osteolytic foci was proved and improvement of the quality of life." | ( Adam, Z; Hájek, D; Hejlová, N; Krejcí, M; Prokes, B; Vorlícek, J; Znojĭl, V, 1996) |
| "Resistance to chemotherapy in multiple myeloma (MM) and acute myeloid leukemia (AML) is frequently caused by multiple drug resistance (MDR), characterized by a decreased intracellular drug accumulation." | ( den Ouden, D; Schoester, M; Sonneveld, P; van den Heuvel, M; van Rens, G, 1996) |
| "A patient with multiple myeloma was treated with several cycles of chemotherapy and developed monoclonal IgA rheumatoid factor." | ( Kashiwazaki, S; Nishinarita, M; Sugai, S, 1996) |
| "30 patients with multiple myeloma were treated with HDM." | ( Boot-Bakker, A; Dräger, AM; Huijgens, PC; Jonkhoff, AR; Legdeur, MC; Ossenkoppele, GJ; Schuurhuis, GJ; van der Hem, KG; Westra, AH, 1996) |
| "In adjuvant therapy of patients with multiple myeloma among others anti-absorption properties of bisphosphonates are used." | ( Cieslar, P; Hulejová, H; Klener, P; Slabý, J; Spacek, P; Spicka, I, 1997) |
| "Mobilization chemotherapy regimens in multiple myeloma (MM) predominantly consist of melphalan or cyclophosphamide that induce marked cytopenia and considerable variability of progenitor cell collection." | ( Engelhardt, M; Henschler, R; Lange, W; Mertelsmann, R; Waller, C; Winkler, J, 1997) |
| "Data from 225 multiple myeloma (MM) patients, undergoing peripheral stem cell (PBSC) mobilization with high-dose cyclophosphamide and hematopoietic growth factors, were analyzed for median CD34+ cell count and median time to post-transplant neutrophil (ANC > 500/microliters) and platelet (> 50,000/microliters) recovery according to age groups (20-49, 50-59 and > or = 60 years) and duration of prior therapy (< or = 12, 13-24, or > 24 months)." | ( Barlogie, B; Bracy, D; Guba, SC; Jagannath, S; Tricot, G; Vesole, DH, 1997) |
| "With conventional therapy, multiple myeloma (MM) has a poor prognosis." | ( Bogen, B; Levy, R; Okada, CY; Reichardt, VL; Stockerl-Goldstein, KE, 1997) |
| "We treated 103 multiple myeloma (MM) patients with 7 g/m2 cyclophosphamide (Cy) followed by 300 micrograms G-CSF/d to harvest peripheral blood progenitor cells (PBPC)." | ( Goldschmidt, H; Haas, R; Hegenbart, U; Hohaus, S; Wallmeier, M, 1997) |
| "Future investigation of topotecan in multiple myeloma including combination therapy and the study of other topoismerase I inhibitors is warranted." | ( Alsina, M; Crowley, JJ; Kraut, EH; Laufman, LR; Salmon, SE; Taylor, SA; Wade, JL, 1998) |
| "In patients with multiple myeloma, despite a major reduction of bone pain achieved with chemotherapy, skeletal disease continues to progress." | ( Chapman, C; Drayson, MT; Dunn, J; Kanis, JA; MacLennan, IC; McCloskey, EV, 1998) |
| "Fifty-five patients with advanced multiple myeloma received purified CD34-selected peripheral blood progenitor cell transplants following myeloablative chemotherapy." | ( Berenson, J; Berenson, R; Cao, J; Freytes, C; Lee, JC; Lee, M; Lichtenstein, A; Lill, M; Schiller, G; Spitzer, G; Vescio, R; Wu, CH, 1998) |
| "We describe a patient with multiple myeloma who was treated with intensive therapy and autologous blood cell transplantation as her first-line treatment." | ( Koskela, K; Lakkala, T; Pelliniemi, TT; Remes, K, 1998) |
| "The first patient, with refractory multiple myeloma, died following massive pneumonia despite therapy with amphotericin B and granulocyte-colony stimulating factor (G-CSF); the second patient, with relapsed acute lymphatic leukemia and persistent fever without any other clinical evidence, finally recovered." | ( Fabbri, A; Fanci, R; Martinez, RL; Nicoletti, P; Pecile, P, 1997) |
| "The authors describe a case of multiple myeloma in which a complete remission was obtained by treatment with high dose dexamethasone." | ( Bertola, G; Grando, D; Meregalli, M, 1998) |
| "Treatment with TGF-beta1 of stroma from multiple myeloma BM samples produced a substantial increase in VLA-5 use by the myeloma cell line NCI-H929 to adhere to this stroma." | ( Hidalgo, A; Robledo, MM; Sanz-Rodriguez, F; Teixidó, J, 1998) |
| "In ten patients with multiple myeloma (MM), serum beta-2-microglobulin (B2M) levels were monitored in order to clarify the influence of alpha interferon (IFN) administration." | ( Karasawa, M; Matsushima, T; Miyawaki, S; Morita, K; Murakami, H; Ogawara, H; Saitoh, T; Satoh, S; Sawamura, M; Schimano, S; Tamura, J; Tsuchiya, J, 1997) |
| "Anemia is a frequent complication of multiple myeloma, becoming chronic in patients who are resistant to chemotherapy." | ( Ascari, E; Bernasconi, C; Caligaris-Cappio, F; Castoldi, GL; Dammacco, F; De Laurenzi, A; Grassi, B; Nadali, G; Perona, G; Pileri, A; Resegotti, L; Rossi Ferrini, PL; Silvestris, F; Torelli, U, 1998) |
| "For patients younger than 60 years with multiple myeloma in a stage requiring chemotherapy high dose chemotherapy followed by autologous blood stem cell transplantation appears to be the best therapeutic option." | ( Aul, C; Bauser, U; Heyll, A; Kobbe, G; Quenzel, EM; Schneider, P; Schneider, W; Söhngen, D, 1998) |
| "Twenty-seven patients with advanced multiple myeloma received high-dose therapy with 220 mg/m2 i." | ( Bataille, R; Harousseau, JL; Juge-Morineau, N; Mahé, B; Milpied, N; Moreau, P; Rapp, MJ, 1999) |
| "About 50% of patients with multiple myeloma are older than 65 years and are not eligible for high-dose therapy, which has proved to be more efficacious than standard-dose chemotherapy in young patients." | ( Facon, T, 1999) |
| "Renal failure (RF) in multiple myeloma (MM) is considered an ominous complication even though, when timely therapy is started in patients with minimal damage, a high percentage of cases can achieve a regression." | ( Bernasconi, C; Bosoni, T; Castagnola, C; Corso, A; Klersy, C; Lazzarino, M; Moratti, R; Pagnucco, G; Serricchio, G; Zappasodi, P, 1999) |
| "A total of 39 multiple myeloma patients were treated with a sequential therapy including double high-dose melphalan therapy followed by a double transplant procedure." | ( Amaddii, G; Coser, P; Drexler, E; Emmerich, B; Fabris, P; Lanthaler, AJ; Mitterer, M; Oduncu, F; Straka, C, 1999) |
| "Ten patients with previously untreated multiple myeloma entered the study." | ( Hassan, M; Lundin, J; Nilsson, C; Olsson, H; Osterborg, A, 1999) |
| "Sixty-six patients with multiple myeloma were divided into four groups: treatment with alpha-2a-interferon (reaferon) 3-5 mln MU/m2 alone (group); alpha-interferon + pulsed therapy with dexamethasone (group II); reaferon at high or low dose + different regemens of polychemotherapy (group III), and polychemotherapy followed by therapeutic support with melfalan and prednisone (MP) (control)." | ( Abdulkadyrov, KM; Bessmel'tsev, SS, 1999) |
| "The established treatment for multiple myeloma (MM) comprises induction with infusional chemotherapy, high dose chemotherapy (HDC) and autologous transplantation followed by maintenance interferon." | ( Kulkarni, S; Mainwaring, PN; Powles, RL; Raje, N; Ramiah, V; Sumpter, K; Treleaven, J, 1999) |
| "The association of leukemia and multiple myeloma is well described usually as a complication of chemotherapy but also in the absence of chemotherapy or at diagnosis." | ( Dunkley, S; Gibson, J; Iland, H; Joshua, D; Li, C, 1999) |
| "The main form of cytotoxic treatment for multiple myeloma (MM) is conventional dose chemotherapy at present." | ( Araki, K; Fukuda, H; Hanada, S; Hirano, M; Ichimaru, M; Inaba, S; Konishi, H; Mikuni, C; Miura, A; Niimi, M; Ohno, Y; Sai, T; Shimamoto, Y; Shimoyama, M; Shirakawa, S; Tajima, K; Takenaka, T; Toki, H, 1999) |
| "Eighty-two patients with advanced multiple myeloma (MM) were enrolled in 2 sequential clinical studies of 1 or 2 courses of myeloablative therapy with stem cell support." | ( Bonifazi, F; Cavo, M; Curti, A; Lemoli, RM; Martinelli, G; Motta, MR; Rizzi, S; Ronconi, S; Rondelli, R; Terragna, C; Tura, S; Zamagni, E, 2000) |
| "Thirty-seven patients with multiple myeloma (stage II and III, 65% increased beta2-microglobulin level) were prospectively treated with a median of 3." | ( Bos, NA; de Wolf, JT; Guikema, JE; Hovenga, S; Klip, H; Smit Sibinga, CT; Smit, JW; Vellenga, E, 2000) |
| "This study demonstrates that in multiple myeloma a significant reduction in the malignant contamination of stem cell autografts can be achieved by combining the in vivo purging effect of cytotoxic therapy with in vitro purging by CD34+ selection." | ( Barrow, L; Brown, R; Dyson, PG; Gibson, J; Horvath, N; Joshua, D; To, LB; Van Holst, NG, 2000) |
| "Patients with multiple myeloma (MM) and chronic renal failure have generally been excluded from myeloablative therapy programs followed by hematopoietic stem cell support because of the potential increase in transplant-related morbidity and mortality." | ( Benni, M; Cavo, M; Motta, MR; Rizzi, S; Ronconi, S; Tosi, P; Tura, S; Zamagni, E, 2000) |
| "Ten patients with multiple myeloma (MM), seven patients with chronic lymphocytic leukemia (CLL), and one patient with diffuse well-differentiated lymphocytic lymphoma (DWDL) were treated with menogaril, 160 mg/m2 (for MM) or 200 mg/m2 (for CLL/DWDL), given as a 2-hour intravenous infusion, repeated every 28 days." | ( Benson, AB; Blough, R; Kilton, L; Kucuk, O; Wade, JL, 2000) |
| "For elderly patients with multiple myeloma (MM), conventional melphalan and prednisone (MP) therapy has been the treatment of choice; the vincristine, doxorubicin and dexamethasone (VAD) regimen is preferred for younger patients who also receive high-dose melphalan in combination with autologous or allogeneic bone marrow transplantation (BMT)." | ( Bourantas, KL; Christou, L; Kapsali, E; Panteli, A; Pritsivelis, N; Tsiara, SN, 2000) |
| "In patients with multiple myeloma where only four cycles of VAD chemotherapy preceded and where radiotherapy of the axial skeleton was not used, optimal collection of haematopoietic stem cells was achieved after administration of cyclohosphamide 5 g/m2 with subsequent administration of 5 micrograms/kg G-CSF." | ( Adam, Z; Hájek, R; Korístek, Z; Krejcí, M; Krivanová, A; Navrátil, M, 2000) |
| "Treatment of multiple myeloma consists of a rapid rehydration and forced diuresis; the usefulness of plasmapheresis has not been demonstrated." | ( Diderich, PP; Pegels, JG; Ruizeveld de Winter, JA; van Zaanen, HC, 2000) |
| "Relapsing patients with multiple myeloma show a response rate higher than 50% with the resumption of the initial chemotherapy." | ( Bladé, J; Esteve, J, 2000) |
| "Patients with multiple myeloma and lymphoma, possibly owing to a combination of disease-related characteristics and prior immunosuppressive treatment, had high rates of CMV reactivation and may require more frequent diagnostic evaluation and prompt therapeutic intervention." | ( Bolaños-Meade, J; Buddharaju, LN; Chen, T; Cottler-Fox, M; Cross, A; Fassas, AB; Lovchik, JC; Rapoport, A; Tricot, G, 2001) |
| "In two patients with multiple myeloma, men aged 72 and 54 years, diarrhoea developed upon chemotherapy with vincristin, doxorubicin and dexamethasone (VAD)." | ( Kerst, JM; Kuijper, EJ; van der Lelie, J, 2001) |
| "In 90 consecutive patients with multiple myeloma, we investigated the feasibility of administering a tandem high-dose therapy regimen, using whole blood for rescue after the first and leucapheresis harvested between the two high doses, for rescue after the second high dose." | ( Admiraal, GC; Dekker-Van Roessel, HM; Huijgens, PC; Jonkhoff, AR; Ossenkoppele, GJ; Schuurhuis, GJ; Zweegman, S, 2001) |
| "Sixteen patients suffering from multiple myeloma in stage II/A and III/A according to Durie and Salmon underwent chemotherapy consisting of a total of three cycles of ifosfamide (3 g/m(2) on days 1 and 2 and epirubicine 80 mg/m(2) on day 1) and G-CSF (10 or 20 microg/kg body weight (BW) daily until harvesting)." | ( Arland, M; Bartsch, R; Florschütz, A; Franke, A; Höffkes, HG; Kahl, C; Lange, S; Leuner, S, 2001) |
| "Patients with relapsed multiple myeloma (MM) have been shown to respond to a combination therapy consisting of vincristine, Adriamycin (doxorubicin) and high-dose dexamethasone (VAD)." | ( Egerer, G; Goldschmidt, H; Haas, R; Hahn, U; Hegenbart, U; Ho, AD; Salwender, H; Schmier, JW, 2001) |
| "Forty-one patients with multiple myeloma were treated with a novel stem cell mobilisation regimen." | ( Bilgrami, S; Bona, RD; Clive, J; Edwards, RL; Fox, J; Furlong, F; Li, Z; Naqvi, B; Shaikh, A; Tutschka, PJ, 2001) |
| "with progressive multiple myeloma are associated with unfavorable parameters of response and survival but nevertheless predict for response to Thal therapy." | ( Benner, A; Egerer, G; Goldschmidt, H; Hillengass, J; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2001) |
| "A cohort of 265 patients with multiple myeloma stages I-III was consecutively treated at our institution in two parallel groups (control group (n = 99): chemotherapy +/-OE for less than 6 months; OE-group (n = 166): chemotherapy + OE for more than 6 months)." | ( Bock, PR; Chabronová, I; Dedík, L; Gazová, S; Hanisch, J; Holomanova, D; Hrubisko, M; Mistrík, M; Sakalová, A; Schiess, W, 2001) |
| "We report on three patients with multiple myeloma who developed drug-induced pneumonitis 1-2(1/2) months following maintenance (post autologous transplantation) chemotherapy with CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) and 6-20 months after exposure to carmustine (BCNU) 300 mg/m(2), used in combination with melphalan 140 mg/m(2), as pre-transplant conditioning regimen." | ( Cottler-Fox, M; Fassas, A; Gojo, I; Meisenberg, B; Papadimitriou, JC; Rapoport, A; Tricot, G, 2001) |
| "Treatment of Multiple Myeloma in the Elderly: Consensus of the Cooperative Group of Geriatric Oncology of the DGHO and DGG Multiple myeloma is an illness of old age." | ( Bokemeyer, C; Genvresse, I; Späth-Schwalbe, E; Wedding, U, 2001) |
| "Patients with multiple myeloma and other forms of cancer receiving pamidronate via intravenous (IV) infusion at the Hamilton Regional Cancer Centre in Hamilton, Ontario, Canada face 2 treatment options: they can have their entire treatment completed at the clinic using traditional IV therapy (e." | ( Broadfield, L; Coyte, PC; Dobrow, MJ, 2001) |
| "Data on all patients with multiple myeloma who attended the Hamilton Regional Cancer Centre for pamidronate therapy from November 1, 1997 to October 31, 1998 were collected from clinic records." | ( Broadfield, L; Coyte, PC; Dobrow, MJ, 2001) |
| "Treatment for multiple myeloma should not be given until the patient is symptomatic or at risk for the occurrence of complications of the disease." | ( Kyle, RA, 2001) |
| "In 22 multiple myeloma patients, immunohistochemical, CD34-stained, paraffin-embedded bone marrow biopsies before and after chemotherapy were studied." | ( Eucker, J; Heider, U; Jakob, C; Kaufmann, O; Niemöller, K; Possinger, K; Sezer, O; Zavrski, I, 2001) |
| "Patients with multiple myeloma (MM) refractory to chemotherapy can only benefit from supportive measures and have a very short survival." | ( Bladé, J; Esteve, J; Montoto, S; Montserrat, E; Perales, M; Rosiñol, L; Tuset, M, 2001) |
| "Three cases of multiple myeloma treated with thalidomide are presented which highlight therapeutic dilemmas presented by therapy with this new agent." | ( Desikan, RK; Jagannath, S, 2001) |
| "Patients with advanced multiple myeloma (n=27) were treated with an oral dose of thalidomide (median 400 mg/day)." | ( Attal, M; Beris, P; Berthou, C; Duguet, C; Dumontet, C; Facon, T; Grosbois, B; Harousseau, JL; Leyvraz, S; Moreau, P; Payen, C; Yakoub-Agha, I, 2000) |
| "Thromboembolism is not uncommon in multiple myeloma (MM) patients on treatment, but its pathogenesis remains poorly understood." | ( Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Fassas, A; Fink, L; Mehta, P; Morris, C; Saghafifar, F; Siegel, E; Toor, A; Tricot, G; Whitfield, D; Zangari, M, 2002) |
| "13 patients with treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronate and thalidomide therapy." | ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
| "Additionally, multiple myeloma is primarily a disease of the elderly, many of whom cannot tolerate aggressive chemotherapy." | ( Hussein, MA, 2002) |
| "The role of maintenance therapy in multiple myeloma is controversial." | ( Barlogie, B; Berenson, JR; Briggs, AD; Crowley, JJ; Grogan, TM; Mills, GM; Salmon, SE; Zangmeister, J, 2002) |
| "Patients with multiple myeloma stage II or III were randomly assigned to receive either ibandronate 2 mg or placebo as a monthly intravenous (IV) bolus injection for 12 to 24 months in addition to conventional chemotherapy." | ( Boewer, C; Delmas, PD; Euller-Ziegler, L; Facon, T; Fiere, D; Fontana, A; Herrmann, Z; Hrubisko, M; Lichinitser, MR; Menssen, HD; Sakalová, A; Singer, CR; Thiel, E; Wetterwald, M, 2002) |
| "Thirty relapsing or resistant multiple myeloma (MM) patients were treated with THAL at a median dose of 400 mg/daily." | ( Bojarska-Junak, A; Dmoszyńska, A; Domański, D; Hus, M; Roliński, J; Soroka-Wojtaszko, M, 2002) |
| "Progressive multiple myeloma may manifest features of 'de-differentiation', including a plasmablastic appearance, failure to secrete paraprotein, extramedullary involvement, and resistance to treatment." | ( Balmaceda, C; Mansukhani, M; Mears, JG; Orazi, A; Rescigno, J; Savage, DG; Shendrik, I, 2002) |
| "A 61-year-old woman had been treated for multiple myeloma for 4 years when she developed abdominal pain." | ( Fukumitsu, H; Hoshikawa, T; Ishikawa, K; Makuuchi, H; Nasu, S; Sadahiro, S; Shibuya, M; Shimakura, Y; Suzuki, T; Tajima, T; Yasuda, S; Yazawa, N, 2001) |
| "Of patients presenting with multiple myeloma, 5% to 15% satisfy criteria for the diagnosis of multiple myeloma but have no or minimal symptoms and do not require chemotherapy (NRC)." | ( Greipp, PR, 2000) |
| "17 patients with multiple myeloma were treated by high-dose chemotherapy regimen." | ( Kmonícek, M; Kopecký, O; Krejsek, J; Maisnar, V; Malý, J; Tousková, M, 2002) |
| "Preliminary data from the multiple myeloma phase II study indicate that a significant number of patients responded to therapy or exhibited stable disease and that the drug had manageable toxicities." | ( Schenkein, D, 2002) |
| "We report a patient with multiple myeloma who was treated with pamidronate disodium every 3 weeks for 18 months without any other chemotherapeutic agents." | ( Kondo, H; Mori, A, 2002) |
| "Recipients of a BMT or PBSCT who have multiple myeloma and are receiving cyclosporine or multiple nephrotoxic drugs at the start of amphotericin B therapy should be considered at high risk for developing amphotericin B-associated nephrotoxicity." | ( Anaissie, E; Gubbins, PO; McConnell, SA; Penzak, SR; Polston, S, 2002) |
| "After myeloablative therapy for multiple myeloma, progression-free survival is shorter for disease in partial remission rather than complete remission." | ( Alexanian, R; Delasalle, K; Giralt, S; Weber, D, 2002) |
| "Twenty-one patients with multiple myeloma were identified with disease in stable partial remission after prior intensive therapy." | ( Alexanian, R; Delasalle, K; Giralt, S; Weber, D, 2002) |
| "In patients with multiple myeloma, a good complete response rate and disease-free survival may be achieved with sequential chemotherapy using VAD and VMCP, which is an alternative effective and less expensive treatment regimen." | ( Kochupillai, V; Kumar, L; Wadhwa, J, 2002) |
| "Patients with advanced multiple myeloma (n=83) were treated with an oral dose of thalidomide (median 400 mg/day)." | ( Attal, M; Bay, JO; Berthou, C; Dauriac, C; Delannoy, V; Dorvaux, V; Duguet, C; Duhamel, A; Dumontet, C; Facon, T; Grosbois, B; Harousseau, JL; Lamy, T; Monconduit, M; Moreau, P; Yakoub-Agha, I, 2002) |
| "In the absence of a cure for multiple myeloma (MM) with standard-dose therapy, any strategy that can be expected to increase tumor reduction and to extend survival duration is likely to be of clinical relevance." | ( Baccarani, M; Benni, M; Cavo, M; Cellini, C; Fiacchini, M; Gozzetti, A; Ronconi, S; Tosi, P; Tura, S; Zamagni, E, 2002) |
| "Thirty-two patients with multiple myeloma were treated with high doses of 166Ho-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonic acid (DOTMP) and were a subset of patients enrolled in a multicenter phase I/II dose escalation myeloablative trial." | ( Bensinger, W; Durack, LD; Eary, JF; Fritzberg, A; Rajendran, JG; Vernon, C, 2002) |
| "In patients with multiple myeloma, autologous transplantation with high-dose chemotherapy preceded allogeneic transplantation possible after dose-reduced conditioning (Tandem protocol; n = 6)." | ( Kolb, HJ; Ledderose, G; Schleuning, M; Schmid, C; Stötzer, O; Weisser, M, 2002) |
| "Patients with multiple myeloma (MM) have increased bone marrow angiogenesis, a low plasma cell labeling index, and multidrug resistance (the primary cause of chemotherapy failure)." | ( Bukowski, RM; Elson, P; Hsi, E; Hussein, MA; Karam, M; Srkalovic, G; Wood, L, 2002) |
| "The treatment of multiple myeloma still remains under investigation." | ( Awedan, AA, 2002) |
| "Patients with multiple myeloma (MM) invariably relapse with chemotherapy-resistant disease, underscoring the need for new agents that bypass these resistance mechanisms." | ( Bahlis, NJ; Boise, LH; Eckman, J; Fernandez, HF; Goodman, M; Jordan-McMurry, I; Kharfan-Dabaja, M; Lee, KP; McCafferty-Grad, J; Neil, J; Reis, I, 2002) |
| "Patients (n = 69) with multiple myeloma undergoing peripheral blood stem cell collection (PBSC) were treated with cyclophosphamide and a combination of recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF, filgrastim) and recombinant methionyl human stem cell factor (r-metHuSCF, ancestim)." | ( Belch, A; Bence-Buckler, I; Bhatia, M; Chin-Yee, IH; Couban, S; Foley, R; Howson-Jan, K; Keeney, M; Paragamian, V; Rubinger, M; Stewart, AK; Stewart, D; Sutherland, R, 2002) |
| "109 patients with multiple myeloma, observed between 1985 and 2000, were treated with cMP; 67 were treated at time of diagnosis (group A; median age 78 years) and 42 as a second or subsequent line of therapy (group B; median age 72 years)." | ( Cavalieri, E; Falcucci, P; La Verde, G; Mandelli, F; Matera, R; Petrucci, MT; Pulsoni, A; Tosti, ME; Villivà, N, 2002) |
| "The treatment of Multiple Myeloma (MM), a malignant plasma cell disorder has changed considerably over the past decade." | ( Segeren, CM; Sonneveld, P, 2003) |
| "Despite the fact that multiple myeloma is a unique entity, defined by the accumulation of malignant plasma cells, a marked heterogeneity is observed among patients (regarding biological and clinical presentation, response to treatment, or survival)." | ( Minvielle, S, 2003) |
| "In contrast, urine samples from seven multiple myeloma patients at steady state levels of thalidomide therapy showed the presence of only three hydrolysis breakdown products and no hydroxylated metabolites." | ( Baguley, BC; Browett, P; Ching, LM; Kestell, P; Lu, J; Muller, G; Palmer, BD, 2003) |
| "Treatment regimens for multiple myeloma are evolving because of new advances in both pharmacotherapy and transplantation strategies." | ( Weber, DM, 2003) |
| "Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i." | ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003) |
| "Twenty-one patients with untreated multiple myeloma were evaluated." | ( Nagai, M; Nishiyama, Y; Ohkawa, M; Satoh, K; Yamamoto, Y, 2003) |
| "Current treatment in multiple myeloma consists of three courses of chemotherapy in low doses with subsequent hematopoietic stem cell mobilization to the peripheral blood using high-dose cyclophosphamide, collection and conditioning with high-dose chemotherapy (melphalan) followed by retransplantation of autologous peripheral blood stem cells (PBSCT)." | ( Awedan, A; Blajer, B; Król, M; Rokicka, M; Torosian, T; Urbanowska, E; Wiktor-Jedrzejczak, W, 2003) |
| "In patients with multiple myeloma (MM) who may ultimately receive active therapy, the combination of VAD (vincristine, doxorubicin, and dexamethasone) has been shown to be effective." | ( Hussein, M, 2003) |
| "Because it targets multiple myeloma and, when associated with an antineoplastic agent, produces therapeutic responses in patients with fewer side effects, LDE has the potential for use as a drug vehicle in the treatment of the disease." | ( Bydlowski, SP; Chiattone, CS; Hungria, VT; Latrilha, MC; Maranhão, RC; Rodrigues, DG, 2004) |
| "Patients with multiple myeloma (MM) with mutated RAS are less likely to respond to chemotherapy and have a shortened survival." | ( Adjei, AA; Ahmann, G; Alsina, M; Belle, AN; Bruzek, LM; Cantor, AB; Dalton, WS; Djulbegovic, B; Fonseca, R; Gerbino, E; Greipp, PR; Kaufmann, SH; Overton, RM; Price-Troska, T; Sebti, SM; Sullivan, D; Wilson, EF; Wright, JJ, 2004) |
| "Thalidomide is a promising therapy for multiple myeloma." | ( Barbero, P; Bergamasco, B; Bergui, M; Bertola, A; Boccadoro, M; Ciaramitaro, P; Cocito, D; Durelli, L; Isoardo, G; Palumbo, A, 2004) |
| "A 55-year-old male affected by multiple myeloma received radiation therapy both on his left coxofemoral area, and lumbar region (D11-L1)." | ( Alessandrino, PE; Ardigò, M; Borroni, G; Borroni, RG; Brazzelli, V; Franchini, P; Martinoli, S; Vassallo, C, 2004) |
| "Treatment regimens for multiple myeloma are evolving because of new advances in both pharmacotherapy and transplantation strategies." | ( Greipp, P, 2004) |
| "Since multiple myeloma responds poorly to conventional chemotherapy or radiotherapy, new therapeutic approaches are needed." | ( Aydin, F; Boruban, C; Esen, N; Kavgaci, H; Ovali, E; Ozdemir, F; Tekelioglu, Y; Yilmaz, M, 2004) |
| "Standard treatment for patients with multiple myeloma is debulking chemotherapy with non-alkylating agents followed by a regimen to mobilize peripheral blood stem cells (PBSC) and the transplantation of the mobilized, autologous PBSC." | ( Alessandrino, EP; Banfi, L; Barbarano, L; Cairoli, R; Corso, A; De Paoli, A; Fava, S; Ferrari, D; Fiumanò, M; Frigerio, G; Isa, L; Klersy, C; Lazzarino, M; Luraschi, A; Mangiacavalli, S; Morra, E; Perego, D; Pinotti, G; Savarè, M; Ucci, G; Uziel, L; Vergani, C; Vismara, A; Zappasodi, P, 2004) |
| "From 1998 to 2002, 120 patients with multiple myeloma were treated with melphalan/fludarabine followed by allogeneic stem cell transplantation." | ( Alegre, A; Ayuk, F; Beyer, J; Brand, R; Fauser, A; Kiehl, M; Klingemann, H; Kröger, N; Leon, A; Martino, R; Myint, H; Nagler, A; Perez-Simon, JA; San Miguel, JF; Sayer, HG; Schwerdtfeger, R; Shimoni, A; Tomas, JF; Zabelina, T; Zander, AR, 2004) |
| "Thalidomide is effective in multiple myeloma (MM), even in patients who have relapsed after high-dose therapy." | ( Attal, M; Blaise, D; Bulabois, CE; Cahn, JY; Facon, T; Garban, F; Gratecos, N; Jouet, JP; Marit, G; Mohty, M; Rio, B; Sotto, JJ; Vernant, JP; Yakoub-Agha, I, 2005) |
| "Sixteen patients with stage III multiple myeloma (MM) and a median age of 51 years were treated with autografting followed by reduced intensity conditioning allotransplantation (RICT)." | ( Beltrami, G; Carella, AM; Corsetti, MT; Musto, P; Scalzulli, P, 2004) |
| "Although multiple myeloma (MM) is sensitive to chemotherapy and radiation therapy, long-term disease-free survival is rare, and MM remains incurable despite conventional and high-dose therapies." | ( Cardinale, G; Gervasi, F; Pagnucco, G, 2004) |
| "In patients with relapsed, refractory multiple myeloma who had received a median of six prior regimens, treatment with bortezomib resulted in a 35% response rate (complete plus partial plus minimal response) using criteria of the European Group for Blood and Marrow Transplantation." | ( Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG, 2005) |
| "Patients with multiple myeloma (MM) typically respond to initial chemotherapy, but almost all patients relapse with a median survival of approximately 5 years." | ( Anderson, KC; Hussein, MA, 2004) |
| "Novel treatment strategies for multiple myeloma include replacing conventional doxorubicin with pegylated liposomal doxorubicin and reducing the dexamethasone dose (DVd) in the widely accepted VAD (vincristine, conventional doxorubicin, dexamethasone) regimen to improve the safety profile." | ( Hussein, MA, 2004) |
| "Cultured multiple myeloma cells were treated with various 4-OHT concentrations and the cellular response was studied: cell proliferation, cell viability, induction of apoptosis, caspase activities, and expression of signaling proteins." | ( Gauduchon, J; Gouilleux, F; Maillard, S; Marsaud, V; Renoir, JM; Sola, B, 2005) |
| "Novel therapies that can target the multiple myeloma (MM) cell, the MM cell-patient bone marrow interaction, and the bone marrow milieu can overcome resistance to conventional therapy in preclinical models and clinical trials." | ( Anderson, KC, 2004) |
| "We report the case of a patient with multiple myeloma in prolonged neutropenia after primary failure of an autologous stem cell graft who developed invasive aspergillosis despite voriconazole monotherapy." | ( Dinser, R; Grgic, A; Kim, YJ; Pfreundschuh, M; Schubert, J, 2005) |
| "Treatment regimens for multiple myeloma are evolving because of advances in both pharmacotherapy and transplantation strategies." | ( Anderson, KC; Palumbo, A, 2005) |
| "In 20 patients with multiple myeloma who had received or were receiving chemotherapy, (99m)Tc-sestamibi and (99m)Tc-V-DMSA scanning was performed to evaluate the effectiveness of chemotherapy." | ( Anagnostopoulos, A; Athanasoulis, T; Dimopoulos, MA; Koutsikos, J; Passadi, M; Velidaki, A; Zerva, C, 2005) |
| "Standard therapy for multiple myeloma, which accounts for 10% of all hematologic malignancies, has been autologous stem cell transplantation (ASCT), alkylator-based chemotherapy, and corticosteroids." | ( Rajkumar, SV, 2005) |
| "(1) First-line treatment of multiple myeloma depends first and foremost on the patient's age." | ( , 2005) |
| "In the human multiple myeloma cell line IM-9, an autocrine IL-6 loop exists, which enables the cell to resist the effects of dexamethasone, a common treatment for multiple myeloma." | ( Cherry, JC; Farrar, WL; Hodge, DR; Munroe, DJ; Peng, B; Xiao, W, 2005) |
| "Patients with metastatic melanoma or multiple myeloma have a dismal prognosis because these aggressive malignancies resist conventional treatment." | ( Bennett, F; Bodner, B; Bonish, BK; Chaturvedi, V; Hendrix, MJ; Miele, L; Nickoloff, BJ; Pollock, PM; Qin, JZ; Rizzo, P; Stennett, L; Trent, JM; Ziffra, J, 2005) |
| "Twenty-one patients with multiple myeloma, all relapsed after frontline autologous stem cell transplantation and all relapsed again after or resistant to thalidomide (employed as second line treatment) received bortezomib (1." | ( Balleari, E; Boccadoro, M; Bodenizza, C; Carella, AM; Cascavilla, N; Catalano, L; Cavallo, F; Dell'Olio, M; Falcone, A; Greco, MM; Guglielmelli, T; La Sala, A; Mantuano, S; Melillo, L; Merla, E; Musto, P; Nobile, M; Palumbo, A; Sanpaolo, G; Scalzulli, PR; Spriano, M; Zambello, R, 2006) |
| "It is an effective treatment for multiple myeloma at disease recurrence and at diagnosis, both as a single agent and in combination with steroids or chemotherapy." | ( Bertola, A; Boccadoro, M; Callea, V; Cangialosi, C; Caravita, T; Falco, P; Grasso, M; Musto, P; Nunzi, M; Palumbo, A, 2005) |
| "Although the treatment of multiple myeloma has improved over the past decade, the disease remains incurable." | ( Bladé, J; Cibeira, MT; Rosiñol, L, 2005) |
| "Treatment in patients with multiple myeloma remain to be defined." | ( Avilés, A; Castañeda, C; Cleto, S; González, M; Huerta-Guzmán, J; Nambo, MJ; Neri, N; Talavera, A, 2005) |
| "More than 50,000 patients with multiple myeloma are estimated to have been treated with thalidomide to date." | ( Glasmacher, A; von Lilienfeld-Toal, M, 2005) |
| "Future therapy options for multiple myeloma may be directed at asymptomatic disease, as only symptomatic myeloma is treated currently." | ( Child, JA; Russell, N; Schey, S; Sonneveld, P, 2005) |
| "Treatment for multiple myeloma typically is chemotherapy, high-dose therapy with stem cell transplantation or radiation." | ( Attal, M; Blade, J; Boccadoro, M; Palumbo, A, 2005) |
"From 2000 to 2004, 152 patients with multiple myeloma aged | ( Astori, C; Bonfichi, M; Cafro, AM; Castagnola, C; Corso, A; Lazzarino, M; Mangiacavalli, S; Morra, E; Nosari, A; Pascutto, C; Rusconi, C; Troletti, D; Varettoni, M; Zappasodi, P, 2005) | |
| "Three multiple myeloma cell lines (LP1, RMI 8226, and U266) were treated with 213Bi-radiolabeled B-B4, a monoclonal antibody that recognizes syndecan-1 (CD138) 24 hours after paclitaxel (1 nmol/L) or doxorubicin (10 nmol/L) treatment." | ( Apostolidis, C; Barbet, J; Charrier, J; Chatal, JF; Cherel, M; Davodeau, F; Gouard, S; Supiot, S, 2005) |
| "Hepatic plasma cell infiltration of multiple myeloma can, in rare cases, manifest as acute cholestatic hepatitis, which may respond to treatment with corticosteroids." | ( Andus, T; Barth, C; Bosse, A, 2005) |
| "Therefore, a challenge for treating multiple myeloma is discovering drugs targeting not only myeloma cells but also osteoclasts and osteoblasts." | ( Abdallah, BM; Andersen, TL; Boissy, P; Delaissé, JM; Kassem, M; Plesner, T, 2005) |
| "Despite intensive therapy, multiple myeloma (MM) remains an incurable disease, and novel treatment approaches are therefore needed to improve outcome." | ( Bladé, J; Boccadoro, M; Cavenagh, J; Glasmacher, A; Jagannath, S; Lonial, S; Ludwig, H; Orlowski, RZ; San Miguel, J; Sonneveld, P, 2006) |
| "Since 1997, 32 newly diagnosed multiple myeloma patients responsive to DAV chemotherapy were autografted with idarubicin-intensified busulphan-melphalan (ida-bu-mel)." | ( Baldacci, E; Capria, S; de Propris, MS; Meloni, G; Petrucci, MT; Pulsoni, A; Ribersani, M, 2006) |
| "Treatment of patients with multiple myeloma has shown considerable progress these last two decades." | ( Leleu, X; Terriou, L; Yakoub-Agha, I, 2006) |
| "Fifty patients with multiple myeloma >or=75 years of age received primary treatment with melphalan (M) 8 mg/m(2) on days 1-4, dexamethasone (D) 12 mg/m2 on days 1-4 and 17-20 and thalidomide (T) 300 mg at bedtime on days 1-4 and 17-20." | ( Anagnostopoulos, A; Anagnostopoulos, N; Delibasi, S; Dimopoulos, MA; Katodritou, E; Kyrtsonis, MC; Maniatis, A; Pouli, A; Repoussis, P; Terpos, E; Vassou, A; Zervas, K; Zomas, A, 2006) |
| "Treatment options for patients with multiple myeloma are a rapidly progressing area of clinical and scientific development." | ( Kaufman, JL; Lonial, S; Sinha, R, 2006) |
| "Forty patients with multiple myeloma scheduled to receive melphalan 200 mg/m(2) followed by autologous stem cell transplantation were randomly assigned to receive oral cryotherapy or room temperature normal saline rinses 30 min before and for 6 h after high-dose therapy." | ( Bensinger, W; Garcia, P; Gooley, T; Holmberg, L; Lilleby, K; Maloney, DG; McDonnnell, P; Press, OW; Taber, R, 2006) |
| "FDA) for the treatment of multiple myeloma (MM) progressing after at least one prior therapy." | ( Farrell, AT; Kane, RC; Pazdur, R; Sridhara, R, 2006) |
| "A major limitation to the treatment of multiple myeloma by the thalidomide analogue CC-4047 (Actimid) is the development of a severe neutropenia." | ( Brown, KA; Macey, MG; McCarthy, DA; Schey, SA; Streetly, M, 2006) |
| "Although multiple myeloma (MM) is incurable with currently available treatments, the introduction of thalidomide and the development of safer and more active thalidomide analogues represent a major advance in the therapy of this disease." | ( Kumar, S; Rajkumar, SV, 2006) |
| "(1) When multiple myeloma relapses more than one year after initial treatment, the median survival time is only 12 to 15 months." | ( , 2006) |
| "We present two patients with multiple myeloma who developed osteonecrosis of the jaws on intravenous treatment with zolendronic acid and pamidronate, respectively." | ( Gregersen, H; Neumann, B, 2006) |
| "We describe a 76-year-old woman with multiple myeloma who was treated with dexamethasone and thalidomide." | ( Hanje, AJ; Meis, GM; Shamp, JL; Thomas, FB, 2006) |
| "We present a patient with multiple myeloma who was treated with melphalan and 4 years later developed acute erythroid leukemia." | ( Guo, C; Ibrahim, S; Inghirami, G; Sen, F, 2006) |
| "Although many multiple myeloma (MM) patients initially respond to cytotoxic therapy, most eventually relapse." | ( Burtrum, D; Ludwig, DL; Moore, MA; Wu, KD; Zhou, L, 2007) |
| "Despite advances in the treatment of multiple myeloma, it remains an incurable disease because of primary and secondary drug resistance." | ( Baumann, P; Emmerich, B; Meinhardt, G; Schmidmaier, R; Simsek, M, 2006) |
| "Current therapies for multiple myeloma include steroids, alkylating agents and high-dose chemotherapy with autologous stem cell transplant." | ( Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG, 2006) |
| "Although multiple myeloma (MM) remains an incurable disease, its treatment has improved over the past decade." | ( Arenillas, L; Bladé, J; Cibeira, MT; Mercadal, S; Muntañola, A; Salamero, O, 2006) |
| "Eight patients with refractory multiple myeloma were treated with clofarabine 4 mg/m2/day on days 1-5 of a 28 day cycle." | ( DiPersio, JF; Ruddell, A; Tomasson, MH; Uy, GL; Vij, R, 2006) |
| "In the 75 patients with multiple myeloma, lenalidomide was the treatment in 24 and lenalidomide and dexamethasone in 51." | ( Davis, MD; Dispenzieri, A; Rajkumar, SV; Sviggum, HP, 2006) |
| "Although treatable, multiple myeloma remains incurable in virtually all cases, with a median survival of 3-4 years." | ( Kenealy, M; Prince, HM, 2006) |
| "It was reported that multiple myeloma (MM)-patients suffer from a higher incidence of osteomyelitis and necrosis of the jaws than patients treated with bisphosphonates for other reasons." | ( Ayalon, S; Elad, S; Hamed, W; Regev, E; Yahalom, R; Yarom, N, 2006) |
| "Patients with multiple myeloma or chronic lymphocytic leukemia who were treated on thalidomide based-combination therapies were treated on low-dose warfarin (1 or 2 mg) continuously through the duration of their therapy." | ( Chanan-Khan, A; Depaolo, D; Dimicelli, L; Doran, V; Landrigan, B; Marshal, P; Miller, KC; Padmanabhan, S; Yu, J, 2006) |
| "A 60-year-old man with multiple myeloma (MM) (IgG-kappa, stage IIIA) had been treated with minodronate at 6 mg orally as a phase 1 clinical trial for myeloma bone disease for 13 months (total dose, 4032 mg)." | ( Akamatsu, S; Horiike, S; Inaba, T; Kanamura, N; Nomura, K; Okamoto, M; Shimazaki, C; Shimura, K; Taniguchi, K; Taniwaki, M; Uchida, R, 2006) |
| "We have treated 27 adults with multiple myeloma with single or tandem autologous SCT." | ( Chen, CK; Hattori, Y; Ikeda, Y; Isshiki, I; Kakimoto, T; Mori, T; Okamoto, S; Yokoyama, K, 2006) |
| "A reduced multiple myeloma risk was found among women who had used antilipid statin therapy [OR, 0." | ( Baris, D; Inskip, P; Landgren, O; Zahm, SH; Zhang, Y; Zheng, T, 2006) |
| "We report a 84 year-old man with multiple myeloma who developed spontaneous osteonecrosis of both jaws, after 36 months of therapy with zoledronate with a cumulative dose of 136 mg." | ( Agurto P, J; Anguita C, T; Laissle C, G; Roa E, I, 2006) |
| "Cure for multiple myeloma is rare; the success of treatment is measured by response, and length of remissions and survival." | ( Boccadoro, M; Cavenagh, J; Dicato, M; Harousseau, JL; Ludwig, H; San Miguel, J; Sonneveld, P, 2006) |
| "Nearly all patients with multiple myeloma (MM) relapse or become refractory to front-line therapy." | ( Avonto, I; Boccadoro, M; Bringhen, S; Corvatta, L; Falco, P; Leoni, P; Marconi, M; Offidani, M; Palumbo, A; Piersantelli, MN; Polloni, C, 2007) |
| "A 39-year-old male with multiple myeloma was admitted for treatment with melphalan and autologous stem cell reinfusion." | ( Hoorn, EJ; Zietse, R, 2007) |
| "For the management of multiple myeloma, high-dose chemotherapy, mainly melphalan with autologous stem cell transplantation, has become the standard treatment even for elderly patients less than 65 years of age." | ( Usui, N, 2007) |
| "The treatment of multiple myeloma has seen significant changes from the time of the initial use of cytotoxic agents such as melphalan, to the introduction of high-dose chemotherapy and stem cell transplantation, and most recently the era of novel targeted agents." | ( Anderson, KC; Ghobrial, IM; Hatjiharissi, E; Hideshima, T; Leleu, X; Mitsiades, C; Richardson, P; Schlossman, R, 2007) |
| "They have an impact on the multiple myeloma treatment strategies and on the disease course itself." | ( Hulin, C, 2007) |
| "Although multiple myeloma remains incurable with conventional treatments, management of the disease has recently been transformed with the introduction of three novel agents, bortezomib, thalidomide, and lenalidomide." | ( Anderson, K; Mitsiades, C; Munshi, N; Richardson, PG; Schlossman, R, 2007) |
| "One hundred de novo multiple myeloma patients with t(4;14) treated with double intensive therapy according to IFM99 protocols were retrospectively analyzed." | ( Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Caillot, D; Casassus, P; Chaleteix, C; Dib, M; Dorvaux, V; Doyen, C; Facon, T; Fuzibet, JG; Garban, F; Garderet, L; Grosbois, B; Harousseau, JL; Hulin, C; Jaubert, J; Kolb, B; Lamy, T; Leyvraz, S; Marit, G; Mathiot, C; Michallet, M; Mohty, M; Moreau, P; Traullé, C; Wetterwald, M; Yakoub-Agha, I, 2007) |
| "We present a patient with refractory multiple myeloma who showed a good response to a combination therapy with oral melphalan, dexamethasone, and thalidomide (MDT)." | ( Asou, N; Hata, H; Ide, K; Izuno, Y; Kawakita, M; Mitsuya, H; Okubo, T; Ueno, H, 2007) |
| "The treatment of multiple myeloma has seen significant changes from the initial use of melphalan to the introduction of stem cell transplantation and, most recently, to the era of novel targeted agents." | ( D'Auria, F; Musto, P, 2007) |
| "Standard frontline therapy for multiple myeloma comprises cytoreductive therapy with or without consolidative high-dose therapy plus stem cell transplantation (HDT-SCT)." | ( Chanan-Khan, AA; Manochakian, R; Miller, KC, 2007) |
| "Peripheral blood was collected from six multiple myeloma (MM) patients at serial time points in connection with treatment and during a follow-up period of 3 months." | ( Johnsen, HE; Nikolajsen, K; Svane, IM, 2007) |
| "The authors present a case of multiple myeloma status post chemotherapy and stem cell transplant with diffuse osseous and extramedullary lesions evaluated by PET/CT." | ( Nguyen, BD; Wiesenthal, AA, 2007) |
| "A substantial number of patients with multiple myeloma did not receive chemotherapy." | ( Coker, AL; Du, XL; Fang, S; Moye, LA; Rohatgi, N; Wang, M, 2007) |
| "To analyse clinical picture of multiple myeloma (MM) and treatment results in MM patients on programmed dialysis (PD)." | ( Biriukova, LS; Chavynchak, RB; Rekhtina, IG; Ryzhko, VV, 2007) |
| "Renal involvement in patients with multiple myeloma complicates their treatment and shortens their life-span." | ( Arimura, A; Batuman, V; Lertora, JJ; Li, M; Maderdrut, JL, 2008) |
| "Chemotherapy-susceptive multiple myeloma (MM) has an indication for high-dose melphalan (HDM) followed by autologous stem cell transplantation (auto-SCT)." | ( Aoyama, T; Imataki, O; Kawakami, K; Tamai, Y, 2007) |
| "As new therapeutic options for multiple myeloma (MM) emerge, identification of biological markers which could predict clinical response to standard treatment with high-dose melphalan (HDM) supported by autologous stem cell transplantation (ASCT) becomes more important." | ( Anagnostopoulos, A; Baltadakis, I; Bamia, C; Dimopoulos, MA; Kyrtopoulos, SA; Pouli, A; Sfikakis, PP; Souliotis, VL; Terpos, E, 2007) |
| "Despite high dose treatment regimes multiple myeloma (MM) disease is still not curable." | ( Armann, J; Baumann, P; Grün, G; Mandl-Weber, S; Oduncu, F; Schmidmaier, R, 2008) |
| "Although multiple myeloma patients often respond to initial therapy, the majority of patients will relapse with disease that is refractory to further drug treatment." | ( Congdon, LM; Dorr, RT; Escalante, AM; Landowski, TH; Pourpak, A, 2008) |
| "Although no cure exists for multiple myeloma, current treatments, such as oral melphalan and prednisone, can slow disease progression and prolong overall survival." | ( Faiman, B, 2007) |
| "The prognosis of patients with multiple myeloma has been improved in the last decade due to the induction of autologous stem cell transplantation and novel drugs including thalidomide, lenalidomide, and bortezomib into the treatment." | ( Handa, H; Murakami, H; Saitoh, T, 2007) |
| "For many years the treatment of multiple myeloma was limited to such regimens as melphalan-prednisone, high-dose dexamethasone, and vincristine-doxorubicin-dexamethasone (VAD)." | ( Richards, TA; Thomas, SK; Weber, DM, 2007) |
| "The risk of VTE is higher in multiple myeloma (MM) patients who receive thalidomide or lenalidomide, especially in combination with dexamethasone or chemotherapy." | ( Anderson, KC; Attal, M; Barlogie, B; Belch, A; Bladé, J; Boccadoro, M; Bringhen, S; Cavo, M; Dimopoulos, MA; Durie, BG; Harousseau, J; Hussein, MA; Joshua, D; Knop, S; Kyle, R; Lonial, S; Ludwig, H; Morgan, GJ; Niesvizky, R; Orlowski, RZ; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Shimizu, K; Sonneveld, P; Vesole, D; von Lilienfeld-Toal, M; Waage, A; Weber, D; Westin, J; Zangari, M; Zonder, JA, 2008) |
| "Seventy-four multiple myeloma patients (MM pts) uniformly treated, were retrospectively studied." | ( Barbarano, L; Corso, A; Fava, S; Lazzarino, M; Mangiacavalli, S; Mazzone, A; Montalbetti, L; Morra, E; Varettoni, M; Zappasodi, P, 2008) |
| "Cases of discordant responses in multiple myeloma (MM) patients after thalidomide therapy have been sometimes reported, in which extramedullary masses progress or present de novo with a simultaneous serum monoclonal protein reduction." | ( Bocchia, M; Bucalossi, A; Cerase, A; Defina, M; Gozzetti, A; Lauria, F; Pirrotta, MT, 2008) |
| "In 2006, multiple myeloma was diagnosed in a 72-year-old man, who received thalidomide-dexamethasone therapy." | ( Chu, PH; Jeng, WJ; Kuo, MC; Shih, LY, 2008) |
| "The treatment of elderly patients with multiple myeloma was based for the last forty years on the combination of alkeran plus prednisone." | ( Garderet, L; Gorin, NC; Isnard, F, 2008) |
| "Treatment of multiple myeloma has changed in recent years." | ( Boccadoro, M; Cavallo, F; Falco, P; Larocca, A; Liberati, AM; Musto, P; Palumbo, A, 2008) |
| "A total of 40 patients with multiple myeloma who had received either 1 or 2 previous treatment regimens were treated with bortezomib at a dose of 1." | ( Barton, J; Farley, C; Greco, FA; Hainsworth, JD; Hon, J; Schreeder, M; Spigel, DR, 2008) |
| "Front-line therapy for multiple myeloma is rapidly evolving with the development of new, highly active regimens based on novel agents such as bortezomib." | ( Anderson, KC; Ghobrial, I; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, PG; Schlossman, R, 2008) |
| "Although multiple myeloma (MM) remains incurable with conventional treatments including high-dose melphalan plus autologous stem cell transplantation, therapeutic strategy has been revised because of the recent introduction of a novel agent such as bortezomib (Bz)." | ( Ohashi, K, 2008) |
| "Smoldering multiple myeloma (SMM) is usually followed expectantly without therapy." | ( Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Hoering, A; Hollmig, K; Jenkins, B; Kumar, NS; Petty, N; Pineda-Roman, M; Shaughnessy, JD; Srivastava, G; Szymonifka, J; van Rhee, F; Yaccoby, S; Zeldis, JB, 2008) |
| "In newly diagnosed patients with multiple myeloma (MM), microarray data were obtained on tumor cells prior to and 48 hours after in vivo treatment using dexamethasone (n = 45) or thalidomide (n = 42); in the case of relapsed MM, microarray data were obtained prior to (n = 36) and after (n = 19) lenalidomide administration." | ( Barlogie, B; Burington, B; Crowley, J; Shaughnessy, JD; Zhan, F, 2008) |
| "We treated six different multiple myeloma cell lines with a Thiadiazolidinone (TDZD), a non-competitive inhibitor of GSK3 and determined its effects on proliferation and apoptosis." | ( Kang, JA; Uddin, S; Ulaszek, J; Wickrema, A; Zhou, Y; Zimmerman, T, 2008) |
| "The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone." | ( Abdulkadyrov, KM; Anderson, KC; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H, 2008) |
| "A diagnosis of erythrophagocytic multiple myeloma was made and treatment with prednisone and melphalan was begun." | ( Almy, F; Chary, P; Northrup, N; Webb, J, 2008) |
| "We treated a patient with multiple myeloma (MM), who was not responding to preceding chemotherapy, who coincidently received therapy with CEP due to thrombocytopenia." | ( Harada, N; Hata, H; Kamizaki, Y; Kikukawa, Y; Mitsuya, H; Nakamura, M; Okuno, Y; Tatetsu, H; Ueno, S, 2008) |
| "To summarize the results of treatment of multiple myeloma in the era of novel agents." | ( Bladé, J; Rosiñol, L, 2008) |
| "Treatment options for patients with multiple myeloma (MM) have increased dramatically with the availability of novel agents." | ( Lonial, S, 2008) |
| "Maintenance therapy was explored in multiple myeloma (MM) patients after conventional thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD)." | ( Alesiani, F; Brunori, M; Burattini, M; Candela, M; Catarini, M; Centurioni, R; Corvatta, L; Ferranti, M; Galieni, P; Gentili, S; Giuliodori, L; Leoni, P; Marconi, M; Mele, A; Offidani, M; Piersantelli, MN; Polloni, C; Samori, A; Visani, G, 2009) |
| "Treatment of multiple myeloma cell lines and patient tumor cells with INCB20 resulted in a significant and dose-dependent inhibition of spontaneous as well as IL-6-induced cell growth." | ( Anderson, KC; Burger, R; Catley, L; Caulder, E; Chauhan, D; Fridman, JS; Gramatzki, M; Hideshima, T; Le Gouill, S; Li, J; Neilan, CL; Neri, P; Podar, K; Shringarpure, R; Tai, YT; Tassone, P; Vaddi, K, 2009) |
| "Human multiple myeloma (MM) cell lines U266, NCI-H929, RPMI 8226, LP-1 and CZ-1 were treated with TH or TH pre-incubated with human liver microsome." | ( Hou, J; Huang, HM; Jiang, H; Li, YH; Zhu, R, 2008) |
| "In patients with smoldering or indolent multiple myeloma who were at risk of progression to active myeloma, treatment with IL-1 inhibitors decreased the myeloma proliferative rate and hs-CRP levels in those who responded, leading to a chronic disease state and an improved PFS." | ( Buadi, FK; Campbell, ME; Dispenzieri, A; Donovan, KA; Gertz, MA; Geyer, SM; Greipp, PR; Hayman, SR; Kline, MP; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Moon-Tasson, LL; Rajkumar, SV; Russell, SJ; Witzig, TE; Xiong, Y; Zeldenrust, SR, 2009) |
| "A 65-year-old male with IgG-kappa multiple myeloma was treated with melphalan-prednisolone (MP) and obtained a minimal response." | ( Handa, H; Karasawa, M; Koiso, H; Mawatari, M; Murakami, H; Nojima, Y; Osaki, Y; Saitoh, T; Sekigami, T; Tahara, K; Tsukamoto, N; Uchiumi, H; Yokohama, A, 2009) |
| "Treatment strategies for multiple myeloma have changed substantially over the past 10 years following the introduction of bortezomib and the immunomodulatory drugs thalidomide and lenalidomide." | ( Cavenagh, J; Lonial, S, 2009) |
| "We screened 49 consecutive multiple myeloma patients treated with thalidomide at baseline for hypercoagulability." | ( Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M, 2009) |
| "In patients with multiple myeloma, prior lenalidomide therapy is associated with failure of stem cell mobilization with filgrastim." | ( Alousi, A; Anderlini, P; Andersson, B; Champlin, R; de Lima, M; Giralt, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Körbling, M; McMannis, J; Nieto, Y; Popat, U; Qazilbash, M; Saliba, R; Shpall, E; Thandi, R; Thomas, S; Wang, M; Weber, D, 2009) |
| "Forty (26 multiple myeloma and 14 non-Hodgkin's lymphoma) patients were treated with plerixafor." | ( Badel, K; Bensinger, WI; Bridger, G; Calandra, G; Dehner, C; Dugan, MJ; Gibney, C; Liesveld, J; Maziarz, RT; Nademanee, A, 2010) |
| "Patients with multiple myeloma (MM) achieving high-quality responses, defined as a complete response (CR) and a very good partial response (VGPR) after transplant, benefit from high-dose therapy followed by autologous stem cell transplantation (ASCT)." | ( Cho, BS; Eom, HS; Kim, CC; Kim, M; Kim, Y; Lee, JW; Lee, S; Min, CK; Min, WS, 2009) |
| "A 68-year-old man with multiple myeloma was admitted to our hospital complaining of slight fever and dyspnea on effort 4 months after treatment with thalidomide." | ( Hasejima, N; Matsushima, H; Oda, T; Sato, A; Takezawa, S; Yamamoto, M, 2009) |
| "Treating multiple myeloma cells with 5-aza-2'-deoxycytidine restored sensitivity to dexamethasone." | ( Asaoku, H; Hayashi, T; Imai, K; Ishida, T; Maruyama, R; Maruyama, Y; Mori, M; Nojima, M; Sakai, H; Sasaki, Y; Shinomura, Y; Suzuki, H; Tarasawa, I; Tokino, T; Toyota, M; Yasui, H, 2009) |
| "High-quality response to multiple myeloma (MM) therapy can be predictive for improved outcomes." | ( Camacho, ES; Crowley, J; Durie, BG; Gabayan, AE; Irwin, D; Jagannath, S; Lutzky, J; Mazumder, A; McKinley, M; Potts, P; Vescio, R; Wolf, JL, 2009) |
| "In the refractory multiple myelomas, other drug regimens have been successfully applied, including thalidomide treatments." | ( Dufer, J; Gorisse, MC; Lavenus, S; Trussardi-Regnier, A, 2009) |
| "We studied 55 patients with multiple myeloma (MM) who received bortezomib as first line therapy and 70 pre-treated patients who received bortezomib in relapse or progression." | ( Corso, A; Lazzarino, M; Mangiacavalli, S; Pascutto, C; Varettoni, M; Zappasodi, P, 2010) |
| "Contrary to Total Therapy (TT) 2 for multiple myeloma patients, FGFR3- translocation bore no adverse effects on outcome in TT3 with added bortezomib." | ( Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Haessler, J; Nair, B; Shaughnessy, JD; van Rhee, F; Waheed, S; Zhou, Y, 2009) |
| "The association of acute leukemia and multiple myeloma (MM) has been usually described not only as a complication of chemotherapy but also in the absence of chemotherapy or together at the time of diagnosis." | ( Erikci, AA; Ozturk, A; Sayan, O; Tekgunduz, E, 2009) |
| "Monoclonal antibody (mAb) therapy for multiple myeloma, a malignancy of plasma cells, has not been clinically efficacious in part due to a lack of appropriate targets." | ( Afar, DE; Balasa, B; Barlogie, B; Chao, D; Dillon, M; Ganguly, B; Garg, TK; Li, X; Moreno-Bost, AM; Rice, AG; Shaughnessy, JD; Shi, J; Stone, MK; Szmania, SM; van Abbema, AM; van Rhee, F; Yaccoby, S; Yun, R; Zhan, F, 2009) |
| "The initial treatment of multiple myeloma (MM) experienced a paradigm shift, in the past decade, with the introduction of novel agents such as thalidomide, lenalidomide and bortezomib, leading to improved outcomes." | ( Cheng, Z; Geng, F; Li, S; Pan, L; Wang, S; Xue, F; Yang, X, 2009) |
| "Although outcomes for patients with multiple myeloma (MM) have improved over the past decade, the disease remains incurable and even patients who respond well to induction therapy ultimately relapse and require additional treatment." | ( Anderson, KC; Carreau, N; Ghobrial, IM; Hideshima, T; Laubach, JP; Mahindra, A; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL, 2009) |
| "A novel treatment for multiple myeloma is bortezomib, a proteasome inhibitor that has shown significant in vitro and in vivo activity." | ( Stadtmauer, EA, 2004) |
| "A 74-year-old man with multiple myeloma was refractory to melphalan/prednisolone (MP), high-dose dexamethasone and VAD chemotherapy." | ( Kakimoto, T; Mihara, A; Nakazato, T; Sanada, Y; Suzuki, K, 2009) |
| "Monitoring of bone disease in multiple myeloma is becoming increasingly important because bone-protecting treatment with bisphosphonate is becoming restricted after the awareness of osteonecrosis of the jaw." | ( Abildgaard, N; Andersen, TL; Delaisse, JM; Lund, T; Plesner, T, 2010) |
| "The treatment of multiple myeloma (MM) has undergone significant developments in recent years." | ( Beksac, M; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Ketterer, N; Kropff, M; Ludwig, H; Mendeleeva, L; Morgan, G; Palumbo, A; Plesner, T; San Miguel, J; Shpilberg, O; Sondergeld, P; Sonneveld, P; Zweegman, S, 2010) |
| "Ten consecutive patients with multiple myeloma who underwent first-time CT treatment with high-dose melphalan (200 mg/m(2)) and ASCT were included in this study." | ( Biemond, BJ; Cheung, YW; Ince, C; Lindeboom, JA; Milstein, DM; te Boome, LC; van den Akker, HP, 2010) |
| "A 65-year-old female with relapsed multiple myeloma developed fluid retention, ascites, and general anasarca following bortezomib administration (1." | ( Chang, H; Hsiao, SC; Pei, SN; Wang, MC, 2010) |
| "In patients with multiple myeloma, bendamustine monotherapy is effective as 1st and 2nd line therapy." | ( Bölke, E; Bruns, I; Czibere, A; Fenk, R; Haas, R; Kobbe, G; Michael, M; Neumann, F; Safaian, NN; Zohren, F, 2010) |
| "The drug is indicated for treatment of multiple myeloma and other hematologic disorders and has rarely been associated with pulmonary toxicity." | ( Chen, Y; Kiatsimkul, P; Nugent, K; Raj, R, 2010) |
| "Recent advances in the treatment of multiple myeloma have resulted in improved response rates and overall survival in patients with multiple myeloma." | ( Richards, T; Weber, D, 2010) |
| "Factors that affect the response of multiple myeloma patients to thalidomide were evaluated in 40 patients who were not eligible for chemotherapy (untreated: 14, relapse/refractory: 26)." | ( Agata, M; Ishiyama, M; Kazama, H; Kondo, T; Mori, N; Motoji, T; Oda, T; Okamura, T; Sagawa, K; Sameshima, Y; Shiseki, M; Teramura, M; Yamada, O; Yasunami, T; Yoshinaga, K, 2010) |
| "LBH589 may be very effective in multiple myeloma after a multitude of preceding treatments that could not induce a long-term anti-myeloma effect." | ( Goldschmidt, H; Ho, AD; Schmitt, S, 2010) |
| "Of 289 elderly patients with multiple myeloma who were randomized to thalidomide-dexamethasone or melphalan-prednisolone induction therapy, 137 finally completed 9 cycles of induction therapy with stable disease or better and thereby qualified for maintenance treatment." | ( Adam, Z; Drach, J; Egyed, M; Gisslinger, H; Hajek, R; Hinke, A; Kuhn, I; Labar, B; Ludwig, H; Spicka, I; Tóthová, E; Zojer, N, 2010) |
| "Despite recent advances in treatment, multiple myeloma (MM) remains an incurable malignancy." | ( Blanco-Prieto, MJ; Campanero, MA; de la Iglesia-Vicente, J; Estella-Hermoso de Mendoza, A; Gajate, C; Mollinedo, F; Villa-Pulgarin, JA, 2010) |
| "Lenalidomide is an active treatment for multiple myeloma (MM) and is increasingly used as part of the initial treatment of this disease." | ( Cook, R; Cunningham, K; Gardler, M; Hummel, K; Luger, SM; Mangan, PA; Nazha, A; O'Doherty, U; Porter, DL; Schuster, S; Siegel, D; Stadtmauer, EA; Vogl, DT, 2011) |
| "The treatment of multiple myeloma has undergone significant changes in the recent past." | ( Bargetzi, M; Betticher, D; Gmür, J; Gregor, M; Heim, D; Hess, U; Ketterer, N; Lerch, E; Matthes, T; Mey, U; Pabst, T; Renner, C; Taverna, C, 2010) |
| "A 67-year-old woman with refractory multiple myeloma was admitted to our hospital for salvage therapy." | ( Hamanaka, S; Iwao, N; Kirito, K; Komatsu, N; Mitsumori, T; Nagashima, T; Nakajima, K; Nozaki, Y, 2010) |
| "The outcome of patients with multiple myeloma has dramatically improved in the past decade, due to the introduction of new, more effective treatments, wider use of high-dose therapy, and better appreciation of potential complications and their management." | ( Kumar, S, 2010) |
| "21 and 31 multiple myeloma patients were enrolled in the PD and VAD groups respectively which received 2 to 5 courses of treatments, and both clinical effects and adverse reactions were observed." | ( Bo, J; Gao, CJ; Han, XP; Huang, WR; Jing, Y; Li, HH; Wang, SH; Yu, L; Zhao, Y; Zhu, HY, 2010) |
| "We studied four multiple myeloma cell lines treated with the KSP inhibitor ARRY-520 to identify factors important for initiating apoptosis while cells are arrested in mitosis." | ( Tunquist, BJ; Walker, DH; Woessner, RD, 2010) |
| "We report 13 multiple myeloma (MM) or lymphoma patients who were failing PBSC mobilization after disease-specific chemotherapy and granulocyte-CSF (G-CSF), and received plerixafor to successfully collect PBSCs." | ( Agis, H; Baccarani, M; Casadei, B; Curti, A; D'Addio, A; Dan, E; Douglas, K; Giudice, V; Kopetzky, G; Lemoli, RM; Motta, MR; Rizzi, S; Soutar, R; Taioli, S; Worel, N, 2011) |
| "In all, 22 multiple myeloma patients were treated with EPOCH-F before RI-alloHSCT." | ( Bishop, MR; Bryant, K; Dean, RM; Fowler, DH; Hakim, F; Jamshed, S; Neelapu, SS; Odom, J; Steinberg, SM, 2011) |
| "We show here that treatment of human multiple myeloma (MM) cells with 17DMAG induces mTOR inhibition and microtubule-associated protein light chain 3 (LC3) conversion (LC3-I to LC3-II), an indicator of autophagy." | ( López-Pérez, AI; López-Rivas, A; Martín-Pérez, R; Palacios, C; Pandiella, A, 2010) |
| "Patients with multiple myeloma progressing on current therapies have limited treatment options." | ( Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V; Russell, SJ; Short, KD; Stewart, AK; Zeldenrust, S, 2010) |
| "Patients with multiple myeloma (MM) are at relatively high risk of developing thromboembolic event (TEE), especially during treatment with immunomodulatory agents." | ( Guo, H; Jiang, Y; Shen, Y; Sun, C; Tong, Y; Wang, J; Wang, Z; Yang, G; Zhou, X, 2011) |
| "We describe a patient with multiple myeloma who developed a pandemic influenza A (H1N1) 2009 virus infection during chemotherapy." | ( Choi, SH; Hong, EH; Kim, MN; Kim, MS; Kim, SH; Kim, YS; Lee, JH; Lee, SO; Park, KH; Woo, JH; Yi, H, 2011) |
| "Patients with multiple myeloma who were starting antimyeloma treatment were randomly assigned in a 1:1 ratio to receive one of two doses of pamidronate (30 mg or 90 mg) given by intravenous infusion once a month for at least 3 years." | ( Abildgaard, N; Ahlberg, L; Andersen, NF; Carlson, K; Dahl, IM; Fayers, P; Gimsing, P; Gluud, C; Gregersen, H; Hjorth, M; Hjorth-Hansen, H; Juliusson, G; Knudsen, LM; Linder, O; Mylin, A; Nesthus, I; Nielsen, JL; Turesson, I; Vangsted, A; Waage, A; Westin, J; Wisløff, F, 2010) |
| "The treatment of multiple myeloma has undergone significant changes in the last few years." | ( Mey, UJ, 2010) |
| "A case of relapsed multiple myeloma (MM) with multiple plasmacytomas of the parietal bone and the right orbit in which was achieved a complete response with bortezomib plus dexamethasone (BD) therapy is reported." | ( Fujita, Y; Fukushima, T; Hirose, Y; Iwao, H; Masaki, Y; Miki, M; Nakajima, A; Nakamura, T; Sakai, T; Sawaki, T; Tanaka, M; Umehara, H, 2010) |
| "The treatment of multiple myeloma (MM) has changed with the advent of thalidomide, bortezomib, and lenalidomide, the so-called novel agents (NAs)." | ( Barnett, MJ; Broady, R; Connors, JM; Forrest, DL; Hamata, L; Hogge, DE; Mourad, YA; Nantel, SH; Narayanan, S; Nevill, TJ; Nitta, J; Power, MM; Shepherd, JD; Smith, CA; Song, KW; Sutherland, HJ; Toze, CL; Venner, CP, 2011) |
| "Until recently, standard treatment of multiple myeloma (MM) in elderly patients who were not candidates for autologous stem cell transplantation was with the combination of melphalan plus prednisone (MP)." | ( Harousseau, JL, 2010) |
| "A total of 168 patients with multiple myeloma or lymphoma received a single dose of subcutaneous G-CSF (lenograstim, 263 μg) after high-dose chemotherapy." | ( Ehninger, G; Einsele, H; Emmerich, B; Engert, A; Franke, D; Freund, M; Giagounidis, A; Grimminger, W; Heinisch, H; Hellmann, P; Hentrich, M; Hinke, A; Hübel, K; Metzner, B; Salwender, H; Sandherr, M; Scheid, C; Schlimok, G; Schwerdtfeger, R; Sezer, O; Silling, G; Straka, C; Wandt, H, 2011) |
| "Bortezomib is a potent agent for multiple myeloma (MM); however, severe treatment-related toxicities such as peripheral neuropathy have been observed in conjunction with its use." | ( Hanzawa, K; Kizaki, M; Mori, S; Nemoto, T; Sagawa, M; Tokuhira, M; Tomikawa, T; Watanabe, R, 2011) |
| "Immunotherapy targeting MAGE-A3 in multiple myeloma (MM) could eradicate highly aggressive and proliferative clonal cell populations responsible for relapse." | ( Barlogie, B; Garg, T; Hoerring, A; Moreno-Bost, A; Prentice, HG; Shaughnessy, J; Stone, K; Szmania, S; Szymonifka, J; van Rhee, F, 2011) |
| "Over the last few decades therapy for multiple myeloma has improved remarkably." | ( Einsele, H; Knop, S; Kortüm, M, 2011) |
| "In some patients with multiple myeloma, extramedullary masses may be present at diagnosis or may develop during treatment." | ( Ando, K; Kojima, M; Moriuchi, M; Nakamura, N; Ogawa, Y; Ohmachi, K; Tsuboi, K, 2010) |
| "Recurrence of multiple myeloma (MM) after therapy suggests the presence of tumor-initiating subpopulations." | ( Adamia, S; Anderson, KC; Blotta, S; Cervi, D; Cholujova, D; Daley, JF; Delmore, J; Jakubikova, J; Klippel, S; Kong, SY; Kost-Alimova, M; Laubach, J; Leiba, M; Mitsiades, CS; Ooi, M; Richardson, PG; Sedlak, J, 2011) |
| "A total of 106 relapsed or refractory multiple myeloma patients received lenalidomide 25mg plus dexamethasone as salvage therapy; 80 patients progressed on thalidomide treatment (thalidomide-resistant) and 26 patients discontinued thalidomide in at least partial remission (thalidomide-sensitive)." | ( Benevolo, G; Berruti, A; Boccadoro, M; Bringhen, S; Caravita, T; Cavallo, F; Corradini, P; Gay, F; Guglielmelli, T; Montefusco, V; Offidani, M; Palumbo, A; Petrucci, MT; Piro, E; Rrodhe, S; Saglio, G, 2011) |
| "Patients with advanced multiple myeloma (MM) often have increased osteolytic activity of osteoclasts and impaired osteogenesis by osteoblasts, resulting in osteolytic bone lesions that increase the risk of skeletal-related events (SREs) including pathologic fracture, the need for radiotherapy or surgery to bone, and spinal cord compression." | ( Berenson, J; Dimopoulos, MA; Terpos, E, 2011) |
| "These results demonstrate that relapsed multiple myeloma patients who respond to initial bortezomib treatment have a sustained susceptibility to bortezomib and do not experience uncommon toxicity to retreatment." | ( Emmerich, B; Frohn, C; Hess, G; Hrusovsky, I; Olie, RA; Pliskat, H; Taverna, C; Voegeli, J; von Rohr, A, 2010) |
| "In this cohort study, patients with multiple myeloma (MM) on intravenous BP therapy were enrolled over 1 year." | ( Burkley, B; Casanova, O; Ferreira, P; Gong, Y; Hou, W; Katz, J; Langaee, TY; Moreb, JS; Salmasinia, D, 2011) |
| "Metaphase chromosome studies in multiple myeloma (MM) are performed as part of the diagnostic workup, as surveillance to monitor the therapeutic response, and at relapse to help direct therapy." | ( Sawyer, JR, 2011) |
| "In newly diagnosed multiple myeloma (MM), three/four-drug combinations as induction therapy seem to be more effective compared with two-drug associations in terms of response rate and duration of remission." | ( Blasi, N; Brunori, M; Caraffa, P; Catarini, M; Corvatta, L; Ferranti, M; Gentili, S; Leoni, P; Malerba, L; Mele, A; Offidani, M; Polloni, C; Rizzi, R; Samori, A, 2011) |
| "Although treatment for multiple myeloma (MM) has considerably improved in the past decade, MM continues to be an incurable hematological malignancy that causes most patients to eventually relapse and die from their illness." | ( Benevolo, G; Boccadoro, M; Botto, B; Evangelista, A; Frairia, C; Gay, F; Gentile, M; Larocca, A; Morabito, F; Palumbo, A; Pregno, P; Vitolo, U, 2011) |
| "One hundred and four patients with multiple myeloma treated with lenalidomide and dexamethasone after ≥2 therapy lines (median, 3) were analyzed." | ( Citro, A; Corradini, P; Crippa, C; De Muro, M; Falcone, AP; Galli, M; Gentili, S; Grasso, M; Guglielmelli, T; Montefusco, V; Olivero, B; Patriarca, F; Rossi, D; Sammassimo, S; Spina, F, 2011) |
| "Forty-three newly diagnosed multiple myeloma patients requiring treatment were enrolled on this study." | ( Ailawadhi, S; Chanan-Khan, A; Czuczman, MS; Hernandez-Ilizaliturri, FJ; Hong, F; Iancu, D; Jamshed, S; Lawrence, W; Lee, K; Manfredi, D; Masood, A; Miller, KC; Sher, T; Soniwala, S; Sood, R; Tan, W; Wilding, G; Wood, M, 2011) |
| "A 57-year-old male patient with multiple myeloma and acute renal failure was treated with HDF using a HCO membrane (Theralite) each or every other day." | ( Buturović-Ponikvar, J; Gubenšek, J; Kersnič, B; Kovač, J; Pernat, AM; Ponikvar, R; Pretnar, J, 2011) |
| "For patients with relapsed or refractory multiple myeloma (MM) treated with a prior high-dose therapy (HDT) followed by autologous peripheral blood stem cell transplantation (PBSCT), the reapplication of HDT is a widely used salvage strategy." | ( Balleisen, S; Bruns, I; Fenk, R; Haas, R; Kobbe, G; Kondakci, M; Liese, V; Neubauer, F; Saure, C; Schröder, T, 2011) |
| "The treatment of patients with multiple myeloma usually includes many drugs including thalidomide, lenalidomide and bortezomib." | ( Adamczyk-Cioch, M; Dmoszynska, A; Grzasko, N; Helbig, G; Hus, M; Jawniak, D; Kozinska, J; Legiec, W; Morawska, M; Pluta, A; Szostek, M; Waciński, P; Woszczyk, D, 2011) |
| "In patients with previously untreated multiple myeloma, long-term outcome with respect to progression-free survival, overall survival, and relapse rate is superior after auto-allo compared with auto only." | ( Beksac, M; Björkstrand, B; Bosi, A; Corradini, P; de Witte, T; Gahrton, G; Goldschmidt, H; Greinix, H; Gruber, A; Hegenbart, U; Iacobelli, S; Milone, G; Morris, C; Musto, P; Narni, F; Niederwieser, D; Volin, L, 2011) |
| "The treatment of newly diagnosed multiple myeloma (MM) has evolved rapidly over recent years." | ( de la Rubia, J; Roig, M, 2011) |
| "One hundred and ten patients with multiple myeloma were treated with bendamustine as part of a French compassionate use program." | ( Banos, A; Caillot, D; Damaj, G; Fitoussi, O; Garidi, R; Hulin, C; Malard, F; Marit, G; Moreau, P; Morineau, N; Royer, B; Stoppa, AM; Tiab, M, 2012) |
| "Patients with multiple myeloma are usually treated with IV bisphosphonates soon after diagnosis." | ( Hewson, ID, 2011) |
| "Their effective concentrations against multiple myeloma cell lines were similar to those of melphalan, a well known DNA-alkylating agent used in a standard therapy against B cell lymphoma and multiple myeloma." | ( Bargou, R; Bringmann, G; Chatterjee, M; Hager, A; Irmer, A; Moos, M; Zhang, G, 2011) |
| "A total of 168 patients with relapsed multiple myeloma (MM) who were refractory to at lest two prior treatments were enrolled in this multicenter, open-label, non-randomized, prospective clinical trial." | ( Chen, WM; Chen, XQ; Hou, J; Huang, XJ; Jin, J; Li, Y; Liu, ZG; Shen, ZX; Yuan, ZG, 2011) |
| "Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation." | ( Bell, SE; Child, JA; Cook, G; Davies, FE; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Johnson, PR; Morgan, GJ; Navarro Coy, N; Owen, RG; Ross, FM; Rudin, C; Russell, NH; Szubert, AJ, 2012) |
| "In patients with multiple myeloma or non-Hodgkin's lymphoma, co-administration of rifampicin decreased the exposure to bortezomib but did not affect the proteasome inhibition or safety profiles; co-administration of dexamethasone did not affect the exposure to bortezomib, proteasome inhibition or safety profiles." | ( Feng, H; Girgis, S; Hellmann, A; Louw, VJ; Patel, H; Rule, S; Shpilberg, O; Skee, DM; van de Velde, H; Walewski, J, 2011) |
| "MAGE-C1/CT7 is frequently expressed in multiple myeloma (MM) that may be a potential target for immunotherapy in this still incurable disease." | ( Andrade, VC; Atanackovic, D; Caballero, OL; Camargo, AA; Colleoni, GW; Costa, ET; de Carvalho, F; Gregorio, JC; Masotti, C; Strauss, BE, 2011) |
| "Thalidomide was approved in Japan for multiple myeloma treatment in October 2008." | ( Aimono, Y; Aoyama, Y; Chikatsu, N; Ebata, S; Hakozaki, M; Isa, S; Kudo, D; Monma, Y; Onozaki, M; Otani, E; Saito, Y; Sato, W; Sawahata, T; Shinagawa, A; Suzuki, M, 2011) |
| "Despite recent advances in therapy, multiple myeloma, the second most common hematologic tumor in the Western world, is still incurable." | ( Greil, R; Hamacher, F; Hermann, M; Jöhrer, K; Kern, J; Maizner, E; Merkel, O; Neureiter, D; Obkircher, M; Parteli, J; Scheideler, M; Wacht, N; Zelle-Rieser, C; Zidorn, C, 2012) |
| "Although multiple myeloma remains an essentially incurable disease, treatment options and patients' quality of life have improved over the last years with the introduction of more effective and less toxic agents." | ( Figueiredo, A; João, C; Martins, HF, 2012) |
| "Despite recent treatment advances, multiple myeloma (MM) remains incurable and patients develop a progressively relapsing disease with subsequent poor prognosis." | ( Hu, R; Li, J; Li, Y; Liao, A; Liu, Z; Wang, H; Yang, W; Yao, K; Zhang, R; Zhao, Q, 2012) |
| "Thalidomide is now an integral part of multiple myeloma (MM) therapy." | ( Jaeger, D; Podar, K; Vallet, S; Witzens-Harig, M, 2012) |
| "Though multiple myeloma (MM) is associated with a high frequency of thrombosis in the context of thalidomide and lenalidomide therapy, prognosis is not affected by its occurrence." | ( Braggio, E; Cesarman-Maus, G; Fonseca, R; Maldonado, H, 2012) |
| "Effectively treating patients with multiple myeloma is challenging." | ( Anderson, K; Laubach, J; Mahindra, A; Munshi, N; Raje, N; Richardson, PG, 2012) |
| "The treatment approach in patients with multiple myeloma (MM) has been essentially changed with introduction of novel agents such as thalidomide, bortezomib and lenalidomide." | ( Bertsch, U; Goldschmidt, H; Hose, D; Schmitt, S, 2011) |
| "A 78-year-old male patient with IgGκ multiple myeloma was repetitively treated with melpharan and prednisolone." | ( Nagai, T; Tabata, C; Tabata, R; Tazoh, A, 2012) |
| "The management of multiple myeloma has undergone profound changes over the recent past as a result of advances in our understanding of the disease biology as well as improvements in treatment and supportive care strategies." | ( Avet-Loiseau, H; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Davies, F; de la Rubia, J; Delimpasi, S; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Hess, U; Ludwig, H; Mellqvist, UH; Moreau, P; Palumbo, A; San-Miguel, J; Sondergeld, P; Sonneveld, P; Udvardy, M, 2012) |
| "A 74-year-old female with relapsed multiple myeloma was treated with twice-weekly bortezomib plus dexamethasone (BD)therapy, but severe gastrointestinal adverse events(grade 3 paralytic ileus and constipation)developed." | ( Fujita, Y; Fukushima, T; Iwao, H; Masaki, Y; Miki, M; Nakajima, A; Nakamura, T; Sakai, T; Sato, T; Sawaki, T; Tanaka, M; Umehara, H, 2012) |
| "A 64-year-old Japanese man with multiple myeloma received low-dose dexamethasone followed by bortezomib monotherapy as the initial therapy." | ( Itoh, K; Sasaki, M; Yamaguchi, T, 2012) |
| "Treatment for multiple myeloma (induction treatment and autologous hematological stem cell transplantation) gained partial remission and was associated with normalization of serum lipids." | ( Brox, J; Hansen, JB; Isaksen, V; Vik, A, 2012) |
| "A patient with multiple myeloma was treated with high-dose chemotherapy followed by two autologous bone marrow transplantations (ABMTs)." | ( Brustia, D; Cantello, R; Comi, C; Conconi, A; De Paoli, L; Gaidano, G; Monaco, F; Mula, M; Nasuelli, N; Ripellino, P; Savio, K; Stecco, A; Varrasi, C, 2011) |
| "For example, in multiple myeloma cells treated with the proteasome inhibitor bortezomib, levels of activating transcription factor-4 increase dramatically early in drug treatment and then decrease upon cleavage by activated caspases." | ( Burlingame, AL; Hsu, GW; Mahrus, S; Nguyen, H; Shimbo, K; Trinidad, JC; Wells, JA, 2012) |
| "Patients with multiple myeloma (MM) undergoing high dose therapy and autologous stem cell transplantation (SCT) remain at risk for disease progression." | ( Chung, HM; Clark, WB; Hazlett, AF; Kmieciak, M; Manjili, MH; McCarty, JM; Payne, KK; Roberts, CH; Sabo, RT; Sanford, K; Toor, AA; Williams, DC, 2012) |
| "Nearly all patients with multiple myeloma will eventually relapse; and, thus, it is critical to identify new treatments that increase therapeutic options for these patients." | ( Berenson, JR; Eshaghian, S, 2012) |
| "Most patients with multiple myeloma in both the frontline and relapsed/refractory settings are now treated with a combination of dexamethasone with the proteasome inhibitor bortezomib and/or an immunomodulatory agent thalidomide or lenalidomide." | ( Berenson, JR; Eshaghian, S, 2012) |
| "Treatment of patients with multiple myeloma (MM) has drastically changed with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, but treatment outcome of elderly patients has remained dismal mainly due to toxicities." | ( Aritaka, N; Hirano, T; Ichikawa, K; Komatsu, N; Matsumoto, T; Nakamura, H; Ogura, K; Yasuda, H, 2012) |
| "The treatment of newly diagnosed multiple myeloma has evolved rapidly over the recent years." | ( Blanes, M; de la Rubia, J, 2012) |
| "One of the greatest challenges in multiple myeloma (MM) treatment is to overcome drug resistance." | ( De Bruyne, E; Hu, J; Menu, E; Schots, R; Van Valckenborgh, E; Vanderkerken, K; Xu, D, 2012) |
| "T cells from 69 multiple myeloma patients were analyzed: 19 patients were treated with IFN-α; 26 were treated with Thalidomide; and 24 patients received no maintenance therapy." | ( Beckhove, P; Engelhardt, M; Goldschmidt, H; Haas, J; Herth, I; Ho, AD; Hose, D; Hundemer, M; Klein, B; Meissner, T; Neben, K; Neuber, B; Witzens-Harig, M, 2013) |
| "VD-DLIs is a safe treatment for multiple myeloma patients relapsing or progressing after alloSCT and may be effective." | ( Bruno, B; Corradini, P; Dodero, A; Fanin, R; Montanari, M; Montefusco, V; Mussetti, A; Offidani, M; Patriarca, F; Scortechini, I; Sperotto, A; Spina, F; Valagussa, P, 2013) |
| "Optimal salvage treatment for multiple myeloma relapsing after allogeneic stem cell transplantation remains to be determined." | ( Bachy, E; Bourhis, JH; Brebion, A; Coman, T; François, S; Hermine, O; Huynh, A; Lapusan, S; Lioure, B; Maury, S; Michallet, M; Milpied, N; Mohty, M; Rubio, MT; Socié, G; Uzunov, M; Vigouroux, S; Yakoub-Agha, I, 2013) |
| "Lenalidomide (LEN) treatment in multiple myeloma (MM) results in a superior outcome." | ( Dai, L; Gollin, SM; Lentzsch, S; Mapara, MY; Monaghan, SA; Normolle, DP, 2013) |
| "A 53-year-old man with Stage III multiple myeloma developed a severe motor predominant polyradiculoneuropathy following bortezomib treatment with electrophysiological features of multiple conduction blocks and pathological evidence of peripheral nerve microvasculitis." | ( Blumenreich, MS; Dispenzieri, A; Mauermann, ML; Staff, NP, 2012) |
| "The treatment of multiple myeloma is evolving rapidly." | ( Rajkumar, SV, 2012) |
| "Patients with newly diagnosed multiple myeloma were included in the HOVON-65/GMMG-HD4 trial, in which postintensification treatment in 1 arm consisted of daily thalidomide (50 mg) for 2 years." | ( Bertsch, U; Broyl, A; Buijs, A; el Jarari, L; Goldschmidt, H; Hose, D; Kuiper, R; Lokhorst, HM; Sonneveld, P; van der Holt, B; van Duin, M; Zweegman, S, 2013) |
| "Patients (n=459) with newly diagnosed multiple myeloma aged 65 years or over were randomized 1:1:1 to nine 4-week cycles of lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance; or lenalidomide, melphalan, and prednisone, or melphalan and prednisone, with no maintenance therapy." | ( Delforge, M; Dimopoulos, MA; Hájek, R; Kropff, M; Lewis, P; Mei, J; Nixon, A; Palumbo, A; Petrucci, MT; Zhang, J, 2013) |
| "The inhibitory rate of multiple myeloma cells was detected by MTT, the morphological and ultrastructural changes of RPMI8226 cells were observed by using inverted fluorescent microscope and transmission electron microscope, the apoptosis-inducing effect of docetaxel on RPMI-8226 cells was determined by flow cytometry with Annexin-V FITC/PI staining, the cell distribution in cell cycle of RPMI-8226 cells was assayed using flow cytometry with PI staining; the effect of docetaxel on expression of BCL-2, caspase-8, caspase-3 mRNA was detected by semiquantitative RT-PCR, the expression changes of BCL-2 protein in RPMI-8226 cells before and after treatment with docetaxel were measured by using Western blot." | ( Liu, BL; Liu, X; Qi, MY; Xu, B; Zhou, NC, 2012) |
| "The treatment options for patients with multiple myeloma (MM) remain limited." | ( Mahindra, A; Saini, N, 2013) |
| "Treatment of multiple myeloma has dramatically improved with the introduction of bortezomib (BOR), thalidomide (THAL), and lenalidomide (LEN)." | ( Ba-Mancini, A; Henk, HJ; Huang, H; Teitelbaum, A, 2013) |
| "The treatment for multiple myeloma has been continued without cyclophosphamide since surgery." | ( Kojima, K; Shibata, Y; Takagi, K; Yuhara, K, 2012) |
| "Novel agents to treat multiple myeloma (MM) have increased complete respone (CR) rates compared with conventional chemotherapy, and the quality of the response to treatment has been correlated with survival." | ( Bae, SH; Chung, JS; Eom, HS; Jo, DY; Kim, HJ; Kim, JS; Kim, K; Kim, MK; Kim, SH; Kim, YS; Lee, HS; Lee, JH; Min, CK; Mun, YC; Suh, C; Yoon, SS, 2013) |
| "Abstract Multiple myeloma is a common hematological malignancy that urgently requires new approaches to treatment, since the disease is not curable using current chemotherapeutic regimens." | ( Conrad, DM; Coombs, MR; Doucette, CD; Hilchie, AL; Hoskin, DW; Liwski, RS; Zemlak, T, 2013) |
| "Induction therapy for multiple myeloma (MM) and remission status before high-dose treatment (HDT) have been shown to be prognostic factors for survival outcome, although the optimal induction therapy is yet to be defined." | ( Admasie, J; Alici, E; Aschan, J; Barendse, M; Carlson, K; Deneberg, S; Liwing, J; Lund, J; Mellqvist, UH; Nahi, H; Uttervall, K, 2013) |
| "To study the clinical profile of multiple myeloma and the effect of thalidomide based treatment on its outcome in the Indian scenario are the aims and objective of the study." | ( Basu, D; Dutta, TK; Sridhar, S, 2011) |
| "The patient was diagnosed with multiple myeloma and received chemotherapy with thalidomide, cyclophosphamide and dexamethasone." | ( An, CH; An, SY; Choi, KS; Heo, MS, 2013) |
| "Representative multiple myeloma cell lines and a myeloma-bearing mice were treated with DCA, alone and in combination with bortezomib." | ( Catley, L; Connor, T; McGee, SL; Mottram, B; Sanchez, WY; Vuckovic, S; Whitehead, JP; Wilkinson, A, 2013) |
| "Although the incidence of multiple myeloma (MM) is increasing, the median overall survival and the number of agents in the pipeline for treating MM also are increasing." | ( Bilotti, E, 2013) |
| "Bortezomib is commonly used in treating multiple myeloma (MM)." | ( Chen, J; Li, S; Que, W, 2013) |
| "Management of multiple myeloma (MM) has been drastically changed in the last 10 years thanks to the introduction of novel agents, which, combined with the backbone of classical chemotherapy, have led to a significant improvement in disease control." | ( Conticello, C; Di Raimondo, F; Romano, A, 2013) |
| "Here we present the case of multiple myeloma who underwent acute respiratory failure caused by non-specific interstitial pneumonia after few days of treatment with lenalidomide." | ( Aoki, T; Danbara, M; Higashihara, M; Katayama, T; Miyazaki, K; Tadera, N; Togano, T, 2013) |
| "A 50-year-old man diagnosed as multiple myeloma of IgA κ type, International Staging System III received a combination therapy of lenalidomide (15 mg, Day 1 - 21) with dexamethasone (40 mg, Day 1, 8, 15, 22)." | ( Aoki, T; Danbara, M; Higashihara, M; Katayama, T; Miyazaki, K; Tadera, N; Togano, T, 2013) |
| "Despite improved outcomes for multiple myeloma, little is known about changes in initial treatment at the population level for US patients." | ( Abel, GA; Harlan, LC; Little, RF; Stevens, J; Warren, JL, 2013) |
| "Initial treatment for multiple myeloma has changed markedly." | ( Abel, GA; Harlan, LC; Little, RF; Stevens, J; Warren, JL, 2013) |
| "A total of 200 patients with multiple myeloma who developed disease recurrence after treatment with upfront ASCT and received an autologous retransplantation as salvage therapy at the study center over a period of 15 years were retrospectively reviewed." | ( Benner, A; Egerer, G; Goldschmidt, H; Heiss, C; Hillengass, J; Ho, AD; Hose, D; Lehners, N; Neben, K; Raab, MS; Sellner, L, 2013) |
| "Bortezomib is an important agent in multiple myeloma treatment, but resistance in cell lines and patients has been described." | ( Anderson, K; Clynes, M; Delmore, J; Jakubikova, J; Klippel, S; Meiller, J; Mitsiades, CS; O'Connor, R; O'Gorman, P; Ooi, MG; Richardson, P, 2013) |
| "A 65-year-old male with multiple myeloma received chemotherapy which included cyclophosphamide, thalidomide and dexamethasone." | ( Ali, A; Hothi, SS; Malik, N; Thompson, A, 2013) |
| "Many advances in the treatment of multiple myeloma have been made due to the use of transplantation and the introduction of novel agents including thalidomide, lenalidomide, and bortezomib." | ( Cerrato, C; Palumbo, A, 2013) |
| "Relapsed/refractory multiple myeloma represents a major challenge in multiple myeloma therapy." | ( Bailey, C; Barlogie, B; Crowley, J; Heuck, CJ; Hoering, A; Johann, D; Keller, J; Mitchell, A; Papanikolaou, X; Petty, N; Rosenthal, A; Szymonifka, J; Usmani, SZ; Van Rhee, F; Waheed, S, 2013) |
| "Management of relapsed and refractory multiple myeloma (RRMM) is challenging owing to disease-, patient- and treatment-related factors, and new therapies for these patients are required." | ( Forsberg, PA; Mark, TM, 2013) |
| "We analyzed 1156 multiple myeloma (MM) patients treated with thalidomide." | ( Adam, Z; Adamova, D; Bacovsky, J; Gregora, E; Gumulec, J; Hajek, R; Jarkovsky, J; Maisnar, V; Melicharova, H; Minarik, J; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Sandecka, V; Scudla, V; Spicka, I; Starostka, D; Straub, J; Walterova, L; Wrobel, M, 2013) |
| "The treatment of multiple myeloma has evolved significantly over the past 2 decades due to the use of high-dose chemotherapy and autologous stem cell transplantation, and the subsequent introduction of the immunomodulatory agents (thalidomide and lenalidomide) and the proteasome inhibitor (bortezomib)." | ( El-Amm, J; Tabbara, IA, 2015) |
| "ATX-101 also increased multiple myeloma cells' sensitivity against melphalan, a DNA damaging agent commonly used for treatment of multiple myeloma." | ( Bachke, S; Bellacchio, E; Gilljam, KM; Holien, T; Misund, K; Müller, R; Otterlei, M; Rø, TB; Sundan, A; Våtsveen, TK, 2013) |
| "Two male patients (aged 41 and 70) with multiple myeloma developed severe, rapidly progressing cognitive impairment (mostly involving episodic memory) and loss of independence in activities of daily living during lenalidomide-based treatment." | ( Delbeuck, X; Facon, T; Le Rhun, E; Leleu, X; Lenfant, P; Mackowiak, MA; Noel, MP; Pasquier, F; Pollet, M; Rollin-Sillaire, A, 2013) |
| "Patients with multiple myeloma (MM) or solid tumor bone metastases (STM) and at least 24 months of regular q3-4w ZOL therapy were followed prospectively for an additional 18 months beyond the 24 months required for study entry." | ( Delabaye, I; Delforge, M; Doyen, C; Duck, L; Van den Wyngaert, T; Wildiers, H; Wouters, C; Wouters, K, 2013) |
| "This drug was approved for patients with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy." | ( Lacy, MQ; McCurdy, AR, 2013) |
| "Treatment of multiple myeloma cells with PRIMA-1(Met) resulted in induction of apoptosis, inhibition of colony formation, and migration." | ( Chang, H; Jiang, H; Reece, D; Saha, MN; Yang, Y, 2013) |
| "The causes of multiple myeloma (MM) remain obscure and there are few known risk factors; however, natural killer T (NKT) cell abnormalities have been reported in patients with MM, and therapeutic targeting of NKT cells is promoted as a potential treatment." | ( Berzins, SP; Chan, AC; Godfrey, DI; Harrison, SJ; Leeansyah, E; Neeson, P; Prince, HM; Quach, H; Ritchie, D; Tainton, K, 2014) |
| "Currently, multiple myeloma is not considered curable, but it is treatable with different strategies that can combine chemotherapy with autologous hematopoietic stem cell transplantation." | ( Gras, J, 2013) |
| "Treatment of multiple myeloma (MM) has evolved significantly over the past two decades with high-dose chemotherapy and autologous stem cell transplant (ASCT), incorporating novel therapies such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) during induction and post-transplant maintenance therapies." | ( Liu, H; McCarthy, P, 2013) |
| "We enrolled 30 multiple myeloma (MM) and 30 breast cancer (BC) patients whereof 10 of each had never received bisphosphonate and 20 had received at least six prior Zol treatments." | ( Delaissé, JM; Hansen, CT; Jakobsen, EH; Plesner, T; Søe, K, 2014) |
| "Initial therapy of multiple myeloma with lenalidomide-based regimens can compromise stem cell collection, which can be overcome with the addition of plerixafor." | ( Bergsagel, LP; Buadi, FK; Dingli, D; Dispenzieri, A; Gastineau, DA; Gertz, MA; Hayman, SR; Kumar, SK; Lacy, MQ; Laplant, B; Laumann, K; Mahlman, M; Miceli, T; Mikhael, J; Reeder, C; Stewart, AK; Winters, JL, 2014) |
| "Progress in the treatment of multiple myeloma in the last decade has been able to delay, but ultimately not to prevent, the development of resistances and most patients still die of the disease or its related complications." | ( Motlló, C; Oriol, A, 2014) |
| "Current chemotherapy for multiple myeloma is based on bortezomib (BOR), dexamethasone (DEX), and thalidomide (THA)." | ( Devine, E; Krause, B; Krieter, DH; Lemke, HD; Storr, M; Wanner, C, 2014) |
| "The heterogeneity of multiple myeloma (MM) contributes to variable responses to therapy." | ( Chen, Z; Kwak, L; McCarty, N; Orlowski, RZ; Wang, M, 2014) |
| "Effective therapy for multiple myeloma has existed for a little more than the last half century." | ( Kyle, RA; Rajkumar, SV, 2014) |
| "Patients with relapsed/refractory (R/R) multiple myeloma (MM) complicated by severe heart failure typically do not tolerate conventional chemotherapy." | ( Guo, L; Hou, J; Li, L; Ling, C; Shi, H; Wei, W; Zhou, F, 2014) |
| "Patients with newly diagnosed multiple myeloma were randomised to zoledronic acid (ZOL; 4 mg intravenously every 21-28 d) or clodronate (CLO; 1600 mg/d orally) plus chemotherapy." | ( Ashcroft, AJ; Bell, SE; Boyd, KD; Byrne, J; Child, JA; Cook, G; Davies, FE; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Morgan, GJ; Navarro Coy, N; Osborne, WL; Owen, RG; Roddie, H; Ross, FM; Rudin, C; Szubert, AJ; Wu, P, 2014) |
| "In 36 multiple myeloma (MM) patients, we measured serial changes in iFLC and M-protein after start of treatment." | ( Abildgaard, N; Hansen, CT; Nielsen, LC; Pedersen, PT, 2014) |
| "Although widely accepted as treatment of multiple myeloma and non-Hodgkin's lymphoma, it has also been shown to be efficacious in a variety of solid tumours such as pancreatic and colonic." | ( Nixon, NA; Parhar, K, 2014) |
| "Bortezomib has significantly improved multiple myeloma (MM) response rates, but strategies for choosing bortezomib-based regimens for initial MM therapy are not standardized." | ( Cai, Z; Fu, J; Han, X; He, J; Huang, H; Huang, W; Li, L; Shi, J; Wei, G; Wu, W; Xie, W; Yang, L; Ye, X; Zhang, J; Zhang, X; Zhao, Y; Zheng, G; Zheng, W, 2014) |
| "Consolidation therapy for patients with multiple myeloma (MM) has been widely adopted to improve treatment response following autologous stem cell transplantation." | ( Akashi, K; Aoki, T; Ito, Y; Iwasaki, H; Kadowaki, M; Kamimura, T; Kato, K; Miyamoto, T; Muta, T; Shima, T; Shiratsuchi, M; Takase, K; Takashima, S; Takenaka, K; Teshima, T; Yoshimoto, G, 2014) |
| "Relapsed multiple myeloma has no standard treatment, and the role of autologous stem-cell transplantation (ASCT) has not been fully defined." | ( Ashcroft, AJ; Bird, JM; Brown, JM; Cairns, DA; Cavenagh, J; Cavet, J; Chalmers, A; Cook, G; Drayson, MT; Fletcher, M; Hunter, H; Morris, TC; O'Connor, S; Parrish, C; Snowden, JA; Williams, C; Yong, K, 2014) |
| "Patients with multiple myeloma may be susceptible to osteonecrosis of the jaw (ONJ) and stress fractures due to long-term aminobisphosphonate (aBP) therapy." | ( Anderson, KC; Ghobrial, IM; Laubach, JP; Munshi, NC; Nemani, N; Patel, CG; Raje, NS; Richardson, PG; Santo, L; Schlossman, RL; Scullen, TA; Yee, AJ, 2014) |
| "Eighteen multiple myeloma patients receiving bortezomib-dexamethasone combination therapy were enrolled." | ( Kaneko, T; Kawakami, J; Mino, Y; Naito, T; Ohnishi, K; Osawa, T; Yamada, H, 2014) |
| "Patients with multiple myeloma (MM) manifesting acute kidney injury (AKI) and who later recover renal function and independence from renal replacement therapy (RRT) are considered to have a better outcome." | ( Campos, M; Gomes, H; Neves, M; Pratas, J; Rodrigues, L; Sá, H, 2014) |
| "The treatment of multiple myeloma has undergone significant changes and has resulted in the achievement of molecular remissions, the prolongation of remission duration, and extended survival becoming realistic goals, with a cure being possible in a small but growing number of patients." | ( Bladé, J; Boccadoro, M; Cavo, M; Davies, F; de la Rubia, J; Delforge, M; Dimopoulos, M; Einsele, H; Facon, T; Goldschmidt, H; Hajek, R; Ludwig, H; Moreau, P; Morgan, G; Nahi, H; Palumbo, A; Plesner, T; San-Miguel, J; Sondergeld, P; Sonneveld, P, 2014) |
| "Advances in drug therapy for multiple myeloma (MM) during the previous decade have improved survival outcomes; however, the disease remains incurable as patients eventually relapse or become refractory to all available therapies." | ( Andreu-Vieyra, C; Berenson, JR, 2014) |
| "Patients with multiple myeloma (MM) frequently experience renal dysfunction owing to patient-specific risk factors, the pathophysiology of MM, and treatment-related adverse events." | ( Shah, JJ, 2013) |
| "Cryoglobulinemia (Cg) in multiple myeloma (MM) is rare and no standard treatment has yet been established." | ( Ando, K; Hata, T; Imaizumi, Y; Imanishi, D; Makiyama, J; Miyazaki, Y; Sawayama, Y; Taguchi, J; Taniguchi, H; Tsushima, H, 2014) |
| "In the present study, multiple myeloma cells were treated with gossypol, which resulted in an increase of cellular reactive oxygen species (ROS) and cell necrosis." | ( Liu, C; Tang, H; Tian, E; Wang, Q; Xu, R, 2014) |
| "Patients with relapsed and/or refractory multiple myeloma (MM) were administered single-agent carfilzomib on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle." | ( Badros, A; Holahan, JR; Lee, P; Lee, S; Papadopoulos, KP; Rosen, ST; Siegel, DS; Vesole, DH; Wang, Z; Zojwalla, N, 2015) |
| "Despite improvements in multiple myeloma therapy, the vast majority of patients continue to suffer relapses." | ( Bátorová, A; Mistrík, M; Roziaková, L, 2014) |
| "Treatment of multiple myeloma (MM), currently an incurable disease, aims to achieve complete remission." | ( Bešše, L; Hájek, R; Sedlaříková, L; Sevčíková, S; Staňková, M; Vrábel, D, 2014) |
| "To describe a case of a patient with multiple myeloma without extraocular end-organ damage but with cystoid macular edema and macular detachments who was treated with bortezomib and dexamethasone." | ( Dewan, VN; Grannis, CH; Wang, RC, 2014) |
| "Patients with relapsed multiple myeloma and ≤5 prior lines of therapy, with measurable disease, were enrolled." | ( Callander, N; Chng, WJ; Erlichman, C; Fonseca, R; Fruth, B; Kumar, SK; LaPlant, B; Roy, V; Stewart, AK; Zonder, J, 2015) |
| "Recent developments in the treatment of multiple myeloma have led to improvements in response rates and to increased survival; however, relapse is inevitable in almost all patients." | ( Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG, 2015) |
| "However, whether it has the same role in multiple myeloma (MM), especially after treatement with chemotherapy, remains unclear." | ( Cao, D; Guo, T; Hu, Y; Jin, L; Yu, W; Zhou, H, 2015) |
| "The outcomes and management of multiple myeloma (MM) in the United States have changed dramatically over the past 15 years with the approval by the US Food and Drug Administration (FDA) of 6 new drugs (thalidomide, lenalidomide, bortezomib, pegylated liposomal doxorubicin [Doxil], carfilzomib, and pomalidomide)." | ( Lonial, S; Usmani, SZ, 2014) |
| "Patients with multiple myeloma and advanced disease managed with multiple lines of therapy are at risk for vRTI, and targeted interventions for prevention/treatment are required." | ( Harrison, SJ; Slavin, MA; Teh, BW; Thursky, KA; Worth, LJ, 2015) |
| "Despite recent treatment improvements, multiple myeloma remains an incurable disease." | ( Andre, P; Lammerts van Bueren, JJ; Lokhorst, HM; Morel, Y; Mutis, T; Nijhof, IS; Parren, PW; van de Donk, NW; van Kessel, B, 2015) |
| "We describe the case of a patient with multiple myeloma who developed acute pancreatitis after treatment with bortezomib, a proteasome inhibitor commonly used in the treatment of this disease." | ( Mir, MA; Pandey, MK; Sivik, J; Talamo, G, 2016) |
| "Therapeutic options for patients with multiple myeloma (MM) whose disease has relapsed after a prior autologous stem cell transplant (ASCT) include an expanding armamentarium of novel agents, often combined with traditional chemotherapy, or a second ASCT, with no clear standard of care." | ( Devlin, SM; Giralt, S; Landau, H; Singh Abbi, KK; Zheng, J, 2015) |
| "Ritonavir-treated multiple myeloma cells exhibited increased reliance on glutamine metabolism." | ( Adekola, KU; Bajpai, R; Dalva-Aydemir, S; Kandela, I; Koblinski, JE; Martinez, M; Raje, NS; Rosen, ST; Shanmugam, M; Singhal, S; Wei, C, 2015) |
| "The introduction of novel drugs in multiple myeloma therapy has changed disease survivals in last 15 years." | ( Gozzetti, A, 2016) |
| "Patients with multiple myeloma who had relapsed after at least one prior treatment were eligible to participate." | ( Arrowsmith, ER; Berdeja, JG; Essell, JH; Flinn, IW; Hainsworth, JD; Hart, LL; Mace, JR; Owera, RS, 2015) |
| "In patients with multiple myeloma (MM), once-weekly intravenous injection or twice-weekly subcutaneous injection (SC) of bortezomib has been proven to offer non-inferior efficacy to standard twice-weekly intravenous administration, with an improved safety profile." | ( Chang, BY; Chen, XQ; Wang, KF; Wang, L; Xia, ZJ, 2015) |
| "We included data on age, gender, type of multiple myeloma, serum albumin, serum creatinine, beta 2 microglobulin, calcemia, imaging studies, disease stage, pre-and post-therapy bone marrow studies, adverse events and rate of progression." | ( Befferman Cordova, N; Espinoza Zelada, M; Galleguillos M, M; Ocqueteau Tachini, M; Ramírez Villanueva, P; Sarmiento Maldonado, M, 2015) |
| "Forty-eight multiple myeloma patients were treated with bortezomib-cyclophosphamide-dexamethasone." | ( Befferman Cordova, N; Espinoza Zelada, M; Galleguillos M, M; Ocqueteau Tachini, M; Ramírez Villanueva, P; Sarmiento Maldonado, M, 2015) |
| "Prognosis of patients with multiple myeloma (MM) has substantially improved in recent years due to the incorporation of novel drugs into their treatment." | ( Gunsilius, E; König, P; Nachbaur, D; Steiner, N; Willenbacher, W, 2015) |
| "Patients with untreated or relapsed multiple myeloma not eligible for high-dose chemotherapy followed by autologous stem cell transplantation and who were scheduled for bortezomib mono- or combination therapy or melphalan-prednisone (MP) alone were included in this study." | ( Alkemper, B; Gaede, B; Knauf, W; Reschke, D; Schlag, R; Schmits, R; Schütz, S; Schwarzer, A; Tapprich, C, 2015) |
| "A bone biopsy confirmed the diagnosis of multiple myeloma, and treatment with chemotherapy resulted in cytological and clinical recovery." | ( Geusens, P; Janssen, M; Reyskens, M; Sleurs, K; van den Berg, J; van den Bergh, J; Verresen, L, 2015) |
| "Treatment options for multiple myeloma dwindle with each relapse." | ( , 2014) |
| "Recent developments in the treatment of multiple myeloma (MM) have led to improvements in response rates and to increased survival." | ( Moreau, P; Touzeau, C, 2015) |
| "Treatment of multiple myeloma with bortezomib can result in severe adverse effects, necessitating the development of targeted inhibitors of the proteasome." | ( Bhaskaran, S; Gupta, A; McCluskey, B; Muñoz, S; Oyajobi, BO; Sharma, R; Williams, PJ, 2015) |
| "The mechanisms allowing residual multiple myeloma (MM) cells to persist after bortezomib (Bz) treatment remain unclear." | ( Adomako, A; Aguirre-Ghiso, JA; Biran, N; Calvo, V; Chari, A; Moore, K; Osman, K; Paton, AW; Paton, JC; Schewe, DM, 2015) |
| "Human multiple myeloma cell line RPMI 8226 cells were treated with or without different concentrations of PTL for various time periods, and then MTT assay was used to detect cell proliferation." | ( Chen, WL; Chen, ZC; Kong, FC; Li, QB; Ren, WX; Wang, HX; Yan, GX; Zeng, C; Zhang, JQ, 2015) |
| "We identified a poor-prognosis subset of multiple myeloma with extensive chromosomal instability and replicative stress, which rely on ATR to compensate for DNA-replicative stress; conversely, silencing of ATR or treatment with a specific ATR inhibitor triggers multiple myeloma cell apoptosis." | ( Anderson, KC; Bianchini, G; Cottini, F; Hideshima, T; Richardson, PG; Suzuki, R; Tai, YT; Tonon, G, 2015) |
| "Induction therapy in patients with multiple myeloma increases the risk of thromboembolism." | ( Dębski, J; Dmoszyńska, A; Helbig, G; Kozińska, J; Kuliczkowski, K; Podolak-Dawidziak, M; Undas, A; Woszczyk, D; Zubkiewicz-Usnarska, L, 2015) |
| "Human multiple myeloma(MM) cells were treated with VPA of non-toxic dose in absence and presence of DOX or MEL at different concentrations (ie." | ( Chen, XQ; Dong, BX; Gao, GX; Gu, HT; Jin, YL; Shu, MM; Tang, HL; Xu, L, 2015) |
| "Patients with multiple myeloma treated primarily with bortezomib and patients with colorectal cancer receiving oxaliplatin evaluated candidate items." | ( Bastida, CC; Cleeland, CS; Dougherty, PM; Mendoza, TR; Shi, Q; Thomas, SK; Vichaya, EG; Wang, XS; Williams, LA; Woodruff, JF; Yucel, E, 2015) |
| "To describe multiple myeloma (MM) treatment patterns and comorbidities over time in the US." | ( Cong, Z; Song, X; Wilson, K, 2016) |
| "For patients with relapsed or refractory multiple myeloma, carfilzomib with dexamethasone could be considered in cases in which bortezomib with dexamethasone is a potential treatment option." | ( Araujo, C; Chng, WJ; Dimopoulos, MA; Facon, T; Feng, S; Gaidano, G; Gillenwater, HH; Goldschmidt, H; Goranova-Marinova, V; Hájek, R; Hungria, V; Joshua, D; Karamanesht, I; Ludwig, H; Masszi, T; Minuk, L; Mohamed, N; Moreau, P; Offidani, M; Oriol, A; Orlowski, RZ; Palumbo, A; Pika, T; Pour, L; Rimashevskaya, E; Rosiñol, L; Schwarer, A; Spencer, A; Straub, J; Suvorov, A; Weisel, K, 2016) |
| "Moreover, multiple myeloma patients treated with pomalidomide demonstrated increased in vivo γ-globin levels in their erythrocytes." | ( Al-Abed, Y; Allen, SL; An, X; Appiah-Kubi, AO; Blanc, L; Chan, KW; Didier, S; Dulmovits, BM; Gallagher, PG; Gould, M; Hale, J; He, M; Husain-Krautter, S; Lipton, JM; Liu, JM; Marambaud, P; Mohandas, N; Papoin, J; Singh, SA; Taylor, N; Vlachos, A, 2016) |
| "We analyzed multiple myeloma (MM) patients receiving chemotherapy in a prospective multicenter study." | ( Huang, H; Huang, X; Li, J; Li, Y; Liu, J; Liu, L; Liu, Z; Lu, J; Ma, J; Ouyang, J; Ren, H; Song, Y; Wang, C; Wang, J; Xiao, Y; Yu, L; Zhou, D; Zhou, J, 2016) |
| "Treatment of multiple myeloma has changed markedly in the past decade due to the development of new drugs such as bortezomib, lenalidomide and thalidomide, which have greatly improved the outcome of PCM." | ( Arai, N; Fujiwara, S; Homma, M; Kabasawa, N; Kawaguchi, Y; Kobayashi, K; Nakamaki, T; Okino, K; Shiozawa, E; Takimoto, M; Tate, G; Tazawa, S; Yamochi, T, 2015) |
| "Thirty-six newly diagnosed multiple myeloma (MM) patients who were treated in Department of Hematology, Tianjin Medical University General Hospital from January 2013 to December 2014 were collected." | ( Ding, K; Ding, S; Fu, R; Guan, J; Li, L; Liu, H; Liu, Z; Peng, F; Qu, W; Ruan, E; Shao, Z; Song, J; Wang, G; Wang, H; Wang, X; Wang, Y; Wu, Y; Xing, L, 2015) |
| "Deciding appropriate therapy for multiple myeloma (MM) is challenging because of the occurrence of multiple chromosomal changes and the fatal nature of the disease." | ( Deng, S; Huo, X; Li, T; Ma, X; Wang, C; Wang, X; Yu, Z; Zhang, B; Zhong, Y, 2016) |
| "We analyzed the overall survival of 347 multiple myeloma patients in Austria by means of a national registry (AMR), focused on results from 3rd and later lines of therapy." | ( Rochau, U; Siebert, U; Weger, R; Willenbacher, E; Willenbacher, W, 2016) |
| "Treatment of multiple myeloma (MM) has significantly improved, although the disease remains incurable." | ( Berno, T; Cortelazzo, S; DE March, E; Marabese, A; Meneghini, V; Mian, M; Mondello, P; Patriarca, F; Pescosta, N; Pizzolo, G; Semenzato, G; Tinelli, M; Turri, G; Zambello, R, 2016) |
| "Today it is part of standard therapy for multiple myeloma and also as part of myeloablative regimens in association with autologous allogenic stem cell transplantation." | ( Delforoush, M; Enblad, G; Gullbo, J; Larsson, R; Strese, S; Wickström, M, 2016) |
| "Recent studies suggest that multiple myeloma is an immunogenic disease, which might be effectively targeted by antigen-specific T-cell immunotherapy." | ( Backert, L; Kanz, L; Kohlbacher, O; Kowalewski, DJ; Rammensee, HG; Rittig, SM; Salih, HR; Schuster, H; Stevanović, S; Stickel, JS; Walz, S; Weisel, K, 2016) |
| "The occurrence of venous thrombosis in multiple myeloma is not only determined by the kind of treatment, but also by several other factors, including disease specific factors, patient-specific factors, changes in pro-and anticoagulant factors and fibrinolysis." | ( Leebeek, FW, 2016) |
| "Advances in the treatment of multiple myeloma have resulted in dramatic improvements in outcomes for patients." | ( Lonial, S; Nooka, AK, 2016) |
| "We analyzed 11 patients with multiple myeloma (MM) treated using denosumab in our institute." | ( Hara, T; Kitagawa, J; Matsumoto, T; Nakamura, H; Nakamura, N; Nannya, Y; Ninomiya, S; Shibata, Y; Tsurumi, H, 2016) |
| "The five year survival for multiple myeloma has increased from 25% to 40% since the seventies due to high-dose chemotherapy followed by autologous stem cell transplantation and the new anti-myeloma drugs which were introduced in the last decade, such as immunomodulators (IMiD) like thalidomide, lenalidomide, pomalidomide and proteasome inhibitors (PI) like bortezomib, carfilzomib, ixazomib." | ( Nagy, Z, 2016) |
| "The use of MSCs for multiple myeloma therapy is a controversial topic because of the contradictory results on the capacity of MSCs to inhibit or to promote cancer growth." | ( Alessandri, G; Benetti, A; Berenzi, A; Boniotti, J; Bonomi, A; Coccè, V; Mazzoleni, G; Pascucci, L; Pessina, A; Sordi, V; Steimberg, N, 2017) |
| "New drugs for the treatment of multiple myeloma (MM) comprise immunomodulatory substances such as lenalidomide and related compounds." | ( Boquoi, A; Bruns, I; Cadeddu, RP; Deenen, R; Dienst, A; Fenk, R; Haas, R; Heinzler, N; Kobbe, G; Köhrer, K; Majidi, F; Schroeder, T; Strapatsas, T; Wilk, CM, 2016) |
| "Progression to multiple myeloma occurred in 53 (86%) of 62 patients in the observation group compared with 22 (39%) of 57 patients in the treatment group." | ( Arguiñano, JM; Bargay, J; Bladé, J; Corral, LL; de Arriba, F; de la Rubia, J; García, JL; Giraldo, P; Hernández, MT; Lahuerta, JJ; López, J; Mateos, MV; Miguel, JS; Oriol, A; Paiva, B; Palomera, L; Prosper, F; Quintana, N; Rosiñol, L, 2016) |
| "A 75-year-old woman diagnosed with multiple myeloma in 2007 began treatment with monthly melphalan and prednisone for a total of 9 cycles in combination with thalidomide in 2009." | ( Amato, D; Bailie, T; Lovering, S; Miao, W, 2016) |
| "For relapsed and/or refractory multiple myeloma (RRMM), the typical patient currently receives more lines of therapy than has been feasible in the past, translating into longer progression-free survival (PFS)." | ( Bloudek, L; Globe, D; Jagannath, S; Kish, JK; Kuriakose, ET; Orloski, L; Roy, A; Siegel, DS, 2016) |
| "Following development of multiple myeloma, the patient was treated with intensive antimyeloma treatment consisting of high-dose melphalan with autologous stem cell transplantation." | ( Jonkman, MF; van Doorn, R; von dem Borne, PA, 2017) |
| "Despite new advances in multiple myeloma treatment and the consequent improvement in overall survival, most patients relapse or become refractory to treatment." | ( Avilés, P; Garayoa, M; González-Méndez, L; Gutiérrez, NC; Hernández-García, S; Herrero, AB; López-Iglesias, AA; Martín-Sánchez, M; Mateos, MV; Ocio, EM; Paíno, T; San-Miguel, JF; San-Segundo, L, 2017) |
| "In the last decades, treatment of multiple myeloma (MM) has greatly improved due to the introduction of novel agents, including proteasome inhibitors (PI) and immunomodulatory agents (IMiDs)." | ( Delforge, M; Kint, N, 2016) |
| "Despite advances in treatment, multiple myeloma (MM) remains incurable." | ( Avigdor, A; Ben-Shushan, D; Duek, A; Jakubikova, J; Leiba, A; Leiba, M; Nagler, A; Paukov, L; Rozic, G, 2016) |
| "However, some multiple myeloma patients display intrinsic resistance to the treatment and most patients acquire resistance over time." | ( Baranowska, K; Bjørkøy, G; Buene, G; Darvekar, S; Holien, T; Johansson, I; Misund, K; Starheim, KK; Sundan, A; Waage, A, 2016) |
| "A 59-year-old patient with multiple myeloma on maintenance chemotherapy presented with fever, weight loss, and night sweats." | ( Eluvathingal, T; Fogel, B; Kothari, A; Mohan, M; Schinke, C, 2016) |
| "Current therapy for multiple myeloma includes a phased-approach, often consisting of initial induction therapy, consolidation and maintenance therapy." | ( Lipe, B; Mikhael, J; Vukas, R, 2016) |
| "The overall goal of treatment for multiple myeloma (MM) is to prolong survival for as long as possible with the minimal treatment burden for each patient." | ( Giralt, SA; Shah, GL, 2016) |
| "Simultaneous multiple myeloma (MM) and pulmonary adenocarcinoma is a rare occurrence, and thus, treatment is a challenge." | ( Deng, M; Lin, Q; Mei, Z; Song, Y; Yang, J; Yin, Q; Zhu, X; Zuo, W, 2017) |
| "In patients with multiple myeloma, treatment disparities are not completely explained by potential access barriers." | ( Fiala, MA; Wildes, TM, 2017) |
| "A 64-year-old man with recurrent multiple myeloma (BJP-κ type) was treated with 15 mg of lenalidomide (LEN) and dexamethasone." | ( Fuchida, SI; Hatsuse, M; Murakami, S; Odaira, E; Okano, A; Shimazaki, C, 2016) |
| "Dexamethasone (dex) induces apoptosis in multiple myeloma (MM) cells and is a frontline treatment for this disease." | ( Azab, AK; Burwick, N; de la Puente, P; Delrow, JJ; Hyun, TS; MacKay, VL; Nakamura, T; Ruiz-Gutierrez, M; Sanchez-Bonilla, M; Shimamura, A; Zhang, MY, 2017) |
| "Patients starting a treatment for multiple myeloma in the period 2011-2014 were identified through hospital and chronic disease diagnoses." | ( Despas, F; Gauthier, M; Lapeyre-Mestre, M; Moulis, G; Palmaro, A; Rougé-Bugat, ME, 2017) |
| "High-dose chemotherapies to treat multiple myeloma (MM) can be life-threatening due to toxicities to normal cells and there is a need to target only tumor cells and/or lower standard drug dosage without losing efficacy." | ( Allamargot, C; Coleman, KL; Frech, I; Nessler, R; Tricot, G; Xia, J; Xu, H; Zhan, F; Zhang, X, 2017) |
| "Although multiple myeloma (MM) treatment has improved in the last decade, it remains largely incurable." | ( Di, W; Dou, J; Gu, N; Li, M; Luo, S; Pan, M; Shi, F; Wu, S; Yang, F; Zhao, F, 2017) |
| "Treatment advances for multiple myeloma (MM) that have prolonged survival emphasise the importance of measuring patients' health-related quality of life (HRQoL) in clinical studies." | ( Arnould, B; Bacon, P; Gilet, H; Kyriakou, C; Leleu, X; Lewis, P; Murphy, P; Petrucci, MT; Vande Broek, I, 2017) |
| "Transplant-eligible patients with multiple myeloma (MM) now have extended survival after diagnosis owing to effective modern treatment strategies that include new agents in induction therapy, autologous stem cell transplant (ASCT), consolidation therapy and posttransplant maintenance therapy." | ( Garderet, L; Malard, F; Mohty, M; Savani, BN; Sengsayadeth, S, 2017) |
| "We randomly assigned 700 patients with multiple myeloma to receive induction therapy with three cycles of RVD and then consolidation therapy with either five additional cycles of RVD (350 patients) or high-dose melphalan plus stem-cell transplantation followed by two additional cycles of RVD (350 patients)." | ( Anderson, KC; Arnulf, B; Attal, M; Avet-Loiseau, H; Belhadj, K; Caillot, D; Escoffre, M; Facon, T; Fermand, JP; Garderet, L; Harousseau, JL; Hulin, C; Lauwers-Cances, V; Leleu, X; Macro, M; Maglio, ME; Mathiot, C; Meuleman, N; Moreau, P; Munshi, N; Payen, C; Richardson, PG; Rollet, S; Roussel, M; Weller, EA; Zeytoonjian, AA, 2017) |
| "Among adults with multiple myeloma, RVD therapy plus transplantation was associated with significantly longer progression-free survival than RVD therapy alone, but overall survival did not differ significantly between the two approaches." | ( Anderson, KC; Arnulf, B; Attal, M; Avet-Loiseau, H; Belhadj, K; Caillot, D; Escoffre, M; Facon, T; Fermand, JP; Garderet, L; Harousseau, JL; Hulin, C; Lauwers-Cances, V; Leleu, X; Macro, M; Maglio, ME; Mathiot, C; Meuleman, N; Moreau, P; Munshi, N; Payen, C; Richardson, PG; Rollet, S; Roussel, M; Weller, EA; Zeytoonjian, AA, 2017) |
| "This is the first case of PGNMID with multiple myeloma successfully treated with bortezomib and dexamethasone in which comparative renal biopsies were performed before and after treatment." | ( Hara, S; Kamiura, N; Noto, R; Ono, Y; Tabata, S; Yanagita, M; Yokoi, H; Yoshimoto, A, 2017) |
| "Curative responses in the treatment of multiple myeloma (MM) are limited by the emergence of therapeutic resistance." | ( Dolloff, NG; Dytfeld, D; Jakubowiak, A; Komarnicki, M; Luczak, M; Manevich, Y; Mitra, AK; Przybylowicz-Chalecka, A; Reyes, L; Robinson, RM; Smith, B; Szczepaniak, T; Thompson, RM; Van Ness, BG, 2017) |
| "Objectives and importance: Patients with multiple myeloma (MM) have an increased risk of cardiovascular comorbidities due to disease burden and treatment-related risk factors." | ( DeCara, JM; Jakubowiak, AJ; Mezzi, K, 2017) |
| "We focus on multiple myeloma cells exposed to bortezomib, a first-line chemotherapy and proteasome inhibitor." | ( Huang, HH; Liu, TY; Song, YS; Wells, JA; Wheeler, D; Wiita, AP; Xu, Y, 2017) |
| "A total of 76 patients with multiple myeloma in our hospital from October 2012 to October 2013 were selected and randomly divided into 2 groups: the patients in 1 group (38 cases) were treated with cellular immunotherapy combined with chemotherapy including bortezomib (combined therapy group), the patients in other group(38 cases) were treated with only chemotherapy including bortezomib(single chemotherapy as control group)." | ( Long, H; Shao, JH; Wang, YM; Yang, D, 2017) |
| "Recent innovations in the treatment of multiple myeloma have enriched our therapeutic repertoire regarding the treatment of multiple myeloma during the last decades." | ( Schmeel, FC; Schmeel, LC; Schmidt-Wolf, IGH, 2017) |
| "Alternatives of treatments for multiple myeloma (MM) have become increasingly available with the advent of new drugs such as proteasome inhibitors, thalidomide derivatives, histone deacetylase inhibitors, and antibody drugs." | ( Fujimori, K; Hattori, Y; Ichikawa, D; Iwasaki, G; Kitabatake, S; Kiuchi, F; Matsushita, M; Okayama, M; Sato, M; Suto, Y; Yamagiwa, N, 2017) |
| "This study aimed to explore multiple myeloma (MM) patients' experience of symptom frequency, intensity, and distress during therapy." | ( De Geest, S; Engelhardt, M; Fierz, K; Ihorst, G; Kirsch, M; Naegele, M, 2018) |
| "Lenalidomide is commonly used for multiple myeloma as either induction or maintenance therapy." | ( Birhiray, R; Przybylski, DJ; Reeves, DJ, 2018) |
| "Although survival of multiple myeloma patients has at least doubled during recent years, most patients eventually relapse, and treatment at this stage may be particularly complex." | ( Lokhorst, HM; Nijhof, IS; van de Donk, NWCJ; Zweegman, S, 2018) |
| "Treatment for relapsed/refractory multiple myeloma (RRMM) remains an unmet need." | ( Anderson, KC; Attal, M; Campana, F; Corzo, K; Hui, AM; Le-Guennec, S; Richardson, PG; Risse, ML, 2018) |
| "A promising approach to the treatment of multiple myeloma (MM) involves agents that target not only the myeloma cells directly, but also the tumor microenvironment which promotes tumor cell growth, angiogenesis, and MM bone disease." | ( Anderson, KC; Breitkreutz, I; Figueroa-Vazquez, V; Hayden, PJ; Podar, K; Raab, MS; Wilhelm, S, 2018) |
| "The treatment of multiple myeloma (MM) has become costly and difficult to access for patients living in low-income to middle-income countries." | ( Arredondo-Campos, D; Cantú-Rodríguez, O; Gómez-Almaguer, D; Gómez-De León, A; Gutiérrez-Aguirre, CH; Jaime-Pérez, JC; Martínez-González, O; Martínez-Pacheco, V; Ramírez-López, A; Tarín-Arzaga, L, 2018) |
| "Prompt recognition of multiple myeloma is critical to institute appropriate therapy and prevention of disease progression." | ( Barletta, PA; Salguero, DA; Sierraalta, W, 2018) |
| "Despite novel agents, multiple myeloma is still an incurable disease, especially for elderly and frail patients, who are difficult to manage for concomitant comorbidities as the therapeutic options are limited and the response to chemotherapy is often short." | ( Catalano, L; Cerchione, C; Di Perna, M; Nappi, D; Pane, F; Pareto, AE; Picardi, M; Zacheo, I, 2018) |
| "Standard induction therapy for multiple myeloma is three-drug combination based on following classes of drugs: proteasome inhibitors, immunomodulators and steroids." | ( Abraham, I; Anwer, F; Iftikhar, A; Kapoor, V; Latif, A; McBride, A; Mushtaq, A; Riaz, IB; Zahid, U, 2018) |
| "A 73-year-old woman with relapsed multiple myeloma was treated with 15 cycles of lenalidomide and dexamethasone, but therapy had to be stopped because of a hip fracture after a fall." | ( Barrio, S; Braggio, E; Collado, L; Folgueira, MD; Hernandez-Lain, A; Linares, M; Martinez-Lopez, J; Ramos, A; Rapado, I; Ruiz, J; Ruiz-Heredia, Y; Sanchez-Vega, B; Stewart, K; Toldos, O, 2019) |
| "Emerging data show that newly diagnosed multiple myeloma patients treated with modern carfilzomib/lenalidomide/dexamethasone (KRd) therapy, on average, take 6 cycles until reaching minimal residual disease (MRD) negativity." | ( Bhutani, M; Kazandjian, D; Korde, N; Kwok, M; Landgren, O; Leitman, SF; Mailankody, S; Manasanch, E; Panch, S; Sportes, C; Stetler-Stevenson, M; Tageja, N; Yuan, C, 2018) |
| "In this review multiple myeloma-related symptoms and adverse events resulting from treatments for multiple myeloma are discussed, with a focus on adverse events related to histone deacetylase inhibitors and histone deacetylase inhibitor combinations." | ( Cavenagh, JD; Popat, R, 2018) |
| ": The introduction of new agents in multiple myeloma therapy has increased the overall response rate and improved clinical outcomes, but the increased risk of thrombotic complications impairs the quality of life of patient and the optimal thromboprophylaxis remains unknown." | ( Dong, R; Gao, Y; Liu, S; Ma, G; Su, Y; Zhang, S, 2018) |
| "The treatment of multiple myeloma (MM) with bortezomib (BTZ) is promising; however, the emergence of resistance is challenging in the clinical treatment." | ( Chen, C; Li, H; Li, Z; Niu, M; Shi, M; Sun, Y; Xu, K; Yang, J; Yao, R; Yao, Y; Zeng, L; Zhang, Q; Zhang, Y, 2018) |
| "Patients with multiple myeloma treated with bortezomib who developed BIPN grade 2 or above, based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), were enrolled and received 10 acupuncture treatments over 10 weeks." | ( Bao, T; Chen, P; Ingram, E; Li, SQ; Piulson, L; Zhi, WI, 2018) |
| "Patients with multiple myeloma (MM) invariably relapse with chemotherapy-resistant disease, underscoring the need for new therapeutic options that bypass these resistance mechanisms." | ( Cai, Z; Deng, G; He, J; Liu, X; Lv, N; Ma, L; Wu, W; Yan, M; Yao, S; Yu, R; Zhang, E; Zhao, Y; Zi, F, 2018) |
| "We apply STL to two multiple myeloma gene expression datasets, containing different treatments (bortezomib and lenalidomide)." | ( Broijl, A; de Ridder, J; Sonneveld, P; Ubels, J; van Beers, EH; van Vliet, MH, 2018) |
| "Introduction Multiple myeloma (MM) treatment has evolved substantially in recent years." | ( Björklöf, K; Coriu, D; Dytfeld, D; Fink, L; Markuljak, I; Mihaylov, G; Niepel, D; Ostojic-Kolonic, S; Spicka, I; Toka, KS, 2018) |
| "Key words: bortezomib; multiple myeloma; meta-analysis; subcutaneous administration." | ( Ai, LS; Hu, Y; Mu, SD; Qin, Y, 2018) |
| "Applying QPOP to bortezomib-resistant multiple myeloma cell lines determined the drug combinations that collectively optimized treatment efficacy." | ( Chng, WJ; Chow, EK; Ho, CM; Ho, D; Hooi, L; Jha, S; Karnani, N; Rashid, MBMA; Silva, A; Tan, PF; Teh, AL; Toh, TB; Zhang, Y, 2018) |
| "Treatment of relapsed/refractory multiple myeloma (RRMM) aims to prolong survival while maintaining health-related quality of life (HRQoL) by managing disease-related symptoms and complications-one of the most frequent and debilitating being bone pain." | ( Cella, D; Davis, C; Kudlac, A; McKendrick, J; Oukessou, A; Palumbo, A; Vij, R; Zyczynski, T, 2018) |
| "Improving outcomes in multiple myeloma will involve not only development of new therapies but also better use of existing treatments." | ( Abbasian, M; Adedayo, T; Ambrose, J; Braganza, N; Cavenagh, JD; Chapman, MA; Clifton-Hadley, L; Cook, G; Cook, M; Counsell, N; Crawley, CR; Crowe, J; Herrero, J; Keats, JJ; Koh, M; Lach, A; Oakervee, H; Owen, RG; Popat, R; Pratt, G; Quinn, MF; Roddie, C; Schey, S; Sive, J; Smith, P; Sonneveld, P; Streetly, MJ; Virchis, AE; Willis, F; Yong, K, 2018) |
| "In patients with multiple myeloma (MM), AHR levels were inversely correlated with survival, suggesting that AHR inhibition may be beneficial for the treatment of this disease." | ( Affronti, HC; Bagati, A; Bergsagel, PL; Bianchi-Smiraglia, A; Fink, EE; Gitlin, II; Gudkov, AV; Han, Z; Kandel, ES; Lee, KP; Leonova, KI; Lightman, SM; Lipchick, BC; Long, MD; Moparthy, K; Moparthy, S; Nikiforov, MA; Polechetti, A; Roll, MV; Rosario, SR; Rowsam, AM; Smiraglia, DJ; Wolff, DW; Yun, DH, 2018) |
| "Outcomes for patients with multiple myeloma (MM) have improved through use of novel treatments, especially lenalidomide combined with autologous stem cell transplantation." | ( Akashi, K; Aoki, T; Eto, T; Henzan, H; Iwasaki, H; Kamimura, T; Kohno, K; Miyamoto, T; Muta, T; Nagafuji, K; Ogawa, R; Ohno, Y; Sugio, Y; Tanimoto, K; Yamasaki, S; Yoshimoto, G, 2019) |
| "In the area of multiple myeloma (MM) therapy, proteasome inhibitors (PI) have emerged with promising responses both in the first- and second-line setting." | ( Sandy, EB; Terjanian, T; Weerasinghe, C, 2020) |
| "Pomalidomide, previously used to treat multiple myeloma, has been reported to cause acute pulmonary toxicity that improves with drug discontinuation." | ( Blanc, PD; Brown, JK; Callahan, EC; Elicker, B; Gajic, S; Ley, B, 2018) |
| "Among patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor had failed, the risk of progression or death was significantly lower among those who received elotuzumab plus pomalidomide and dexamethasone than among those who received pomalidomide plus dexamethasone alone." | ( Dimopoulos, MA; Dytfeld, D; Grosicki, S; Hori, M; Jou, YM; LeBlanc, R; Leleu, X; Moreau, P; Popa McKiver, M; Raab, MS; Rafferty, B; Richardson, PG; Robbins, M; San-Miguel, J; Shelat, SG; Suzuki, K; Takezako, N, 2018) |
| "In preclinical mouse models of multiple myeloma, treatment with blocking anti-sclerostin antibody increased osteoblast numbers and bone formation rate reducing osteolytic bone lesions." | ( Bolzoni, M; Ferretti, M; Giuliani, N; Palumbo, C; Toscani, D, 2018) |
| "Patients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation." | ( Cairns, DA; Collett, C; Cook, G; Davies, FE; Drayson, MT; Garg, M; Gregory, WM; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Karunanithi, K; Kishore, B; Lindsay, J; Morgan, GJ; Owen, RG; Pawlyn, C; Russell, NH; Striha, A; Williams, CD, 2019) |
| "Patients with multiple myeloma (MM) are at risk of cardiovascular events (CVEs) as a result of disease burden- and treatment-related risk factors." | ( Bao, L; Chu, B; Fang, L; Fu, L; Gao, S; Lu, M; Shi, L; Wang, Y; Xiang, Q, 2019) |
| "Decision making for patients with multiple myeloma (MM) not transplant eligible (NTE) is complicated by a lack of head-to-head comparisons of standards of care, the increase in the choice of treatment modalities, and the promising results that are rapidly evolving from studies with novel regimens." | ( Blommestein, HM; Franken, MG; Sonneveld, P; Uyl-de Groot, CA; van Beurden-Tan, CHY; Zweegman, S, 2019) |
| "The survival of multiple myeloma patients is increasing due to new medications, the widespread implementation of autologous stem cell transplantation and better supportive treatments." | ( Gertz, M; Vaxman, I, 2019) |
| "Patients with relapsed or refractory multiple myeloma who have received several lines of therapy have no satisfactory treatment options." | ( , 2016) |
| "In an unblended trial in 1623 multiple myeloma patients, treatment with lenalidomide + dexamethasone until disease progression appeared to prolong survival by a few months more than with the thalidomide + melphalan + prednisone combination given for 18 months, but serious adverse effects were more frequent." | ( , 2016) |
| "We provide a real-world overview of multiple myeloma (MM) treatment patterns, outcomes and healthcare resource use (HRU) in Portugal." | ( Antunes, L; Bento, MJ; Chacim, S; Lefèvre, C; Pereira, M; Pereira, S; Rocha-Gonçalves, F; Zagorska, A, 2019) |
| "Multiple myeloma treatment." | ( Roussel, M; Royer, B; Talbot, A, 2018) |
| "In cultured multiple myeloma cells, pretreatment with exosomes resulted in a decreased sensitivity of the cells to bortezomib, and longer treatment durations and higher exosome concentrations consistently enhanced the resistance of the cells to the same Btz concentration." | ( Chen, Q; Duan, S; Tang, J; Xiao, D; Zhang, F; Zhang, W, 2019) |
| "At our center, patients with multiple myeloma (MM) were treated upfront with bortezomib, cyclophosphamide, and dexamethasone (VCD) until cyclophosphamide was replaced with lenalidomide in the combination (VRD)." | ( Alici, E; Borg Bruchfeld, J; Gahrton, G; Gran, C; Lund, J; Månsson, R; Nahi, H; Uttervall, K; Wålinder, G, 2019) |
| "Patients aged at least 18 years with multiple myeloma, an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, previously treated with at least two lines of therapy (excluding pomalidomide) and refractory to the last line were randomly assigned 1:1 to the pembrolizumab plus pomalidomide and dexamethasone group or the pomalidomide and dexamethasone group via an interactive voice response or integrated web response system." | ( Avivi, I; Benyamini, N; Blacklock, H; Chanan-Khan, A; Farooqui, M; George, A; Goldschmidt, H; Iida, S; Jagannath, S; Kher, U; Larocca, A; Liao, J; Lonial, S; Marinello, P; Mateos, MV; Matsumoto, M; Ocio, EM; Oriol, A; Ribrag, V; Rodriguez-Otero, P; San Miguel, J; Schjesvold, F; Sherbenou, D; Simpson, D; Suzuki, K; Usmani, SZ, 2019) |
| "We apply this method to a network of multiple myeloma treatments in newly diagnosed patients (ndMM), where the outcome is progression free survival." | ( Leahy, J; Walsh, C, 2019) |
| "The clinical data of 97 patients with multiple myeloma treated with chemotherapy in Department of Hematology, the 1st Hospital of Hainan Medical College were analyzed retrospectively." | ( Chen, Y; Chen, ZL; Hu, M; Su, GH; Tao, S; Xu, L, 2019) |
| "Patients with multiple myeloma are generally older and vary in fitness levels, which may influence the clinical benefit of treatment." | ( Attal, M; Belch, A; Boyle, E; Chen, WM; Costa, B; Dimopoulos, MA; Facon, T; Guo, S; Houck, V; Hulin, C; Kim, K; Leleu, X; Lorraine Chretien, M; Ludwig, H; Macro, M; Manier, S; Meuleman, N; Mohty, M; Moreau, P; Renwick, W; Rodriguez-Otero, P; Rose, C; Silvia Monzini, M; Sturniolo, M; Tempescul, A; Tinel, A; Yves Mary, J; Zamagni, E, 2020) |
| "Adult patients with multiple myeloma undergoing high-dose melphalan chemotherapy and autologous peripheral blood HSCT were randomized to receive either true (TA) or sham acupuncture (SA) once daily for five days starting on the day after chemotherapy." | ( Chung, DJ; Deng, G; Giralt, S; Landau, H; Lapen, K; Li, QS; Mao, JJ; Siman, J, 2020) |
| "We present a rare case of multiple myeloma without concomitant amyloidosis that presented with life-threatening bleeding from acquired deficiency of factor X and responded remarkably to treatment for underlying multiple myeloma." | ( Hashmi, H; Maghavani, DP; Reynolds, SB, 2019) |
| "Patients with relapsed/refractory multiple myeloma (RRMM) for whom the benefits of lenalidomide have been exhausted in early treatment lines need effective therapies." | ( Agajanian, R; Agarwal, A; Bahlis, NJ; Chung, W; Kaya, H; Malek, E; Mouro, J; Pierceall, WE; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, KW; Srinivasan, S; Stockerl-Goldstein, K; Talamo, G; Zafar, F, 2020) |
| "Treatment results for multiple myeloma and plasma cell leukemia have considerably improved, but cure remains elusive and establishing new therapeutic approaches constitutes a major unmet clinical need." | ( Flögel, B; Greil, R; Jöhrer, K; Kircher, B; Willenbacher, E; Willenbacher, W, 2019) |
| "A 50-year-old male was diagnosed with multiple myeloma (MM) and treated by high-dose melphalan followed by autologous stem cell transplantation in April 2014." | ( Fuchida, SI; Hatsuse, M; Matsui-Maegawa, S; Murakami, S; Okano, A; Shimazaki, C; Shimura, K; Taminishi-Katsuragawa, Y, 2019) |
| "Induction therapy of multiple myeloma patients prior to autologous stem cell transplantation has changed from conventional chemotherapy to treatment based on proteasome inhibitors or immunomodulatory drugs." | ( Ahmed, AB; Bruserud, Ø; Ersvær, E; Rundgren, IM; Ryningen, A, 2019) |
| "Fifty-seven consecutive multiple myeloma or AL amyloidosis patients commencing bortezomib-based therapy were included." | ( De-Silva, D; Garcia Mingo, A; Griffiths, PD; Hughes, D; Kyriakou, C; Mahmood, S; Mehta, A; Ramsay, I; Sachchithanantham, S; Sharpley, FA; Wechalekar, AD; Worthington, S, 2020) |
| "For patients with multiple myeloma (MM) that relapsed after treatment with bortezomib- and lenalidomide-based regimens, there were no other treatment options in Korea until 2016." | ( Eom, HS; Jung, KS; Kim, HJ; Kim, JS; Kim, K; Kim, SH; Lee, JJ; Lee, JO; Min, CK; Shin, HJ, 2020) |
| "Elderly multiple myeloma (MM) patients, who are generally ineligible for transplantation, have high risks of death and treatment discontinuation, and require a regimen incorporating novel agents that balance safety, tolerability, and efficacy." | ( Kada, A; Komeno, T; Saito, AM; Sawamura, M; Sunami, K; Takezako, N; Yokoyama, A, 2019) |
| "Furthermore, down regulation of SENP2 in multiple myeloma cell line RPMI8226 alleviated bortezomib induced cell proliferation inhibition and apoptosis, whereas, overexpression of SENP2 sensitized these cells to bortezomib treatment." | ( Gu, Y; Lu, M; Reddy, BA; Shu, P; Wang, W; Wang, X; Xie, H; Xin, C; Ye, X, 2020) |
| "The treatment for relapsed/refractory multiple myeloma (RRMM) continues to be challenging despite recent therapeutic advancements." | ( Basali, D; Chakraborty, R; Dysert, H; Kalaycio, M; Karam, M; Reed, J; Rosko, N; Rybicki, L; Schlueter, K; Valent, J, 2020) |
| "The treatment landscape for multiple myeloma (MM) has progressed significantly, and over the past decade, bortezomib-based induction therapy has been a standard of care." | ( Chng, WJ; De Mel, S; Low, JZ; Oh, J; Ooi, M; Soekojo, CY, 2020) |
| "The treatment of patients with multiple myeloma (MM) has evolved in recent years, and the disease-associated prognosis has improved substantially." | ( Cantero-Fortiz, Y; Cruz-Mora, A; García-Navarrete, YI; León-Peña, A; Murrieta-Álvarez, I; Olivares-Gazca, JC; Olivares-Gazca, M; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Steensma, DP, 2020) |
| "Patients with multiple myeloma (MM) inevitably relapse on initial treatment regimens, and novel combination therapies are needed." | ( Anderson, LD; Chari, A; Chhabra, S; Cornell, RF; Gasparetto, C; Girnius, S; Karanes, C; Lee, Y; Liu, E; Lunning, M; Matous, JV; Niesvizky, R; Salman, Z; Shustik, C; Stuart, R; Usmani, SZ; Valent, J, 2020) |
| "An 87-year-old male was diagnosed with multiple myeloma and started on treatment with bortezomib, dexamethasone, and lenalidomide (VRd)." | ( Mulay, S; Singh, M; Thomas, VM, 2020) |
| "Forty-eight primary multiple myeloma cells were collected prior to treatment with Len and dexamethasone (Ld) and 25 paired samples were obtained post-Ld therapy." | ( Aoki, S; Asano, A; Fukuda, S; Iida, S; Ito, A; Kanamori, T; Kinoshita, S; Komatsu, H; Kubo, K; Kusumoto, S; Ri, M; Tachita, T; Tohkin, M; Totani, H; Yamagata, K; Yoshida, T, 2020) |
| "We reviewed 437 patients with multiple myeloma treated with selinexor and assessed the kinetics of adverse events and impact of supportive care measures." | ( Abonour, R; Bahlis, N; Baz, R; Berdeja, JG; Chai, Y; Chari, A; Chen, C; Choquet, S; Cornell, RF; Dimopoulos, MA; Dingli, D; Gasparetto, C; Gavriatopoulou, M; Hofmeister, CC; Huff, CA; Jagannath, S; Jakubowiak, A; Kauffman, MG; Lentzsch, S; Li, K; Li, L; Lonial, S; Mohty, M; Moreau, P; Nooka, AK; Parker, TL; Reece, D; Richter, J; Shacham, S; Shah, J; Siegel, D; Tuchman, S; Unger, TJ; Vogl, DT; Weisel, KC; White, D; Yee, AJ, 2020) |
| "Many patients with multiple myeloma (MM) initially respond to treatment with modern combination regimens including immunomodulatory agents (lenalidomide and pomalidomide) and proteasome inhibitors." | ( Alexander, M; Baculi, F; Carmichael, J; Cathers, B; Correa, M; Daniel, T; Ebinger, K; Grant, V; Hamann, LG; Hansen, JD; Harris, R; Havens, CG; Huang, D; Kercher, T; Khambatta, G; LeBrun, LA; Leftheris, K; Leisten, J; Lopez-Girona, A; Mendy, D; Moghaddam, M; Nagy, MA; Narla, RK; Piccotti, J; Plantevin, V; Tang, Y; Vessey, R; Whitefield, B, 2020) |
| "The risk of second malignancy after multiple myeloma is affected by a combination of patient-, disease- and therapy-related risk factors." | ( Diamond, B; Hillengass, J; Kazandjian, D; Landgren, CO; Maclachlan, K; Maura, F; Turesson, I, 2020) |
| "Treatment for multiple myeloma has evolved to include treatment of precursor stages (early treatment) as these therapies are shown to be safe and effective also in smoldering myeloma." | ( Kunacheewa, C; Manasanch, EE, 2020) |
| "It has emerged as a potential new multiple myeloma treatment, particularly for late-stage forms of the disease." | ( Aschan, J; Pour, L; Robak, P; Schjesvold, F; Sonneveld, P, 2020) |
| "Treatment of multiple myeloma is not curative, but targeting CD38 improves patient survival." | ( Agis, H; Blank, A; Blau, IW; Chatterjee, M; Einsele, H; Engelhardt, M; Ferstl, B; Goldschmidt, H; Griese, J; Härtle, S; Jarutat, T; Peschel, C; Raab, MS; Röllig, C; Schub, N; Weirather, J; Weisel, K; Winderlich, M, 2020) |
| "Renal impairment (RI) is one of the multiple myeloma (MM)-defining events for initiating therapy." | ( Basak, GW; Biecek, P; Biliński, J; Blajer, B; Boguradzki, P; Drozd-Sokołowska, J; Dwilewicz-Trojaczek, J; Feliksbrot-Bratosiewicz, M; Jedrzejczak, WW; Jurczyszyn, A; Kobylińska, K; Kozłowski, P; Król, M; Krzanowska, K; Maciejewska, M; Mądry, K; Małyszko, J; Rodziewicz-Lurzyńska, A; Skwierawska, K; Snarski, E; Stefaniak, A; Tomaszewska, A; Urbanowska, E; Vesole, DH; Vyas, P; Waszczuk-Gajda, A; Zborowska, H; Ziarkiewicz, M, 2020) |
| "A 56-year-old man diagnosed with multiple myeloma was treated with CBD (cyclophosphamide, bortezomib, and dexamethasone; DEX), which was discontinued because of bortezomib-associated adverse events." | ( Fujieda, A; Ino, K; Kashima, E; Katayama, N; Masuya, M; Nato, Y; Tawara, I, 2020) |
| "Future progress in the treatment of multiple myeloma (MM) requires both the characterisation of key drivers of the disease and novel, innovative approaches to tackle these vulnerabilities." | ( Bolomsky, A; Branstrom, A; Breid, H; Caers, J; Duray, E; Hübl, W; Lejeune, M; Ludwig, H; Muller, J; Pfeiffer, C; Stangelberger, K; Vrancken, L; Weetall, M; Willheim, M; Zojer, N, 2020) |
| "We report two cases of patients with multiple myeloma with t(11,14)(q13;q32) who were treated with venetoclax/carfilzomib/dexamethasone with rapid initial response; however, the response was short-lived." | ( Abuelgasim, KA; Alhejazi, A; Alherz, N; Damlaj, M, 2020) |
| "Patients with multiple myeloma who have relapsed after or become refractory to lenalidomide in early treatment lines represent a clinically important population in need of effective therapies." | ( Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Matous, J; Pierceall, WE; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K; Talamo, G; Zafar, F, 2020) |
| "A total of 43 patients with multiple myeloma were given ixazomib-based chemotherapy, including 16 patients with relapsed/refractory multiple myeloma (RRMM group), 27 patients newly diagnosed multiple myeloma with serious adverse events initially treated with bortezomib (conversion treatment group)." | ( Chen, S; He, Y; Hu, J; Jiang, D; Zhang, K; Zhu, Y; Zou, L, 2020) |
| "Newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulatory drugs are at high risk of venous thromboembolism (VTE), but data are lacking from large prospective cohorts." | ( Bradbury, CA; Cairns, DA; Child, JA; Cook, G; Craig, Z; Davies, FE; Drayson, MT; Gregory, WM; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Morgan, GJ; Owen, RG; Paterson, A; Pawlyn, C, 2020) |
| "A mainstay of multiple myeloma treatment is lenalidomide, which is an immunomodulatory drug (IMiD) that changed the treatment paradigm for multiple myeloma." | ( Schoenbeck, KL; Wildes, TM, 2020) |
| "Patients with newly diagnosed multiple myeloma (n = 2042) were randomized to induction therapy with cyclophosphamide, thalidomide, and dexamethasone (CTD) or cyclophosphamide, lenalidomide, and dexamethasone (CRD)." | ( Allotey, D; Cairns, DA; Clinical Studies Group, UNHO; Collett, C; Cook, G; Davies, FE; Drayson, MT; Garg, M; Gregory, WM; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Karunanithi, K; Kishore, B; Lindsay, J; Morgan, GJ; Owen, RG; Pawlyn, C; Russell, NH; Shafeek, S; Striha, A; Waterhouse, A; Williams, CD, 2021) |
| "Key Words: Multiple myeloma, Bortezomib, Triplet therapy, Remission induction, Peripheral neuropathy." | ( Iftikhar, R; Mahmood, SK; Rehman, JU; Satti, TM; Shamshad, GU; Toor, SH, 2020) |
| "This study evaluates real-life multiple myeloma (MM) patients receiving proteasome inhibitor (PI)-based treatments in the second or third therapy line in 2017 in Germany." | ( Gonzalez-McQuire, S; Lebioda, A; Poenisch, W; Rieth, A; Schoehl, M; Singh, M; Steinmetz, HT, 2020) |
| "We report a case of multiple myeloma patient after one cycle of chemotherapy consisting of bortezomib and dexamethasone diagnosis of Sheehan syndrome with obstinate diarrhea, low blood glucose, and coma symptom, especially, the fluorodeoxyglucose positron emission tomography (FDG-PET) and brain magnetic resonance imaging (MRI) revealed that the manifestations in the saddle area were in accordance with empty sella syndrome." | ( Bing, X; Peifang, L, 2019) |
| "Here, we report eight patients with multiple myeloma that underwent immunomodulatory therapies with daratumumab or lenalidomide-based combination treatments and one patient with smoldering multiple myeloma, all of which presented with symptomatic COVID-19." | ( Alici, E; Gran, C; Ljunggren, HG; Nahi, H; Susek, KH, 2020) |
| "Relapsed/refractory multiple myeloma patients treated with pomalidomide and dexamethasone have an overall response rate (ORR) of ∼30% and median progression-free survival (PFS) of 4-5 months." | ( Chan, E; Chari, A; Cho, HJ; Couto, S; Florendo, E; Ip, C; Jagannath, S; Kim-Schulze, S; La, L; Laganà, A; Lau, K; Leshchenko, VV; Madduri, D; Mancia, IS; Melnekoff, DT; Parekh, S; Pierceall, WE; Richter, J; Strumolo, G; Thakurta, A; Thomas, J; Van Oekelen, O; Verina, D; Vishnuvardhan, N; Wang, M; Zarychta, K, 2020) |
| "Longer survival in patients with multiple myeloma (MM) after treatment with novel agents (NA) such as thalidomide, bortezomib, and lenalidomide may be associated with increased risks of developing second primary malignancies (SPM)." | ( Hou, HA; Liu, Y; Qiu, H; Tang, CH, 2020) |
| "Despite the advances in the treatment of multiple myeloma (MM), complete remission is usually challenging." | ( Asghari, MH; Moloudizargari, M; Mortaz, E; Mosaffa, N; Redegeld, F, 2020) |
| "Isatuximab is used to treat multiple myeloma (MM), characterized by the excessive production of abnormal "myeloma proteins" (M-proteins) that may interact with therapeutic IgG mAb on the neonatal Fc receptor (FcRn)-mediated recycling pathway." | ( Brillac, C; Campana, F; El-Cheikh, R; Fau, JB; Koiwai, K; Mace, N; Nguyen, L; Semiond, D, 2020) |
| "Gastrointestinal complications of multiple myeloma (MM) treatment are common and include nausea, constipation, and diarrhea." | ( Al Saleh, AS; Buadi, F; Dingli, D; Dispenzieri, A; Fonder, A; Gertz, MA; Gonsalves, W; Hayman, S; Hobbs, M; Hwa, L; Kapoor, P; Kourelis, T; Kumar, S; Kyle, R; Lacy, M; Leung, N; Lust, J; Muchtar, E; Nitin, M; Rajkumar, V; Siddiqui, M; Vaxman, I; Visram, A; Warsame, R, 2020) |
| "In the haematological cancer multiple myeloma, we sought to identify analogous synthetic lethality mechanisms that could be leveraged upon established cancer treatments." | ( Belloni, D; Bianchessi, S; Bongiovanni, L; Botrugno, OA; Di Terlizzi, S; Ferrarini, M; Ferrero, E; Frenquelli, M; Girlanda, S; Marcatti, M; Ponzoni, M; Tonon, G; Zambroni, D, 2020) |
| "For patients with multiple myeloma (MM), each additional line of therapy (LOT) is associated with lower response rates, shorter treatment duration and treatment-free intervals, and increased rates of toxicities and comorbidities." | ( Cote, S; Fonseca, R; He, J; Lam, A; Maiese, EM; Mehra, M; Nair, S; Potluri, R; Slavcev, M; Ukropec, J; Usmani, SZ; Voorhees, PM, 2020) |
| "Although multiple myeloma is a low-risk disease for developing tumor lysis syndrome (TLS), treatment with these novel therapies might increase TLS risk." | ( Hotta, Y; Iida, S; Kimura, K; Komatsu, H; Kondo, M; Sanagawa, A; Yamauchi, K, 2020) |
| "Bone marrow biopsies from patients with multiple myeloma revealed significant loss of BMAT with myeloma cell infiltration of the marrow, whereas BMAT was restored after treatment for multiple myeloma." | ( Andersen, TL; Costa, S; DeMambro, V; Driscoll, HE; Dudakovic, A; Fairfield, H; Falank, C; Farrell, M; Hinge, M; Jafari, A; Kassem, M; Khatib, CM; Lary, CW; McDonald, MM; Murphy, CS; Pettitt, JA; Reagan, MR; Rosen, C; van Wijnen, AJ, 2021) |
| "Ten patients with multiple myeloma who were up to 6 months after high dose chemotherapy with autologous stem cell support, were enrolled." | ( Aagaard, TG; Ahmad, SM; Andersen, MH; Breinholt, MF; Do, TH; Grauslund, JH; Hansen, M; Helleberg, C; Jørgensen, NG; Klausen, TW; Klausen, U; Knudsen, LM; Martinenaite, E; Met, Ö; Olsen, LR; Svane, IM, 2020) |
| "It is part of first line treatment for multiple myeloma when combined with lenalidomide and dexamethasone." | ( Dougherty, JA; Elder, CT, 2022) |
| "Induction therapy for multiple myeloma with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (d) (VRd) was traditionally administered as bortezomib given twice weekly on a 3 week cycle." | ( Buadi, F; Cook, J; Dingli, D; Dispenzieri, A; Fonder, A; Gertz, MA; Go, R; Gonsalves, W; Hayman, S; Higgins, A; Hobbs, M; Hwa, YL; Johnson, I; Kapoor, P; Kourelis, T; Kumar, S; Kyle, R; Lacy, M; Leung, N; Rajkumar, VS; Sidana, S; Warsame, R, 2021) |
| "The analysis of adherence in Multiple Myeloma patients treated with lenalidomide one year from the beginning of therapy reveal a concerning lack of adherence." | ( Costantini, A; Lasala, R; Morelli, AM; Pulini, S; Ranucci, E; Rocchi, M; Santoleri, F; Spadano, A, 2022) |
| "Carfilzomib is mainly used to treat multiple myeloma." | ( Chu, TH; Jung, SH; Kim, C; Kim, JY; Lee, C; Lee, JJ; Mai, TT; Vo, MC, 2021) |
| "The clinical data of 85 patients with multiple myeloma treated by bortezomib in our hospital from January 2015 to January 2019 was analyzed." | ( Feng, YF; Li, G; Sun, YQ; Wei, XF; Yang, WH; Zhang, QK, 2021) |
| "Although multiple myeloma (MM) patients benefit from standard bortezomib (BTZ) chemotherapy, they develop drug resistance, resulting in relapse." | ( Jeon, YH; Kim, GW; Kim, SY; Kwon, SH; Lee, DH; Lee, SW; Yeon, SK; Yoo, J, 2021) |
| "The treatment of multiple myeloma (MM) has advanced with the introduction of immunomodulators (IMiDS)." | ( Costa, NL; Drummond, PLM; Hauck, LM; Machado, TRL; Malta, JS; Pádua, CAM; Reis, AMM; Santos, RMMD; Silveira, LP, 2022) |
| "The cell viability of a multiple myeloma cell line was strongly reduced by VO treatment in a dose- and time-dependent manner, while osteosarcoma and chondrosarcoma cell lines viability was significantly affected only by the highest dose assessed." | ( Campos-Toimil, M; Carvalho, GR; Conde, J; Cordero-Barreal, A; Costa Pereira, TM; Francisco, V; Gómez, R; González-Rodríguez, M; Gualillo, O; Lago, F; Pino, J; Ruiz-Fernández, C; Viñuela, JE, 2021) |
| "Treatment of multiple myeloma (MM) aims at inducing cell apoptosis by surpassing the limited capacity of MM cells to cope with oxidative stress." | ( Aisen, Y; Bar-Tana, J; Gatt, ME; Hertz, R; Smeir, E, 2021) |
| "Treatment of relapsed/refractory multiple myeloma (RRMM) is highly challenging, especially for patients with disease refractory to initial therapy, and in particular for disease developing refractoriness to lenalidomide." | ( Anguita, M; Arguiñano, JM; Arnao, M; Bladé, J; Blanchard, MJ; Cabañas, V; Casado, F; de Cabo, E; de Coca, AG; Encinas, C; García, R; González-Rodríguez, AP; Hernández-Rivas, JÁ; Iñigo, B; Lafuente, AP; Lahuerta, JJ; Lavilla, E; López, A; Maldonado, R; Martí, JM; Mateos, MV; Motlló, C; Murillo, I; Pérez-Persona, E; Ribas, P; Rodriguez-Otero, P; Sampol, A; San Miguel, JF; Sirvent, M, 2021) |
| "Bortezomib is a common multiple myeloma therapy that can cause treatment-related peripheral neuropathy, a risk factor for falls." | ( Fiala, MA; Schoenbeck, KL; Wildes, TM, 2021) |
| "Elderly and frail patients with multiple myeloma (MM) are more vulnerable to the toxicity of combination therapies, often resulting in treatment modifications and suboptimal outcomes." | ( Anderson, LD; Arazy, M; Auner, HW; Badros, A; Bahlis, NJ; Benjamin, R; Cavo, M; Chai, Y; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Doronin, V; Facon, T; Garg, M; Gavriatopoulou, M; Grosicki, S; Hajek, R; Jagannath, S; Kauffman, MG; Kriachok, I; Leleu, X; Levy, M; Mateos, MV; Moreau, P; Pour, L; Pylypenko, H; Quach, H; Richardson, PG; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Spicka, I; Stevens, DA; Usenko, G; Venner, CP, 2021) |
| "Patients with multiple myeloma (MM) experience substantial cancer/treatment-related symptom burden during maintenance therapy." | ( Chen, TH; Chen, TY; Cleeland, CS; Garcia-Gonzalez, A; Heijnen, C; Kamal, M; Mendoza, TR; Orlowski, RZ; Shi, Q; Wang, XS, 2021) |
| "A 67-year-old man with multiple myeloma had been treated with carfilzomib, lenalidomide, and dexamethasone (KRd) therapy." | ( Hashimura, M; Ichihara, H; Mugitani, A; Nakako, S; Shiragami, H, 2021) |
| "Patients with advanced/aggressive multiple myeloma have limited treatment options to achieve rapid disease control." | ( Alsouqi, A; Cornell, RF; Dhakal, B; Du, L; Hari, P; Harrell, S; Khan, M, 2021) |
| "Treatment benefit in multiple myeloma (MM) patients with high-risk cytogenetics remains suboptimal." | ( Alegre, A; Campana, F; Delimpasi, S; Facon, T; Harrison, SJ; Hulin, C; Inchauspé, M; Macé, S; Perrot, A; Richardson, P; Risse, ML; Simpson, D; Spencer, A; Sunami, K; van de Velde, H; Vlummens, P; Wang, MC; Yong, K, 2021) |
| "The prevalence of multiple myeloma is increasing and there is a need to evaluate escalating therapy costs (Canadian Cancer Statistics A, 2020)." | ( Bhella, S; Castonguay, V; Chen, BE; Cheung, MC; Dudebout, J; Gul, E; Hay, AE; Kukreti, V; Lalancette, M; Monteith, BE; Pater, J; Phua, C; Reece, D; Richardson, H; Shepherd, L; Sherry, M; Tiedemann, R; Venner, CP; Yen, H, 2021) |
| "Patients with relapsed or refractory multiple myeloma aged at least 18 years who had received one to three previous lines of therapy and had measurable serum or urine M-protein were eligible." | ( Asset, G; Baker, R; Capra, M; Dimopoulos, MA; Facon, T; Hajek, R; Kim, K; Koh, Y; Leleu, X; Macé, S; Martin, T; Martinez, G; Mikhael, J; Min, CK; Moreau, P; Oriol, A; Pour, L; Risse, ML; Špička, I; Suzuki, K; Yong, K, 2021) |
| "The treatment of newly diagnosed multiple myeloma is constantly changing with the advent of novel therapies." | ( Berbari, HE; Kumar, SK, 2021) |
| "Current improvements in multiple myeloma treatment created the need to monitor minimal residual disease (MRD) with high sensitivity." | ( Atenafu, EG; Gorospe, K; Liu, Q; Liyasova, M; Ma, B; McDonald, Z; Piza, G; Reece, D; Taylor, P; Trudel, S; Xu, X; Yang, L; Yao, C, 2021) |
| "Despite recent therapeutic advances, multiple myeloma (MM) patients experience relapses as they become resistant to various classes and combinations of treatment." | ( Al-Janazreh, H; Canale, FA; Cutrona, G; D'Arrigo, G; Gentile, M; Martino, EA; Martino, M; Mendicino, F; Morabito, F; Morabito, L; Neri, A; Todoerti, K; Tripepi, G; Vigna, E, 2021) |
| "Major progress has occurred in multiple myeloma (MM) treatment in recent years, but this is not seen in low- and middle-income countries." | ( Aliaga, K; Casanova, L; Quintana, S; Ruiz, R; Valencia, F; Vasquez, J; Vidaurre, T; Villena, M, 2021) |
| "In mice with established human or murine multiple myeloma, treatment with BT-GSI decreased tumor burden and prevented the progression of multiple myeloma-induced osteolytic disease by inhibiting bone resorption more effectively than unconjugated GSI at equimolar doses." | ( Adhikari, M; Amorim, T; Anderson, J; Bellido, T; Boeckman, RK; Cregor, M; Cuevas, PL; Delgado-Calle, J; Ebetino, FH; Ferrari, AJ; Helms, JA; Khan, S; Kurihara, N; Lehal, R; McAndrews, K; Roodman, GD; Sabol, HM; Srinivasan, V; Vigolo, M, 2021) |
| "Nearly all patients with multiple myeloma undergo multiple rounds of therapy." | ( Dolph, M; Leong, H; Tremblay, G, 2021) |
| "Patients with multiple myeloma often relapse and require multiple treatments to extend survival while maintaining quality of life." | ( Dolph, M; Leong, H; Tremblay, G, 2021) |
| "Bortezomib is the first-line drug for multiple myeloma chemotherapy." | ( Huang, Z; Li, H; Liu, D; Peng, S; Tan, H; Wang, Y, 2022) |
| "Although multiple myeloma (MM) is still considered as an incurable disease by current standards, the development of several combination therapies, and immunotherapy approaches has raised the hope towards transforming MM into an indolent, chronic disease, and possibly achieving a cure." | ( Rayan, A; Zahran, AM; Zahran, ZAM, 2021) |
| "Despite great advances in therapy, multiple myeloma is still a largely incurable disease, therefore the importance of salvage therapies is paramount." | ( Alizadeh, H; Demeter, J; Hardi, A; Illés, Á; Kosztolányi, S; Masszi, T; Mikala, G; Nagy, Z; Plander, M; Schneider, T; Varga, G; Váróczy, L, 2021) |
| "The idea of long-term therapy of multiple myeloma is gaining widespread acceptance." | ( Alizadeh, H; Demeter, J; Hardi, A; Illés, Á; Kosztolányi, S; Masszi, T; Mikala, G; Nagy, Z; Plander, M; Schneider, T; Varga, G; Váróczy, L, 2021) |
| "The treatment of relapsed multiple myeloma remains challenging." | ( Banerjee, R; Lo, M; Martin, TG, 2021) |
| "Relapsed/refractory multiple myeloma (RRMM) is known to have a high burden of disease and complications associated with refractoriness to prior lines of therapy." | ( Alegre, A; Bakker, NA; Bladé, J; Cavo, M; Larocca, A; Laubach, J; Leleu, X; Maisel, C; Mateos, MV; Mazumder, A; Nadeem, O; Oriol, A; Orre, M; Paner, A; Raptis, A; Richardson, PG; Rodriguez-Otero, P; Sandberg, A; Torrång, A; Touzeau, C, 2022) |
| "Prognosis of patients with multiple myeloma (MM) who have relapsed on or become refractory to immunomodulators and bortezomib is poor, and treatment options are limited." | ( Aldaoud, A; Behlendorf, T; Dechow, T; Eschenburg, H; Grebhardt, S; Groschek, M; Hansen, R; Knauf, W; Potthoff, K; Siebenbach, HU; Söling, U; Vannier, C, 2022) |
| "Patients with relapsed and refractory multiple myeloma (RRMM) have a poor prognosis and limited treatment options after exposure to an immunomodulatory drug, proteasome inhibitor (PI), and anti-CD38 antibody (triple-class exposure [TCE])." | ( Davies, FE; Dhanasiri, S; Dhanda, DS; Hollier-Hann, G; Rodriguez-Otero, P; Stothard, C, 2021) |
| "Improvements in multiple myeloma therapy have led to deeper responses that are beyond the limit of detection by historical immunohistochemistry and conventional flow cytometry in bone marrow samples." | ( Raje, N; Yee, AJ, 2021) |
| "Human multiple myeloma cell line RPMI 8226 cells were cultured and treated with 0, 1, 2, 4, 8 nmol/L arsenous acid and 0, 40, 80, 160, 320 μmol/L artesunate, respectively." | ( Dong, JF; Dong, K; Gao, W; Hu, GF; Wang, Y, 2021) |
| "He was recently diagnosed with multiple myeloma, treated with lenalidomide, dexamethasone and carfilzomib." | ( Alterini, B; Cesaroni, E; Merilli, I; Scheggi, V, 2022) |
| "In the treatment of relapsed/refractory multiple myeloma patients with multidrug resistance, the total oral regimens containing ixazomib demonstrate reliable efficacy and safety." | ( Fu, CC; Jin, S; Shang, JJ; Wang, J; Wu, DP; Yan, Z; Yao, Y, 2022) |
| "Despite recent advances, multiple myeloma remains an incurable disease for most patients, and initial remission will be followed by relapses requiring therapy." | ( Dimopoulos, MA; Kastritis, E; Terpos, E, 2022) |
| "For patients with multiple myeloma who are eligible for high-dose melphalan therapy and autologous stem cell transplant (ASCT), the strategy of maintenance with low-dose lenalidomide therapy has become the current standard of care." | ( Holstein, SA; Kesireddy, M, 2022) |
| "The rapidly evolving landscape of multiple myeloma therapy in conjunction with ongoing clinical trials should enable a future where an individualized approach based on disease characteristics, response to induction and ASCT (or even non-ASCT consolidation approaches such as CAR T-cell therapy or bispecific antibodies), as well as patient preferences will influence the use of lenalidomide maintenance." | ( Holstein, SA; Kesireddy, M, 2022) |
| "Bortezomib is a neurotoxic drug used in multiple myeloma and responsible for chemotherapy-induced peripheral neuropathy (CIPN)." | ( Balayssac, D; Barreau, F; Bay, JO; Busserolles, J; Cabrespine, A; Chaleteix, C; Giraudet, F; Kerckhove, N; Lemal, R; Nguyen, D; Pereira, B; Selvy, M; Soubrier, M, 2022) |
| "Based on 66 multiple myeloma patients from a single center, auditory difficulties were assessed with a self-questionnaire and compared to sensory CIPN (QLQ-CIPN20 questionnaire), patients' characteristics and anticancer treatments." | ( Balayssac, D; Barreau, F; Bay, JO; Busserolles, J; Cabrespine, A; Chaleteix, C; Giraudet, F; Kerckhove, N; Lemal, R; Nguyen, D; Pereira, B; Selvy, M; Soubrier, M, 2022) |
| "Patients with relapsed/refractory multiple myeloma (RRMM) need proven subsequent therapies after early-line lenalidomide treatment failure." | ( Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Lee, K; Matous, J; Mouro, J; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K, 2022) |
| "The management of multiple myeloma (MM) is challenging: An assortment of available drug combinations adds complexity to treatment selection, and treatment resistance frequently develops." | ( Cremaschi, A; Gade, A; Giliberto, M; Munthe, LA; Schjesvold, F; Skånland, SS; Taskén, K; Thimiri Govinda Raj, DB; Tjønnfjord, GE, 2022) |
| "She was later diagnosed with multiple myeloma and secondary gastrointestinal amyloidosis, and achieved complete response of myeloma and amyloidosis after 9 cycles of chemotherapy." | ( Cui, R; Ding, J; Huo, L; Luo, Y, 2022) |
| "Major developments in the treatment of multiple myeloma (MM) over the past decade have led to a continued improvement in survival." | ( Goel, U; Kumar, S; Usmani, S, 2022) |
| "An 88-year-old woman was diagnosed with multiple myeloma received third-line chemotherapy, including DBd (daratumumab [DARA], bortezomib, and dexamethasone [Dex]), and the myeloma was in remission." | ( Fujii, T; Kitahara, S; Kobayashi, S; Matsunaga, T; Ohno, N; Sahara, N, 2022) |
| "However, multiple myeloma remains incurable, as most patients eventually relapse and become refractory to current treatments." | ( Aziz, A; Cui, Y; Dai, C; Gong, F; Hu, L; Li, R; Li, Z; Liang, L; Liu, J; Liu, X; Luo, S; Peng, H; Wang, H; Wang, Y; Xiang, R; Xiao, L; Xiao, X; Yi, H; Yuan, L; Zhou, H; Zhu, L; Zhu, Y, 2022) |
| "The treatment of multiple myeloma has dramatically improved due to the availability of novel therapies that are highly effective and are quickly moving into first-line therapy." | ( Aslam, M; Gul, E; Jimenez-Zepeda, VH; Kardjadj, M; Kotb, R; LeBlanc, R; Louzada, M; Masih-Khan, E; McCurdy, A; Mian, H; Reece, D; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D, 2022) |
| "The treatment of relapse or refractory multiple myeloma (RRMM) is still a big challenge in clinic." | ( Chen, SL; Chen, XQ; Dai, YJ; Hu, F; Li, XP; Liang, Y; Lu, YX; Wang, DW, 2022) |
| "Patients with high-risk, newly diagnosed multiple myeloma (HR-NDMM) who are ineligible for autologous stem cell transplant (ASCT) have limited first-line treatment options." | ( Cortoos, A; He, J; Jakubowiak, AJ; Kaila, S; Kumar, S; Lafeuille, MH; Lefebvre, P; Lin, TS; Londhe, A; Mavros, P; Medhekar, R; Pei, H; Usmani, SZ, 2022) |
| "Induction therapy for multiple myeloma is traditionally capped at 6 cycles of lenalidomide due to concerns that longer treatment compromises the ability to collect sufficient stem cells for autologous stem cell transplantation (ASCT)." | ( Badros, AZ; Hardy, N; Kocoglu, M; Rapoport, AP; Rybinski, B, 2022) |
| "Treatment for multiple myeloma (MM) can involve apheresis to mobilize hematopoietic stem cells for later autologous stem cell transplantation (ASCT), which can become costly over time." | ( Crawford, B; Iida, S; Ishida, T; Kanamori, R; Miyamoto, T; Shirai, H; Tajima, Y; Teramukai, S; Teshima, T; Yi, J, 2022) |
| "In patients with newly diagnosed multiple myeloma, the effect of adding autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib, and dexamethasone [RVD]), followed by lenalidomide maintenance therapy until disease progression, is unknown." | ( Agha, ME; Alsina, M; Anderson, KC; Anderson, LD; Andreescu, AC; Attal, M; Avet-Loiseau, H; Campagnaro, EL; Cohen, AD; Cornell, RF; Foley, A; Fulciniti, M; Gasparetto, C; Gentile, T; Ghobrial, IM; Giralt, SA; Godby, KN; Gowin, K; Hashmi, H; Hassoun, H; Hebert, K; Hurd, DD; Jacobus, SJ; Jagannath, S; Kamble, RT; Kaufman, JL; Khan, AM; Laubach, JP; Libby, EN; Liedtke, M; Lonial, S; Maglio, ME; Masone, K; McCarthy, PL; Medvedova, E; Milner, CP; Moreau, P; Munshi, NC; Nadeem, O; Nathwani, N; Openshaw, TH; Orlowski, RZ; Paba-Prada, C; Pasquini, MC; Perrot, A; Raje, NS; Richardson, PG; Samur, MK; Schlossman, RL; Scott, E; Torka, P; Voorhees, PM; Weller, EA; Yee, AJ; Zeytoonjian, AA; Zonder, JA, 2022) |
| "Although patients with multiple myeloma (MM) have improved survival with current therapies, there remains a long-term risk of treatment-associated second primary malignancies." | ( El-Masry, M; Fanous, C; Oveisi, D; Puliafito, B, 2022) |
| "Patients with refractory relapsed multiple myeloma respond to combination treatment with elotuzumab and lenalidomide." | ( Beavis, PA; Bezman, NA; Campbell, K; D'Souza, C; Darcy, PK; Harrison, SJ; Jenkins, MR; Keam, SP; Macdonald, S; Meyran, D; Neeson, PJ; Prince, HM; Quach, H; Richardson, K; Ritchie, DS; Robbins, M; Todd, K; Trapani, JA; Zhu, JJ, 2023) |
| "For patients with newly diagnosed multiple myeloma, survival outcomes continue to improve significantly: however, nearly all patients will relapse following induction treatment." | ( Gandolfi, S; McCaughan, GJ; Moore, JJ; Richardson, PG, 2022) |
| "Treatment of newly diagnosed multiple myeloma (NDMM) with a quadruplet regimen consisting of a monoclonal antibody, proteasome inhibitor, immunomodulatory imide, and corticosteroid has been associated with improved progression-free survival (PFS) compared with triplet regimens." | ( Anderson, LD; Derman, BA; Grinblatt, DL; Gurbuxani, S; Jakubowiak, AJ; Jasielec, J; Jiang, K; Kansagra, A; Karrison, T; Kin, A; Major, A; Narula, S; Rayani, S; Stefka, AT; Zonder, J, 2022) |
| "Many patients with multiple myeloma (MM) have comorbidities and are treated with PPAR agonists." | ( Kang, Y; Li, Z; Mathews, P; McDonnell, DP; Norris, J; Paul, B; Sha, Y; Wang, E; Wu, J; Zhao, Y, 2022) |
| "IgG-κ type multiple myeloma was confirmed by bone marrow biopsy, and the patient was synchronously diagnosed with SLE and MM after BC treatment." | ( Chen, PH; Huang, KP; Lin, CH; Lin, CY; Ni, YL; Tung, HH, 2022) |
| "The treatment landscape in multiple myeloma (MM) has changed drastically in the past two decades with new treatment paradigms evolving." | ( Mai, EK, 2022) |
| "Herpes zoster is not common in multiple myeloma (MM) patients treated with lenalidomide-based regimens." | ( Cao, X; Jiao, B; Wu, G; Zhang, X, 2022) |
| "Treatment options for multiple myeloma (MM) have rapidly expanded over the past few years with several newly approved drugs." | ( Goel, U; Kumar, S, 2022) |
| "For eligible patients with multiple myeloma (MM) and amyloid light chain (AL) amyloidosis, high-dose chemotherapy and autologous hematopoietic cell transplantation (HCT) is a standard and widely used consolidation therapy." | ( Applebaum, A; Cazeau, N; Chung, D; Devlin, SM; Funnell, T; Giralt, SA; Hambright, KA; Khan, N; Landau, HJ; LeStrange, NJ; McElrath, CM; Mitchell, HR; Orlando, E; Peled, JU; Perales, MA; Rodriguez, ES; Scordo, M; Shah, GL, 2022) |
| "IT848 treatment of multiple myeloma cell lines and patient samples inhibited proliferation and induced caspase-dependent and independent apoptosis." | ( Bariana, M; Cassella, E; Colorado, I; Feinman, R; Heller, C; Heller, G; Liou, HC; Makhdoom, A; Mondello, P; Ouk, S; Rateshwar, J; Siegel, DS; Tuckett, A; Zakrzewski, JL, 2022) |
| "Patients aged 18 years or older with multiple myeloma who had received at least two previous lines of therapy, including lenalidomide or pomalidomide and a proteasome inhibitor, were enrolled into the dose-escalation cohort." | ( Abdallah, AO; Amatangelo, M; Amin, A; Badros, AZ; Chen, M; Cheng, Y; Facon, T; Hulin, C; Jagannath, S; Knop, S; Larsen, JT; Lonial, S; Minnema, MC; Nguyen, TV; Oriol, A; Peluso, T; Popat, R; Richardson, PG; Stadtmauer, EA; van de Donk, NWCJ; Weisel, K, 2022) |
| "Patients with multiple myeloma (MM) who are treated with lenalidomide rarely develop a secondary B-cell acute lymphoblastic leukemia (B-ALL)." | ( Abro, B; Barnell, EK; Campbell, KM; Chavez, M; Cotto, KC; Duncavage, EJ; Fiala, MA; Frater, JL; Griffith, M; Griffith, OL; Hassan, A; King, JA; Kohnen, DR; Kreisel, F; Lee, YS; Newcomer, KF; Parikh, BA; Ruzinova, MB; Skidmore, ZL; Spies, NC; Uy, GL; Vij, K; Vij, R; Wang, T; Wartman, LD; Welch, JS, 2023) |
| "Rapidly progressing relapsed/refractory multiple myeloma (RRMM) patients with compromised marrow have limited treatment options." | ( Chari, A; Cho, HJ; Jakubowski, R; Moshier, E; Mouhieddine, TH; Parekh, S; Puliafito, B; Rattu, M; Richard, S; Richter, J; Rodriguez, C; Rossi, A; Sanchez, L; Steinberg, A; Thibaud, S, 2023) |
| "Patients with smoldering multiple myeloma (SMM) are observed until progression, but early treatment may improve outcomes." | ( Aguet, F; Anand, S; Aranha, MP; Badros, AZ; Baginska, J; Bhutani, M; Boruchov, A; Bustoros, M; Dutta, AK; Flechon, L; Getz, G; Ghobrial, IM; Hallisey, M; Haradhvala, NJ; Heilpern-Mallory, D; Jakubowiak, A; Laubach, J; Lightbody, ED; Manier, S; Mateos, MV; Matous, J; Mouhieddine, TH; Nadeem, O; Redd, RA; Richardson, P; Rosenblatt, JM; Savell, A; Sklavenitis-Pistofidis, R; Su, NK; Tahri, S; Trippa, L; Ujwary, S; Usmani, SZ; Varmeh, S; Vredenburgh, JJ; Wu, T; Yee, AJ; Zavidij, O; Zonder, J, 2022) |
| "Patients with smoldering multiple myeloma (SMM) are observed until progression, but early treatment may improve outcomes." | ( Aguet, F; Anand, S; Aranha, MP; Badros, AZ; Baginska, J; Bhutani, M; Boruchov, A; Bustoros, M; Dutta, AK; Flechon, L; Getz, G; Ghobrial, IM; Hallisey, M; Haradhvala, NJ; Heilpern-Mallory, D; Jakubowiak, A; Laubach, J; Lightbody, ED; Manier, S; Mateos, MV; Matous, J; Mouhieddine, TH; Nadeem, O; Redd, RA; Richardson, P; Rosenblatt, JM; Savell, A; Sklavenitis-Pistofidis, R; Su, NK; Tahri, S; Trippa, L; Ujwary, S; Usmani, SZ; Varmeh, S; Vredenburgh, JJ; Wu, T; Yee, AJ; Zavidij, O; Zonder, J, 2022) |
| "Patients with smoldering multiple myeloma (SMM) are observed until progression, but early treatment may improve outcomes." | ( Aguet, F; Anand, S; Aranha, MP; Badros, AZ; Baginska, J; Bhutani, M; Boruchov, A; Bustoros, M; Dutta, AK; Flechon, L; Getz, G; Ghobrial, IM; Hallisey, M; Haradhvala, NJ; Heilpern-Mallory, D; Jakubowiak, A; Laubach, J; Lightbody, ED; Manier, S; Mateos, MV; Matous, J; Mouhieddine, TH; Nadeem, O; Redd, RA; Richardson, P; Rosenblatt, JM; Savell, A; Sklavenitis-Pistofidis, R; Su, NK; Tahri, S; Trippa, L; Ujwary, S; Usmani, SZ; Varmeh, S; Vredenburgh, JJ; Wu, T; Yee, AJ; Zavidij, O; Zonder, J, 2022) |
| "Although treatment options for multiple myeloma (MM) are rapidly evolving, there still remain difficult-to-treat situations, especially in relapsed and/or refractory (r/r) disease." | ( Alihodzic, D; Bokemeyer, C; Ghandili, S; Leypoldt, LB; Weisel, K; Wiessner, C, 2023) |
| "Although treatment options for multiple myeloma (MM) are rapidly evolving, there still remain difficult-to-treat situations, especially in relapsed and/or refractory (r/r) disease." | ( Alihodzic, D; Bokemeyer, C; Ghandili, S; Leypoldt, LB; Weisel, K; Wiessner, C, 2023) |
| "Although treatment options for multiple myeloma (MM) are rapidly evolving, there still remain difficult-to-treat situations, especially in relapsed and/or refractory (r/r) disease." | ( Alihodzic, D; Bokemeyer, C; Ghandili, S; Leypoldt, LB; Weisel, K; Wiessner, C, 2023) |
| "We treated mice carrying Vκ*MYC multiple myeloma cells with the TAK1-inhibitors 5Z-7-oxozeaenol and NG25." | ( Håland, E; Moen, IN; Starheim, KK; Vandsemb, EN, 2022) |
| "We treated mice carrying Vκ*MYC multiple myeloma cells with the TAK1-inhibitors 5Z-7-oxozeaenol and NG25." | ( Håland, E; Moen, IN; Starheim, KK; Vandsemb, EN, 2022) |
| "We treated mice carrying Vκ*MYC multiple myeloma cells with the TAK1-inhibitors 5Z-7-oxozeaenol and NG25." | ( Håland, E; Moen, IN; Starheim, KK; Vandsemb, EN, 2022) |
| "The treatment landscape for relapsed multiple myeloma (MM) has increased." | ( Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Goldman-Mazur, S; Gonsalves, W; Hayman, SR; Kapoor, P; Kourelis, T; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Muchtar, E; Rajkumar, SV; Visram, A; Warsame, R, 2022) |
| "The treatment landscape for relapsed multiple myeloma (MM) has increased." | ( Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Goldman-Mazur, S; Gonsalves, W; Hayman, SR; Kapoor, P; Kourelis, T; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Muchtar, E; Rajkumar, SV; Visram, A; Warsame, R, 2022) |
| "A 72-years-old male, treated for multiple myeloma with dexamethasone, pomalidomide and daratumumab, presented dyspnea, hypoxemia, biological inflammatory syndrome, ground glass opacities on computed tomography scan (CT-scan) and lymphocytic and eosinophilic alveolitis, with no specific cytologic or microbiological findings, 2 months after pomalidomide initiation." | ( Ancel, J; Deslee, G; Dury, S; Godet, S; Launois, C; Perotin, JM; Vivien, A, 2023) |
| "For patients with multiple myeloma (MM) who have undergone autologous stem cell transplant (auto-SCT), the immunomodulatory agent lenalidomide is a first-line option for maintenance therapy." | ( Banerjee, R; Banez, MT; Cheplowitz, H; Chung, A; Costello, C; Fine, J; Guglielmo, J; Kumar, A; Lo, M; Patel, N; Rath, C; Rosenberg, AS; Saunders, IM; Wilson, M; Yoo, C; Young, R, 2023) |
| "Outcomes of multiple myeloma (MM) patients who are refractory to daratumumab are dismal and no standard of treatment exists for this patients' population." | ( Binder, M; Brioli, A; Engelhardt, M; Ernst, T; Gengenbach, L; Heidel, FH; Hilgendorf, I; Hochhaus, A; Mancuso, K; Stauch, T; von Lilienfeld-Toal, M; Zamagni, E, 2023) |
| "Proteasomes are overexpressed in multiple myeloma (MM) and proteasomal inhibitors (PIs) have been widely used for the treatment of MM." | ( Cui, YL; He, GS; He, YM; Liang, JP; Mao, XL; Sun, YN; Zhu, ZG, 2023) |
| "Newly diagnosed multiple myeloma patients have many available treatment options." | ( Barth, P; Olszewski, AJ; Pelcovits, A; Reagan, JL; Rosati, V; Sturtevant, A; Winer, ES; Wood, R, 2023) |
| "Almost all patients with multiple myeloma (MM) will eventually develop disease that has relapsed with or become refractory to available treatments and will require additional therapy." | ( Iida, S; Mateos, MV; Raje, N; Reece, D, 2023) |
| "In patients with multiple myeloma (MM), SARS-CoV-2 infection has been associated with a severe clinical course and high mortality rates due to the concomitant disease- and treatment-related immunosuppression." | ( Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gavriatopoulou, M; Kastritis, E; Malandrakis, P; Migkou, M; Ntanasis-Stathopoulos, I; Roussou, M; Spiliopoulou, V; Terpos, E; Theodorakakou, F, 2023) |
| "Because patients with newly diagnosed multiple myeloma (NDMM) do not always receive any treatment beyond first-line (1L) therapy, it is imperative that patients receive the best treatment in the 1L setting." | ( Ammann, E; Facon, T; Fonseca, R; Hashim, M; He, J; Kumar, S; Lam, A; Nair, S; Wildgust, M, 2023) |
| "The treatment of aggressive multiple myeloma (MM) patients, resistant to several treatment modalities, is very difficult in the real-world-evidence conditions." | ( Štork, M, 2023) |
| "No adequate data exist on the impact of multiple myeloma (MM) with extramedullary disease (EMD) after autograft and maintenance therapy." | ( Anagnostopoulos, A; Arcese, W; Beksac, M; Bolaman, AZ; Bulabois, CE; Bunjes, D; Deconinck, E; Delforge, M; Eikema, DJ; Fenk, R; Gagelmann, N; Hayden, PJ; Itälä-Remes, M; Koster, L; Labussière-Wallet, H; Lund, J; McDonald, A; Nabil, Y; Netelenbos, T; Reményi, P; Schönland, S; Stoppa, AM; Thurner, L; van Gorkom, G; Yakoub-Agha, I, 2023) |
| "She was diagnosed with multiple myeloma 7 years ago and had been on carfilzomib, lenalidomide, and dexamethasone (KRd) therapy for a month because her disease had a relapsed/refractory." | ( Endo, T; Hamada, T; Hatta, Y; Iizuka, K; Iriyama, N; Koike, T; Kurihara, K; Matsumoto, S; Miura, K; Nakagwa, M; Nakamura, H; Nakayama, T; Takahashi, H, 2023) |
| "Treatment of patients with multiple myeloma (MM) in first relapse remains a challenge." | ( Atrash, S; Bhutani, M; Druhan, LJ; Fesenkova, K; Foureau, DM; Friend, R; Guo, F; Norek, S; Paul, B; Pineda-Roman, M; Rigby, K; Robinson, M; Symanowski, JT; Tucker, MR; Usmani, SZ; Varga, C; Voorhees, PM, 2023) |
| "Treatment of multiple myeloma has undergone significant advances in the last two decades, leading to meaningful improvement in overall and progression free survival." | ( Jain, K; Paul, D; Sharma, R; Singh, J; Singh, S, 2023) |
| "Treatment of multiple myeloma (MM) has seen great advances in recent years, and a key contributor to this change has been the effective use of combination therapies, which have improved both the depth and duration of patient responses." | ( Neri, P; Nijhof, I, 2023) |
| "Canine multiple myeloma (MM) is typically treated with melphalan chemotherapy." | ( Hume, KR; O'Connor, KS; Sylvester, SR; Teddy, L, 2023) |
| "Although multiple myeloma is still incurable, an abundance of novel treatments have become available for relapsed and or refractory multiple myeloma (RRMM)." | ( Chen, H; Xu, W; Xu, Y; Yu, J; Zhou, F; Zhou, Y, 2023) |
| "A 66-year-old female with multiple myeloma underwent an autologous stem cell transplant with melphalan conditioning chemotherapy followed by maintenance therapy with lenalidomide." | ( Ginn, M; Strouse, C; Struble, E, 2023) |
| "For patients with newly diagnosed multiple myeloma, reaching minimal residual disease (MRD) negativity after treatment is associated with improved outcomes; however, the use of MRD to modulate therapy remains elusive." | ( Bal, S; Callander, NS; Chhabra, S; Cornell, RF; Costa, LJ; D'Souza, A; Dhakal, B; Dholaria, BR; Giri, S; Godby, KN; Hall, AC; Hardwick, P; Hari, P; Medvedova, E; Omel, J; Schmidt, TM; Silbermann, R, 2023) |
| "Treatment outcomes of multiple myeloma (MM) have dramatically improved in the past 20 years." | ( Tsukada, N, 2023) |